WO2018151830A1 - Inhibiteurs de kinase de régulation du signal apoptotique à base de pyridinyle - Google Patents
Inhibiteurs de kinase de régulation du signal apoptotique à base de pyridinyle Download PDFInfo
- Publication number
- WO2018151830A1 WO2018151830A1 PCT/US2018/000044 US2018000044W WO2018151830A1 WO 2018151830 A1 WO2018151830 A1 WO 2018151830A1 US 2018000044 W US2018000044 W US 2018000044W WO 2018151830 A1 WO2018151830 A1 WO 2018151830A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- optionally substituted
- compound
- alkyl
- another embodiment
- heterocycloalkyl
- Prior art date
Links
- 125000004076 pyridyl group Chemical group 0.000 title abstract description 4
- 230000006907 apoptotic process Effects 0.000 title description 2
- 229940043355 kinase inhibitor Drugs 0.000 title description 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 title description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 47
- 238000000034 method Methods 0.000 claims abstract description 39
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 34
- 201000010099 disease Diseases 0.000 claims abstract description 29
- 239000001257 hydrogen Substances 0.000 claims description 422
- 229910052739 hydrogen Inorganic materials 0.000 claims description 422
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 400
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 389
- 125000001072 heteroaryl group Chemical group 0.000 claims description 374
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 335
- 150000001875 compounds Chemical class 0.000 claims description 323
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 295
- 229910052736 halogen Inorganic materials 0.000 claims description 258
- 150000002367 halogens Chemical class 0.000 claims description 258
- 125000003107 substituted aryl group Chemical group 0.000 claims description 224
- 125000004426 substituted alkynyl group Chemical group 0.000 claims description 182
- 125000001188 haloalkyl group Chemical group 0.000 claims description 170
- 125000005017 substituted alkenyl group Chemical group 0.000 claims description 150
- 229910052757 nitrogen Inorganic materials 0.000 claims description 143
- 125000000217 alkyl group Chemical group 0.000 claims description 139
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 131
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 85
- 229910052760 oxygen Inorganic materials 0.000 claims description 79
- 229910052717 sulfur Inorganic materials 0.000 claims description 77
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 70
- 239000000243 solution Substances 0.000 claims description 63
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 53
- 150000003839 salts Chemical class 0.000 claims description 44
- 125000004429 atom Chemical group 0.000 claims description 43
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 39
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 33
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims description 28
- 239000000725 suspension Substances 0.000 claims description 27
- 239000012453 solvate Substances 0.000 claims description 25
- 125000005842 heteroatom Chemical group 0.000 claims description 23
- 150000003852 triazoles Chemical class 0.000 claims description 20
- 241000124008 Mammalia Species 0.000 claims description 19
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 19
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 18
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims description 17
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 15
- 239000007788 liquid Substances 0.000 claims description 15
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims description 14
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims description 14
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 14
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 14
- 229930192474 thiophene Natural products 0.000 claims description 14
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 12
- 125000006582 (C5-C6) heterocycloalkyl group Chemical group 0.000 claims description 12
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 11
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims description 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 10
- 150000003536 tetrazoles Chemical class 0.000 claims description 10
- 239000002775 capsule Substances 0.000 claims description 9
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 claims description 9
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims description 8
- 208000033679 diabetic kidney disease Diseases 0.000 claims description 8
- 208000017169 kidney disease Diseases 0.000 claims description 8
- 230000004770 neurodegeneration Effects 0.000 claims description 8
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 8
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims description 8
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims description 7
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 7
- 239000000839 emulsion Substances 0.000 claims description 7
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 claims description 7
- 208000019423 liver disease Diseases 0.000 claims description 7
- 241000894007 species Species 0.000 claims description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 6
- 206010061218 Inflammation Diseases 0.000 claims description 6
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims description 6
- 208000018737 Parkinson disease Diseases 0.000 claims description 6
- 230000004054 inflammatory process Effects 0.000 claims description 6
- 201000006417 multiple sclerosis Diseases 0.000 claims description 6
- 230000001590 oxidative effect Effects 0.000 claims description 6
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 6
- 239000000829 suppository Substances 0.000 claims description 6
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims description 5
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 5
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 claims description 5
- 201000002793 renal fibrosis Diseases 0.000 claims description 5
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- 201000001320 Atherosclerosis Diseases 0.000 claims description 4
- 208000023275 Autoimmune disease Diseases 0.000 claims description 4
- 208000019838 Blood disease Diseases 0.000 claims description 4
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 4
- 206010016654 Fibrosis Diseases 0.000 claims description 4
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 4
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims description 4
- 208000010159 IgA glomerulonephritis Diseases 0.000 claims description 4
- 206010021263 IgA nephropathy Diseases 0.000 claims description 4
- 208000019693 Lung disease Diseases 0.000 claims description 4
- 208000003221 Lysosomal acid lipase deficiency Diseases 0.000 claims description 4
- 206010003246 arthritis Diseases 0.000 claims description 4
- 230000000747 cardiac effect Effects 0.000 claims description 4
- 206010012601 diabetes mellitus Diseases 0.000 claims description 4
- 208000010706 fatty liver disease Diseases 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 208000014951 hematologic disease Diseases 0.000 claims description 4
- 208000018706 hematopoietic system disease Diseases 0.000 claims description 4
- 150000002460 imidazoles Chemical class 0.000 claims description 4
- 208000027866 inflammatory disease Diseases 0.000 claims description 4
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims description 4
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 4
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 4
- 208000030761 polycystic kidney disease Diseases 0.000 claims description 4
- 150000003222 pyridines Chemical class 0.000 claims description 4
- 208000007056 sickle cell anemia Diseases 0.000 claims description 4
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 3
- 206010019708 Hepatic steatosis Diseases 0.000 claims description 3
- 206010020772 Hypertension Diseases 0.000 claims description 3
- 125000006580 bicyclic heterocycloalkyl group Chemical group 0.000 claims description 3
- 229910021386 carbon form Inorganic materials 0.000 claims description 3
- 239000006210 lotion Substances 0.000 claims description 3
- 239000002674 ointment Substances 0.000 claims description 3
- 230000003287 optical effect Effects 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 230000010118 platelet activation Effects 0.000 claims description 3
- 208000030090 Acute Disease Diseases 0.000 claims description 2
- 201000011374 Alagille syndrome Diseases 0.000 claims description 2
- 208000022309 Alcoholic Liver disease Diseases 0.000 claims description 2
- 208000024985 Alport syndrome Diseases 0.000 claims description 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 2
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 2
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims description 2
- 208000023328 Basedow disease Diseases 0.000 claims description 2
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims description 2
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims description 2
- 206010008609 Cholangitis sclerosing Diseases 0.000 claims description 2
- 206010008635 Cholestasis Diseases 0.000 claims description 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 2
- 206010010317 Congenital absence of bile ducts Diseases 0.000 claims description 2
- 102000012437 Copper-Transporting ATPases Human genes 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 2
- 206010012289 Dementia Diseases 0.000 claims description 2
- 201000004624 Dermatitis Diseases 0.000 claims description 2
- 206010014561 Emphysema Diseases 0.000 claims description 2
- 206010048554 Endothelial dysfunction Diseases 0.000 claims description 2
- 208000024720 Fabry Disease Diseases 0.000 claims description 2
- 208000001640 Fibromyalgia Diseases 0.000 claims description 2
- 208000024412 Friedreich ataxia Diseases 0.000 claims description 2
- 208000027472 Galactosemias Diseases 0.000 claims description 2
- 208000009139 Gilbert Disease Diseases 0.000 claims description 2
- 208000022412 Gilbert syndrome Diseases 0.000 claims description 2
- 206010018374 Glomerulonephritis minimal lesion Diseases 0.000 claims description 2
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims description 2
- 208000015023 Graves' disease Diseases 0.000 claims description 2
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims description 2
- 206010019280 Heart failures Diseases 0.000 claims description 2
- 208000018565 Hemochromatosis Diseases 0.000 claims description 2
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims description 2
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 claims description 2
- 206010019851 Hepatotoxicity Diseases 0.000 claims description 2
- 208000023105 Huntington disease Diseases 0.000 claims description 2
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims description 2
- 208000000913 Kidney Calculi Diseases 0.000 claims description 2
- 208000009829 Lewy Body Disease Diseases 0.000 claims description 2
- 201000002832 Lewy body dementia Diseases 0.000 claims description 2
- 208000004883 Lipoid Nephrosis Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 2
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims description 2
- 208000009525 Myocarditis Diseases 0.000 claims description 2
- 206010029148 Nephrolithiasis Diseases 0.000 claims description 2
- 206010029164 Nephrotic syndrome Diseases 0.000 claims description 2
- 206010029240 Neuritis Diseases 0.000 claims description 2
- 206010034277 Pemphigoid Diseases 0.000 claims description 2
- 241000721454 Pemphigus Species 0.000 claims description 2
- 208000031845 Pernicious anaemia Diseases 0.000 claims description 2
- 206010035664 Pneumonia Diseases 0.000 claims description 2
- 241000097929 Porphyria Species 0.000 claims description 2
- 208000010642 Porphyrias Diseases 0.000 claims description 2
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 2
- 208000010378 Pulmonary Embolism Diseases 0.000 claims description 2
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims description 2
- 206010037394 Pulmonary haemorrhage Diseases 0.000 claims description 2
- 206010037423 Pulmonary oedema Diseases 0.000 claims description 2
- 201000007981 Reye syndrome Diseases 0.000 claims description 2
- 206010039710 Scleroderma Diseases 0.000 claims description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 2
- 201000009594 Systemic Scleroderma Diseases 0.000 claims description 2
- 206010042953 Systemic sclerosis Diseases 0.000 claims description 2
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims description 2
- 208000007536 Thrombosis Diseases 0.000 claims description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 2
- 206010046851 Uveitis Diseases 0.000 claims description 2
- 206010047642 Vitiligo Diseases 0.000 claims description 2
- 208000018839 Wilson disease Diseases 0.000 claims description 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims description 2
- 206010069351 acute lung injury Diseases 0.000 claims description 2
- 208000004631 alopecia areata Diseases 0.000 claims description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims description 2
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims description 2
- 201000005271 biliary atresia Diseases 0.000 claims description 2
- 206010006451 bronchitis Diseases 0.000 claims description 2
- 230000009787 cardiac fibrosis Effects 0.000 claims description 2
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 2
- 201000001883 cholelithiasis Diseases 0.000 claims description 2
- 231100000359 cholestasis Toxicity 0.000 claims description 2
- 230000007870 cholestasis Effects 0.000 claims description 2
- 230000007882 cirrhosis Effects 0.000 claims description 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 2
- 206010009887 colitis Diseases 0.000 claims description 2
- 239000000084 colloidal system Substances 0.000 claims description 2
- 208000029078 coronary artery disease Diseases 0.000 claims description 2
- 201000001981 dermatomyositis Diseases 0.000 claims description 2
- 239000006185 dispersion Substances 0.000 claims description 2
- 208000007784 diverticulitis Diseases 0.000 claims description 2
- 239000003221 ear drop Substances 0.000 claims description 2
- 230000008694 endothelial dysfunction Effects 0.000 claims description 2
- 239000003889 eye drop Substances 0.000 claims description 2
- 208000006275 fascioliasis Diseases 0.000 claims description 2
- 230000004761 fibrosis Effects 0.000 claims description 2
- 230000003176 fibrotic effect Effects 0.000 claims description 2
- 201000005206 focal segmental glomerulosclerosis Diseases 0.000 claims description 2
- 231100000854 focal segmental glomerulosclerosis Toxicity 0.000 claims description 2
- 208000001130 gallstones Diseases 0.000 claims description 2
- 208000006454 hepatitis Diseases 0.000 claims description 2
- 231100000283 hepatitis Toxicity 0.000 claims description 2
- 231100000304 hepatotoxicity Toxicity 0.000 claims description 2
- 230000007686 hepatotoxicity Effects 0.000 claims description 2
- 208000003215 hereditary nephritis Diseases 0.000 claims description 2
- 208000037906 ischaemic injury Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 206010025135 lupus erythematosus Diseases 0.000 claims description 2
- 206010028417 myasthenia gravis Diseases 0.000 claims description 2
- 229940097496 nasal spray Drugs 0.000 claims description 2
- 239000007922 nasal spray Substances 0.000 claims description 2
- 201000008383 nephritis Diseases 0.000 claims description 2
- 230000016273 neuron death Effects 0.000 claims description 2
- 201000008482 osteoarthritis Diseases 0.000 claims description 2
- 229960005489 paracetamol Drugs 0.000 claims description 2
- 208000030613 peripheral artery disease Diseases 0.000 claims description 2
- 201000006292 polyarteritis nodosa Diseases 0.000 claims description 2
- 208000005987 polymyositis Diseases 0.000 claims description 2
- 201000000742 primary sclerosing cholangitis Diseases 0.000 claims description 2
- 208000005333 pulmonary edema Diseases 0.000 claims description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 claims description 2
- 208000023504 respiratory system disease Diseases 0.000 claims description 2
- 201000000306 sarcoidosis Diseases 0.000 claims description 2
- 208000010157 sclerosing cholangitis Diseases 0.000 claims description 2
- 230000028327 secretion Effects 0.000 claims description 2
- 208000002320 spinal muscular atrophy Diseases 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- 230000009885 systemic effect Effects 0.000 claims description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 2
- DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 claims description 2
- 206010043778 thyroiditis Diseases 0.000 claims description 2
- 201000011296 tyrosinemia Diseases 0.000 claims description 2
- 238000010253 intravenous injection Methods 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 abstract description 18
- 238000003786 synthesis reaction Methods 0.000 abstract description 17
- 239000003814 drug Substances 0.000 abstract description 15
- 108010075639 MAP Kinase Kinase Kinase 5 Proteins 0.000 abstract description 8
- 229940124597 therapeutic agent Drugs 0.000 abstract description 4
- 239000003112 inhibitor Substances 0.000 abstract description 3
- 230000004913 activation Effects 0.000 abstract description 2
- 230000005784 autoimmunity Effects 0.000 abstract description 2
- 230000002526 effect on cardiovascular system Effects 0.000 abstract description 2
- 230000002757 inflammatory effect Effects 0.000 abstract description 2
- 208000030159 metabolic disease Diseases 0.000 abstract description 2
- 230000000626 neurodegenerative effect Effects 0.000 abstract description 2
- 230000011664 signaling Effects 0.000 abstract description 2
- 102000011853 MAP Kinase Kinase Kinase 5 Human genes 0.000 abstract 2
- 239000000203 mixture Substances 0.000 description 120
- 125000004438 haloalkoxy group Chemical group 0.000 description 81
- -1 -CN radical Chemical class 0.000 description 80
- 229910052799 carbon Inorganic materials 0.000 description 80
- 125000005415 substituted alkoxy group Chemical group 0.000 description 76
- 229910001868 water Inorganic materials 0.000 description 76
- 125000000623 heterocyclic group Chemical group 0.000 description 67
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 58
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 49
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 49
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 47
- 235000002639 sodium chloride Nutrition 0.000 description 47
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 46
- 239000007787 solid Substances 0.000 description 45
- 229910002092 carbon dioxide Inorganic materials 0.000 description 42
- 239000000047 product Substances 0.000 description 39
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical group CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 34
- 125000004432 carbon atom Chemical group C* 0.000 description 33
- 239000002904 solvent Substances 0.000 description 30
- 239000011541 reaction mixture Substances 0.000 description 27
- 125000003118 aryl group Chemical group 0.000 description 26
- 125000000304 alkynyl group Chemical group 0.000 description 23
- 235000019439 ethyl acetate Nutrition 0.000 description 23
- 230000002829 reductive effect Effects 0.000 description 23
- 239000000651 prodrug Substances 0.000 description 21
- 229940002612 prodrug Drugs 0.000 description 21
- 150000001721 carbon Chemical group 0.000 description 20
- 125000004043 oxo group Chemical group O=* 0.000 description 19
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 18
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
- 239000003795 chemical substances by application Substances 0.000 description 17
- 239000003480 eluent Substances 0.000 description 17
- 239000011734 sodium Substances 0.000 description 17
- 125000001424 substituent group Chemical group 0.000 description 17
- 238000002953 preparative HPLC Methods 0.000 description 16
- 238000005160 1H NMR spectroscopy Methods 0.000 description 15
- 239000012044 organic layer Substances 0.000 description 15
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 14
- 238000009472 formulation Methods 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 13
- 125000003545 alkoxy group Chemical group 0.000 description 12
- 239000012267 brine Substances 0.000 description 12
- 239000012043 crude product Substances 0.000 description 12
- 239000000706 filtrate Substances 0.000 description 12
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 12
- 239000004480 active ingredient Substances 0.000 description 11
- 125000004122 cyclic group Chemical group 0.000 description 11
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 11
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 10
- 239000002253 acid Substances 0.000 description 10
- 229910000024 caesium carbonate Inorganic materials 0.000 description 10
- 239000000969 carrier Substances 0.000 description 10
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 10
- 238000010898 silica gel chromatography Methods 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 239000000499 gel Substances 0.000 description 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 239000003921 oil Substances 0.000 description 8
- 235000019198 oils Nutrition 0.000 description 8
- 239000003208 petroleum Substances 0.000 description 8
- 150000003254 radicals Chemical class 0.000 description 8
- 229910052705 radium Inorganic materials 0.000 description 8
- 239000003381 stabilizer Substances 0.000 description 8
- 239000000872 buffer Substances 0.000 description 7
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 7
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 6
- 102100033127 Mitogen-activated protein kinase kinase kinase 5 Human genes 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- 125000002947 alkylene group Chemical group 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 6
- 239000012074 organic phase Substances 0.000 description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 6
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000003755 preservative agent Substances 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 235000011121 sodium hydroxide Nutrition 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 108010010803 Gelatin Proteins 0.000 description 5
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 5
- 239000004698 Polyethylene Substances 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 125000003342 alkenyl group Chemical group 0.000 description 5
- 150000005840 aryl radicals Chemical class 0.000 description 5
- 230000004071 biological effect Effects 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 238000003818 flash chromatography Methods 0.000 description 5
- 229920000159 gelatin Polymers 0.000 description 5
- 239000008273 gelatin Substances 0.000 description 5
- 235000019322 gelatine Nutrition 0.000 description 5
- 235000011852 gelatine desserts Nutrition 0.000 description 5
- 150000002430 hydrocarbons Chemical class 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 125000002950 monocyclic group Chemical group 0.000 description 5
- 150000002825 nitriles Chemical class 0.000 description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
- 229910000029 sodium carbonate Inorganic materials 0.000 description 5
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 5
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 239000000443 aerosol Substances 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- 239000000945 filler Substances 0.000 description 4
- 125000004474 heteroalkylene group Chemical group 0.000 description 4
- 239000001301 oxygen Chemical group 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical group OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- 229910019213 POCl3 Inorganic materials 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 229920002125 Sokalan® Polymers 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 125000003282 alkyl amino group Chemical group 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 235000010323 ascorbic acid Nutrition 0.000 description 3
- 239000011668 ascorbic acid Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 125000005605 benzo group Chemical group 0.000 description 3
- 125000002619 bicyclic group Chemical group 0.000 description 3
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 239000008298 dragée Substances 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 235000011167 hydrochloric acid Nutrition 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 229940098779 methanesulfonic acid Drugs 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- XBXCNNQPRYLIDE-UHFFFAOYSA-M n-tert-butylcarbamate Chemical compound CC(C)(C)NC([O-])=O XBXCNNQPRYLIDE-UHFFFAOYSA-M 0.000 description 3
- 239000006186 oral dosage form Substances 0.000 description 3
- 150000007530 organic bases Chemical class 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 235000011007 phosphoric acid Nutrition 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 239000011593 sulfur Chemical group 0.000 description 3
- 125000004434 sulfur atom Chemical group 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 125000001544 thienyl group Chemical group 0.000 description 3
- 230000037317 transdermal delivery Effects 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- GBLRQXKSCRCLBZ-YVQAASCFSA-N (1R,2S,1'R,2'S)-doxacurium Chemical compound COC1=C(OC)C(OC)=CC(C[C@H]2[N@+](CCC3=C2C(=C(OC)C(OC)=C3)OC)(C)CCCOC(=O)CCC(=O)OCCC[N@@+]2(C)[C@@H](C3=C(OC)C(OC)=C(OC)C=C3CC2)CC=2C=C(OC)C(OC)=C(OC)C=2)=C1 GBLRQXKSCRCLBZ-YVQAASCFSA-N 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Chemical compound C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 2
- QMNUDYFKZYBWQX-UHFFFAOYSA-N 1H-quinazolin-4-one Chemical compound C1=CC=C2C(=O)N=CNC2=C1 QMNUDYFKZYBWQX-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 2
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 241000792859 Enema Species 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 239000007821 HATU Substances 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
- 150000001204 N-oxides Chemical class 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 229910006124 SOCl2 Inorganic materials 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 125000003636 chemical group Chemical group 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 229960002086 dextran Drugs 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- OSVXSBDYLRYLIG-UHFFFAOYSA-N dioxidochlorine(.) Chemical compound O=Cl=O OSVXSBDYLRYLIG-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000007920 enema Substances 0.000 description 2
- 229940079360 enema for constipation Drugs 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000010685 fatty oil Substances 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 230000037353 metabolic pathway Effects 0.000 description 2
- 238000006241 metabolic reaction Methods 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- TXXHDPDFNKHHGW-UHFFFAOYSA-N muconic acid Chemical group OC(=O)C=CC=CC(O)=O TXXHDPDFNKHHGW-UHFFFAOYSA-N 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000003791 organic solvent mixture Substances 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Chemical group OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 125000002098 pyridazinyl group Chemical group 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 2
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 238000009736 wetting Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 2
- 229910052727 yttrium Inorganic materials 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- 125000005988 1,1-dioxo-thiomorpholinyl group Chemical group 0.000 description 1
- AEBWATHAIVJLTA-UHFFFAOYSA-N 1,2,3,3a,4,5,6,6a-octahydropentalene Chemical compound C1CCC2CCCC21 AEBWATHAIVJLTA-UHFFFAOYSA-N 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- 125000005871 1,3-benzodioxolyl group Chemical group 0.000 description 1
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
- NLMDJJTUQPXZFG-UHFFFAOYSA-N 1,4,10,13-tetraoxa-7,16-diazacyclooctadecane Chemical compound C1COCCOCCNCCOCCOCCN1 NLMDJJTUQPXZFG-UHFFFAOYSA-N 0.000 description 1
- XKEHLMZHBXCJGZ-UHFFFAOYSA-N 1,4,7,10,13,16,19-heptaoxacyclohenicosane Chemical compound C1COCCOCCOCCOCCOCCOCCO1 XKEHLMZHBXCJGZ-UHFFFAOYSA-N 0.000 description 1
- JBCHLRJXUSEBMN-UHFFFAOYSA-N 1,4,7,10,13,16-hexaoxa-19-azacyclohenicosane Chemical compound C1COCCOCCOCCOCCOCCOCCN1 JBCHLRJXUSEBMN-UHFFFAOYSA-N 0.000 description 1
- NBXKUSNBCPPKRA-UHFFFAOYSA-N 1,4,7,10,13-pentaoxa-16-azacyclooctadecane Chemical compound C1COCCOCCOCCOCCOCCN1 NBXKUSNBCPPKRA-UHFFFAOYSA-N 0.000 description 1
- 125000005877 1,4-benzodioxanyl group Chemical group 0.000 description 1
- HVCFCNAITDHQFX-UHFFFAOYSA-N 1-cyclopropylethanone Chemical compound CC(=O)C1CC1 HVCFCNAITDHQFX-UHFFFAOYSA-N 0.000 description 1
- AMMPLVWPWSYRDR-UHFFFAOYSA-N 1-methylbicyclo[2.2.2]oct-2-ene-4-carboxylic acid Chemical compound C1CC2(C(O)=O)CCC1(C)C=C2 AMMPLVWPWSYRDR-UHFFFAOYSA-N 0.000 description 1
- 125000005987 1-oxo-thiomorpholinyl group Chemical group 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- XQQZRZQVBFHBHL-UHFFFAOYSA-N 12-crown-4 Chemical compound C1COCCOCCOCCO1 XQQZRZQVBFHBHL-UHFFFAOYSA-N 0.000 description 1
- VFTFKUDGYRBSAL-UHFFFAOYSA-N 15-crown-5 Chemical compound C1COCCOCCOCCOCCO1 VFTFKUDGYRBSAL-UHFFFAOYSA-N 0.000 description 1
- XEZNGIUYQVAUSS-UHFFFAOYSA-N 18-crown-6 Chemical compound C1COCCOCCOCCOCCOCCO1 XEZNGIUYQVAUSS-UHFFFAOYSA-N 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- HNLXNOZHXNSSPN-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(OCCOCCOCCOCCOCCOCCOCCO)C=C1 HNLXNOZHXNSSPN-UHFFFAOYSA-N 0.000 description 1
- WCCCDMWRBVVYCQ-UHFFFAOYSA-N 2-bromo-1-cyclopropylethanone Chemical compound BrCC(=O)C1CC1 WCCCDMWRBVVYCQ-UHFFFAOYSA-N 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- UPHOPMSGKZNELG-UHFFFAOYSA-N 2-hydroxynaphthalene-1-carboxylic acid Chemical group C1=CC=C2C(C(=O)O)=C(O)C=CC2=C1 UPHOPMSGKZNELG-UHFFFAOYSA-N 0.000 description 1
- HZLCGUXUOFWCCN-UHFFFAOYSA-N 2-hydroxynonadecane-1,2,3-tricarboxylic acid Chemical compound CCCCCCCCCCCCCCCCC(C(O)=O)C(O)(C(O)=O)CC(O)=O HZLCGUXUOFWCCN-UHFFFAOYSA-N 0.000 description 1
- 125000004918 2-methyl-2-pentyl group Chemical group CC(C)(CCC)* 0.000 description 1
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 1
- 125000006088 2-oxoazepinyl group Chemical group 0.000 description 1
- 125000004638 2-oxopiperazinyl group Chemical group O=C1N(CCNC1)* 0.000 description 1
- 125000004637 2-oxopiperidinyl group Chemical group O=C1N(CCCC1)* 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical compound C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 description 1
- XLZYKTYMLBOINK-UHFFFAOYSA-N 3-(4-hydroxybenzoyl)benzoic acid Chemical compound OC(=O)C1=CC=CC(C(=O)C=2C=CC(O)=CC=2)=C1 XLZYKTYMLBOINK-UHFFFAOYSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
- 125000004919 3-methyl-2-pentyl group Chemical group CC(C(C)*)CC 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- 125000004920 4-methyl-2-pentyl group Chemical group CC(CC(C)*)C 0.000 description 1
- 125000005986 4-piperidonyl group Chemical group 0.000 description 1
- QWKFFKNJNIXOOF-UHFFFAOYSA-N 5-(4-cyclopropylimidazol-1-yl)-2-fluoro-4-methyl-N-[6-(2-propan-2-ylpyrazol-3-yl)pyridin-2-yl]benzamide Chemical compound C1(CC1)C=1N=CN(C=1)C=1C(=CC(=C(C(=O)NC2=NC(=CC=C2)C2=CC=NN2C(C)C)C=1)F)C QWKFFKNJNIXOOF-UHFFFAOYSA-N 0.000 description 1
- XOTARYQIYJRYGW-UHFFFAOYSA-N 5-(4-cyclopropylimidazol-1-yl)-2-fluoro-4-methyl-N-[6-(3-propan-2-yl-1,2-oxazol-4-yl)pyridin-2-yl]benzamide Chemical compound C1(CC1)C=1N=CN(C=1)C=1C(=CC(=C(C(=O)NC2=NC(=CC=C2)C=2C(=NOC=2)C(C)C)C=1)F)C XOTARYQIYJRYGW-UHFFFAOYSA-N 0.000 description 1
- DRZHGLUXGOCNHW-UHFFFAOYSA-N 5-(4-cyclopropylimidazol-1-yl)-2-fluoro-4-methyl-N-[6-(5-propan-2-yltetrazol-1-yl)pyridin-2-yl]benzamide Chemical compound C1(CC1)C=1N=CN(C=1)C=1C(=CC(=C(C(=O)NC2=NC(=CC=C2)N2N=NN=C2C(C)C)C=1)F)C DRZHGLUXGOCNHW-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
- 239000004155 Chlorine dioxide Substances 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Chemical group OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Chemical group OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 229920001499 Heparinoid Polymers 0.000 description 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 1
- 102000001399 Kallikrein Human genes 0.000 description 1
- 108060005987 Kallikrein Proteins 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical group OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 244000062730 Melissa officinalis Species 0.000 description 1
- 235000010654 Melissa officinalis Nutrition 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-N Metaphosphoric acid Chemical compound OP(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- TXXHDPDFNKHHGW-CCAGOZQPSA-N Muconic acid Chemical group OC(=O)\C=C/C=C\C(O)=O TXXHDPDFNKHHGW-CCAGOZQPSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- 229910017852 NH2NH2 Inorganic materials 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229920001774 Perfluoroether Polymers 0.000 description 1
- 229920000148 Polycarbophil calcium Polymers 0.000 description 1
- 239000004721 Polyphenylene oxide Chemical group 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical group [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229920002807 Thiomer Polymers 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- FIULGFJIHJJXMT-UHFFFAOYSA-N [C]1[N]C=CC=C1 Chemical class [C]1[N]C=CC=C1 FIULGFJIHJJXMT-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- XPOLVIIHTDKJRY-UHFFFAOYSA-N acetic acid;methanimidamide Chemical compound NC=N.CC(O)=O XPOLVIIHTDKJRY-UHFFFAOYSA-N 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 231100000439 acute liver injury Toxicity 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229940040563 agaric acid Drugs 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000005107 alkyl diaryl silyl group Chemical group 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940027983 antiseptic and disinfectant quaternary ammonium compound Drugs 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 125000002785 azepinyl group Chemical group 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000005870 benzindolyl group Chemical group 0.000 description 1
- 125000005873 benzo[d]thiazolyl group Chemical group 0.000 description 1
- 125000000928 benzodioxinyl group Chemical group O1C(=COC2=C1C=CC=C2)* 0.000 description 1
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000005878 benzonaphthofuranyl group Chemical group 0.000 description 1
- 125000005872 benzooxazolyl group Chemical group 0.000 description 1
- 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 125000005874 benzothiadiazolyl group Chemical group 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- JSMRMEYFZHIPJV-UHFFFAOYSA-N bicyclo[2.1.1]hexane Chemical compound C1C2CC1CC2 JSMRMEYFZHIPJV-UHFFFAOYSA-N 0.000 description 1
- GPRLTFBKWDERLU-UHFFFAOYSA-N bicyclo[2.2.2]octane Chemical compound C1CC2CCC1CC2 GPRLTFBKWDERLU-UHFFFAOYSA-N 0.000 description 1
- GNTFBMAGLFYMMZ-UHFFFAOYSA-N bicyclo[3.2.2]nonane Chemical compound C1CC2CCC1CCC2 GNTFBMAGLFYMMZ-UHFFFAOYSA-N 0.000 description 1
- WMRPOCDOMSNXCQ-UHFFFAOYSA-N bicyclo[3.3.2]decane Chemical compound C1CCC2CCCC1CC2 WMRPOCDOMSNXCQ-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 235000010338 boric acid Nutrition 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 125000004452 carbocyclyl group Chemical group 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- AOGYCOYQMAVAFD-UHFFFAOYSA-M carbonochloridate Chemical compound [O-]C(Cl)=O AOGYCOYQMAVAFD-UHFFFAOYSA-M 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- NFCRBQADEGXVDL-UHFFFAOYSA-M cetylpyridinium chloride monohydrate Chemical compound O.[Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 NFCRBQADEGXVDL-UHFFFAOYSA-M 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000019398 chlorine dioxide Nutrition 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- NNBZCPXTIHJBJL-AOOOYVTPSA-N cis-decalin Chemical compound C1CCC[C@H]2CCCC[C@H]21 NNBZCPXTIHJBJL-AOOOYVTPSA-N 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000005507 decahydroisoquinolyl group Chemical group 0.000 description 1
- 125000004855 decalinyl group Chemical group C1(CCCC2CCCCC12)* 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 125000005265 dialkylamine group Chemical group 0.000 description 1
- 125000005105 dialkylarylsilyl group Chemical group 0.000 description 1
- 125000005266 diarylamine group Chemical group 0.000 description 1
- 125000005509 dibenzothiophenyl group Chemical group 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 1
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 125000005879 dioxolanyl group Chemical group 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 125000005883 dithianyl group Chemical group 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical group CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000003118 drug derivative Substances 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 150000002081 enamines Chemical class 0.000 description 1
- 238000003821 enantio-separation Methods 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 125000003844 furanonyl group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000000174 gluconic acid Chemical group 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Chemical group 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 208000027096 gram-negative bacterial infections Diseases 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 239000002554 heparinoid Substances 0.000 description 1
- 229940025770 heparinoids Drugs 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 150000007857 hydrazones Chemical group 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical group [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- BNRNAKTVFSZAFA-UHFFFAOYSA-N hydrindane Chemical compound C1CCCC2CCCC21 BNRNAKTVFSZAFA-UHFFFAOYSA-N 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 150000003949 imides Chemical class 0.000 description 1
- 150000002466 imines Chemical group 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000003965 isoxazolidinyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- REPVNSJSTLRQEQ-UHFFFAOYSA-N n,n-dimethylacetamide;n,n-dimethylformamide Chemical compound CN(C)C=O.CN(C)C(C)=O REPVNSJSTLRQEQ-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- ZHCAAFJSYLFLPX-UHFFFAOYSA-N nitrocyclohexatriene Chemical group [O-][N+](=O)C1=CC=C=C[CH]1 ZHCAAFJSYLFLPX-UHFFFAOYSA-N 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- UMRZSTCPUPJPOJ-KNVOCYPGSA-N norbornane Chemical compound C1C[C@H]2CC[C@@H]1C2 UMRZSTCPUPJPOJ-KNVOCYPGSA-N 0.000 description 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical group CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Chemical group CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 125000005060 octahydroindolyl group Chemical group N1(CCC2CCCCC12)* 0.000 description 1
- 125000005061 octahydroisoindolyl group Chemical group C1(NCC2CCCCC12)* 0.000 description 1
- 229920004905 octoxynol-10 Polymers 0.000 description 1
- 229920004914 octoxynol-40 Polymers 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008816 organ damage Effects 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- CQDAMYNQINDRQC-UHFFFAOYSA-N oxatriazole Chemical compound C1=NN=NO1 CQDAMYNQINDRQC-UHFFFAOYSA-N 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 150000002923 oximes Chemical group 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- 125000005476 oxopyrrolidinyl group Chemical group 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 229940043138 pentosan polysulfate Drugs 0.000 description 1
- 125000005010 perfluoroalkyl group Chemical group 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229950005134 polycarbophil Drugs 0.000 description 1
- 229920000570 polyether Chemical group 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 229920000151 polyglycol Polymers 0.000 description 1
- 239000010695 polyglycol Substances 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- WSHYKIAQCMIPTB-UHFFFAOYSA-M potassium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate Chemical compound [K+].[O-]C=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 WSHYKIAQCMIPTB-UHFFFAOYSA-M 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 230000029983 protein stabilization Effects 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 230000000541 pulsatile effect Effects 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- USPWKWBDZOARPV-UHFFFAOYSA-N pyrazolidine Chemical compound C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- DNXIASIHZYFFRO-UHFFFAOYSA-N pyrazoline Chemical compound C1CN=NC1 DNXIASIHZYFFRO-UHFFFAOYSA-N 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- ILVXOBCQQYKLDS-UHFFFAOYSA-N pyridine N-oxide Chemical compound [O-][N+]1=CC=CC=C1 ILVXOBCQQYKLDS-UHFFFAOYSA-N 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- ZVJHJDDKYZXRJI-UHFFFAOYSA-N pyrroline Natural products C1CC=NC1 ZVJHJDDKYZXRJI-UHFFFAOYSA-N 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- MCJGNVYPOGVAJF-UHFFFAOYSA-N quinolin-8-ol Chemical compound C1=CN=C2C(O)=CC=CC2=C1 MCJGNVYPOGVAJF-UHFFFAOYSA-N 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229910052703 rhodium Inorganic materials 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008117 stearic acid Chemical group 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 238000003419 tautomerization reaction Methods 0.000 description 1
- LFKDJXLFVYVEFG-UHFFFAOYSA-N tert-butyl carbamate Chemical compound CC(C)(C)OC(N)=O LFKDJXLFVYVEFG-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- YGNGABUJMXJPIJ-UHFFFAOYSA-N thiatriazole Chemical compound C1=NN=NS1 YGNGABUJMXJPIJ-UHFFFAOYSA-N 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 125000004001 thioalkyl group Chemical group 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 229960004906 thiomersal Drugs 0.000 description 1
- DHCDFWKWKRSZHF-UHFFFAOYSA-L thiosulfate(2-) Chemical compound [O-]S([S-])(=O)=O DHCDFWKWKRSZHF-UHFFFAOYSA-L 0.000 description 1
- 125000000464 thioxo group Chemical group S=* 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 239000012443 tonicity enhancing agent Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- NNBZCPXTIHJBJL-UHFFFAOYSA-N trans-decahydronaphthalene Natural products C1CCCC2CCCCC21 NNBZCPXTIHJBJL-UHFFFAOYSA-N 0.000 description 1
- NNBZCPXTIHJBJL-MGCOHNPYSA-N trans-decalin Chemical compound C1CCC[C@@H]2CCCC[C@H]21 NNBZCPXTIHJBJL-MGCOHNPYSA-N 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 125000005208 trialkylammonium group Chemical group 0.000 description 1
- 125000004665 trialkylsilyl group Chemical group 0.000 description 1
- 125000005106 triarylsilyl group Chemical group 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 125000005455 trithianyl group Chemical group 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 229920003176 water-insoluble polymer Polymers 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Definitions
- Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds to treat, prevent or diagnose diseases, disorders or conditions associated with apoptosis signal- regulating kinase 1 inhibitors.
- Apoptosis signal-regulating kinase 1 (ASK1) activation and signaling have been reported to play an important role in a broad range of diseases including neurodegenerative, cardiovascular, inflammatory, autoimmunity and metabolic disorders.
- ASK1 has been implicated in mediating organ damage following ischemia and reperfusion of the heart, brain and kidney.
- ASK1 has also been identified as an important signaling pathway in non-alcoholic steatohepatitis (NASH), a type of non-alcoholic fatty liver disease (NAFLD), chronic obstructive pulmonary disease (COPD), hypertension, multiple sclerosis, Alzheimer's disease, Parkinson's disease, platelet activation, Sickle cell disease, kidney disease and oxidative stress. Therefore, therapeutic agents that function as inhibitors of ASK1 have potential to remedy or improve the lives of patients suffering from such conditions.
- NASH non-alcoholic steatohepatitis
- NAFLD non-alcoholic fatty liver disease
- COPD chronic obstructive pulmonary disease
- Y 2 is NR Y3 ;
- R 63 is O or S
- R Y3 is hydrogen or optionally substituted alkyl
- R 64 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted heteroalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl;
- R 63 and R 64 are taken together with the atoms to which they are attached to form an optionally substituted heterocycloalkyl or an optionally substituted heteroaryl;
- R 65 is optionally substituted fused bicyclic heterocycloalkyl or optionally substituted fused bicyclic heteroaryl;
- each R 67 and R 68 is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted heteroalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl;
- R 67 and R 68 together with the nitrogen atom to which they are attached, form an optionally substituted heterocycloalkyl or optionally substituted heteroaryl;
- R 69 is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted heteroalkyl, optionally substituted cycloalkyl, optionally substituted
- heterocycloalkyl optionally substituted aryl, or optionally substituted heteroaryl
- s3 is 0-3.
- Amino refers to the -NH 2 radical.
- Niro refers to the -N0 2 radical.
- Alkoxy refers to a radical of the formula -OR j where R j is an alkyl radical as defined. Unless stated otherwise specifically in the specification, an alkoxy group may be optionally substituted as described below.
- Alkyl refers to an optionally substituted straight-chain, or optionally substituted branched- chain saturated hydrocarbon monoradical having from one to about ten carbon atoms, more preferably one to six carbon atoms, wherein a sp3 -hybridized carbon of the alkyl residue is attached to the rest of the molecule by a single bond.
- Examples include, but are not limited to methyl, ethyl, n-propyl, isopropyl, 2- methyl- 1 -propyl, 2-methyl-2-propyl, 2-methyl-l -butyl, 3 -methyl- 1 -butyl, 2-methyl-3-butyl, 2,2- dimethyl-l -propyl, 2-methyl-l-pentyl, 3-methyl-l-pentyl, 4-methyl-l-pentyl, 2-methyl-2-pentyl, 3- methyl-2-pentyl, 4-methyl-2-pentyl, 2,2-dimethyl-l -butyl, 3,3-dimethyl-l-butyl, 2-ethyl-l -butyl, n-butyl, isobutyl, sec-butyl, t-butyl, n-pentyl, isopentyl, neopentyl, tert-amyl and hexyl, and longer alky
- -6 alkyl” means that the alkyl group may consist of 1 carbon atom, 2 carbon atoms, 3 carbon atoms, 4 carbon atoms, 5 carbon atoms or 6 carbon atoms, although the present definition also covers the occurrence of the term "alkyl” where no numerical range is designated.
- an alkyl group may be optionally substituted as described below, for example, with oxo, amino, nitrile, nitro, hydroxyl, alkyl, alkylene, alkynyl, alkoxy, aryl, cycloalkyl, heterocyclyl, heteroaryl, and the like.
- Alkenyl refers to an optionally substituted straight-chain, or optionally substituted branched- chain hydrocarbon monoradical having one or more carbon-carbon double-bonds and having from two to about ten carbon atoms, more preferably two to about six carbon atoms, wherein a sp2 -hybridized carbon of the alkenyl residue is attached to the rest of the molecule by a single bond.
- the group may be in either the cis or trans conformation about the double bond(s), and should be understood to include both isomers.
- a numerical range such as "C 2 -C 6 alkenyl” or "C 2 - 6 alkenyl”, means that the alkenyl group may consist of 2 carbon atoms, 3 carbon atoms, 4 carbon atoms, 5 carbon atoms or 6 carbon atoms, although the present definition also covers the occurrence of the term "alkenyl” where no numerical range is designated.
- an alkenyl group may be optionally substituted as described below.
- Alkynyl refers to an optionally substituted straight-chain or optionally substituted branched- chain hydrocarbon monoradical having one or more carbon-carbon triple-bonds and having from two to about ten carbon atoms, more preferably from two to about six carbon atoms. Examples include, but are not limited to ethynyl, 2-propynyl, 2-butynyl, 1,3-butadiynyl and the like.
- a numerical range such as "C 2 -C 6 alkynyl” or "C 2 - 6 alkynyl” means that the alkynyl group may consist of 2 carbon atoms, 3 carbon atoms, 4 carbon atoms, 5 carbon atoms or 6 carbon atoms, although the present definition also covers the occurrence of the term "alkynyl” where no numerical range is designated. Unless stated otherwise specifically in the specification, an alkynyl group may be optionally substituted as described below.
- alkylene or "alkylene chain” refers to a straight or branched divalent hydrocarbon chain. Unless stated otherwise specifically in the specification, an alkylene group may be optionally substituted as described below.
- Heteroalkyl or “heteroalkylene” refers to an alkyl radical as described above where one or more carbon atoms of the alkyl is replaced with a O, N or S atom.
- Heteroalkylene or “heteroalkylene chain” refers to a straight or branched divalent heteroalkyl chain linking the rest of the molecule to a radical group. Unless stated otherwise specifically in the specification, the heteroalkyl or heteroalkylene group may be optionally substituted as described below.
- Alkylamino refers to a radical of the formula -NHR or -NR where each R is, independently, an alkyl radical as defined above. Unless stated otherwise specifically in the specification, an alkylamino group may be optionally substituted as described below.
- Aryl refers to a radical derived from a hydrocarbon ring system comprising hydrogen, 6 to 30 carbon atoms and at least one aromatic ring.
- the aryl radical is a monocyclic, bicyclic, tricyclic or tetracyclic ring system, wherein at least one of the rings in the ring system is fully unsaturated, i.e., it contains a cyclic, delocalized (4n+2) ⁇ -electron system in accordance with the Hiickel theory.
- the aryl radical may include fused or bridged ring systems.
- Aryl radicals include, but are not limited to, aryl radicals derived from the hydrocarbon ring systems of benzene, indane, indene, and naphthalene. Unless stated otherwise specifically in the specification, the term “aryl” or the prefix “ar-” (such as in “aralkyl”) is meant to include aryl radicals that are optionally substituted.
- Cycloalkyl or “carbocycle” or “carbocyclyl” refers to a stable, monocyclic or polycyclic carbocyclic ring, which may include fused or bridged ring systems, which is saturated or unsaturated.
- Representative cycloalkyls or carbocycles include, but are not limited to, cycloalkyls having from three to fifteen carbon atoms, from three to ten carbon atoms, from three to eight carbon atoms, from three to six carbon atoms, from three to five carbon atoms, or three to four carbon atoms.
- Monocyclic cycloalkyls or carbocycles include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, cycloheptyl, and cyclooctyl.
- Polycyclic cycloalkyls or carbocycles include, for example, adamantyl, norbornyl, decalinyl, bicyclo[3.3.0]octane, bicyclo[4.3.0]nonane, cis-decalin, trans-decalin,
- a cycloalkyl or carbocycle group may be optionally substituted.
- fused refers to any ring structure described herein which is fused to an existing ring structure.
- the fused ring is a heterocyclyl ring or a heteroaryl ring
- any carbon atom on the existing ring structure which becomes part of the fused heterocyclyl ring or the fused heteroaryl ring may be replaced with a nitrogen atom.
- Halo or "halogen” refers to bromo, chloro, fluoro or iodo.
- Haloalkyl refers to an alkyl radical, as defined above, that is substituted by one or more halo radicals, as defined above, e.g., trifluoromethyl, difluoromethyl, fluoromethyl, trichloromethyl,
- haloalkyl group may be optionally substituted.
- Haloalkoxy similarly refers to a radical of the formula -OR a where R a is a haloalkyl radical as defined. Unless stated otherwise specifically in the specification, a haloalkoxy group may be optionally substituted as described below.
- Perhalo or “perfluoro” refers to a moiety in which each hydrogen atom has been replaced by a halo atom or fluorine atom, respectively.
- Heterocycloalkyl or “heterocyclyl” or “heterocyclic ring” or “heterocycle” refers to a stable 3- to 24-membered non-aromatic ring radical comprising 2 to 23 carbon atoms and from one to 8 heteroatoms selected from the group consisting of nitrogen, oxygen, phosphorous and sulfur.
- the heterocyclyl radical may be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which may include fused or bridged ring systems; and the nitrogen, carbon or sulfur atoms in the heterocyclyl radical may be optionally oxidized; the nitrogen atom may be optionally quaternized; and the heterocyclyl radical may be partially or fully saturated.
- heterocyclyl radicals include, but are not limited to, azetidinyl, dioxolanyl, thienyl[l,3]dithianyl, decahydroisoquinolyl, imidazolinyl, imidazolidinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, oxazolidinyl, piperidinyl, piperazinyl, 4-piperidonyl, pyrrolidinyl, pyrazolidinyl, quinuclidinyl, thiazolidinyl, tetrahydrofuryl, trithianyl, tetrahydropyranyl, thiomorpholinyl, thiamorpholinyl
- heterocyclyl group may be optionally substituted.
- heterocycloalkyl also includes all ring forms of the carbohydrates, including but not limited to the monosaccharides, the disaccharides and the oligosaccharides. Unless otherwise noted, heterocycloalkyls have from 2 to 10 carbons in the ring.
- the number of carbon atoms in the heterocycloalkyl is not the same as the total number of atoms (including the heteroatoms) that make up the heterocycloalkyl (i.e. skeletal atoms of the heterocycloalkyl ring). Unless stated otherwise specifically in the specification, a heterocycloalkyl group may be optionally substituted.
- Heteroaryl refers to a radical derived from a 3- to 18-membered aromatic ring radical that comprises two to seventeen carbon atoms and from one to six heteroatoms selected from nitrogen, oxygen and sulfur.
- the heteroaryl radical is a monocyclic, bicyclic, tricyclic or tetracyclic ring system, wherein at least one of the rings in the ring system is fully unsaturated, i.e., it contains a cyclic, delocalized (4n+2) ⁇ -electron system in accordance with the Hiickel theory.
- Heteroaryl includes fused or bridged ring systems.
- the heteroatom(s) in the heteroaryl radical is optionally oxidized.
- heteroaryl is attached to the rest of the molecule through any atom of the ring(s).
- heteroaryls include, but are not limited to, azepinyl, acridinyl, benzimidazolyl, benzindolyl, 1,3-benzodioxolyl, benzofuranyl, benzooxazolyl, benzo[d]thiazolyl, benzothiadiazolyl, benzo[6][l,4]dioxepinyl, benzo[b][l,4]oxazinyl,
- All the above groups may be either substituted or unsubstituted.
- substituted as used herein means any of the above groups (e.g. alkyl, alkylene, alkoxy, aryl, cycloalkyl, haloalkyl, heterocyclyl and/or heteroaryl) may be further functionalized wherein at least one hydrogen atom is replaced by a bond to a non-hydrogen atom substituent.
- a substituted group may include one or more substituents selected from: halogen, oxo, amino, -CO 2 H, nitrile, nitro, hydroxyl, thiooxy, alkyl, alkylene, alkoxy, aryl, cycloalkyl, heterocyclyl, heteroaryl, dialkylamines, arylamines, alkylarylamines, diarylamines, trialkylammonium (-N + R 3 ), N-oxides, imides, and enamines; a silicon atom in groups such as trialkylsilyl groups, dialkylarylsilyl groups,
- alkyldiarylsilyl groups triarylsilyl groups, perfluoroalkyl or perfluoroalkoxy, for example,
- the substituent group one or more substituents selected from: halogen, oxo, amino, -CO 2 H, nitrile, hydroxyl, alkyl, haloalkyl, alkoxy, aryl, cycloalkyl, heterocyclyl, or heteroaryl.
- the substituent group one or more substituents selected from: halogen, amino, nitrile, hydroxyl, alkyl, haloalkyl, or alkoxy.
- “Substituted” also means any of the above groups in which one or more hydrogen atoms are replaced by a higher-order bond ⁇ e.g.
- a double- or triple-bond to a heteroatom such as oxygen in oxo, carbonyl, carboxyl, and ester groups; and nitrogen in groups such as imines, oximes, hydrazones, and nitriles.
- a heteroatom such as oxygen in oxo, carbonyl, carboxyl, and ester groups
- nitrogen in groups such as imines, oximes, hydrazones, and nitriles.
- R g and R h are the same or different and independently hydrogen, alkyl, alkoxy, alkylamino, thioalkyl, aryl, cycloalkyl, haloalkyl, heterocyclyl and heteroaryl.
- each of the foregoing substituents may also be optionally substituted with one or more of the above substituents.
- any of the above groups may be substituted to include one or more internal oxygen, sulfur, or nitrogen atoms.
- an alkyl group may be substituted with one or more internal oxygen atoms to form an ether or polyether group.
- an alkyl group may be substituted with one or more internal sulfur atoms to form a thioether, disulfide, etc.
- each of the foregoing substituents may also be optionally substituted with one or more of the above substituents.
- R 15 is selected from the group consisting of optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted alkoxy, optionally substituted haloalkyl, optionally substituted haloalkoxy, optionally substituted phenyl, and optionally substituted 5- or 6-membered heteroaryl.
- an optionally substituted group may be un- substituted (e.g., -CH 2 CH 3 ), fully substituted (e.g., -CF 2 CF 3 ), mono-substituted (e.g., -CH 2 CH 2 F) or substituted at a level anywhere in-between fully substituted and mono-substituted (e.g., -CH 2 CHF 2 , - CH 2 CF 3 , -CF 2 C3 ⁇ 4, -CFHCHF 2) etc).
- un- substituted e.g., -CH 2 CH 3
- fully substituted e.g., -CF 2 CF 3
- mono-substituted e.g., -CH 2 CH 2 F
- any substituents described should generally be understood as having a maximum molecular weight of about 1,000 Daltons, and more typically, up to about 500 Daltons.
- co-administration are meant to encompass administration of the selected therapeutic agents to a single patient, and are intended to include treatment regimens in which the agents are administered by the same or different route of administration or at the same or different time.
- an “effective amount” or “therapeutically effective amount,” as used herein, refer to a sufficient amount of an agent or a compound being administered which will relieve to some extent one or more of the symptoms of the disease or condition being treated. The result can be reduction and/or alleviation of the signs, symptoms, or causes of a disease, or any other desired alteration of a biological system.
- an “effective amount” for therapeutic uses is the amount of the composition comprising a compound as disclosed herein required to provide a clinically significant decrease in disease symptoms.
- An appropriate "effective" amount in any individual case may be determined using techniques, such as a dose escalation study.
- the term "pharmaceutical combination” as used herein, means a product that results from the mixing or combining of more than one active ingredient and includes both fixed and non-fixed combinations of the active ingredients.
- the term "fixed combination” means that the active ingredients, e.g. a compound disclosed herein and a co-agent, are both administered to a patient simultaneously in the form of a single entity or dosage.
- the term “non-fixed combination” means that the active ingredients, e.g. a compound disclosed herein and a co-agent, are administered to a patient as separate entities either simultaneously, concurrently or sequentially with no specific intervening time limits, wherein such administration provides effective levels of the two compounds in the body of the patient.
- cocktail therapy e.g. the administration of three or more active ingredients.
- subject or "patient” encompasses mammals. Examples of mammals include, but are not limited to, humans. In one embodiment, the mammal is a human.
- treat include alleviating, abating or ameliorating at least one symptom of a disease or condition, preventing additional symptoms, inhibiting the disease or condition, e.g., arresting the development of the disease or condition, relieving the disease or condition, causing regression of the disease or condition, relieving a condition caused by the disease or condition, or stopping the symptoms of the disease or condition either prophylactically and/or therapeutically.
- a "tautomer” refers to a proton shift from one atom of a molecule to another atom of the same molecule.
- the compounds presented herein may exist as tautomers. Tautomers are compounds that are interconvertible by migration of a hydrogen atom, accompanied by a switch of a single bond and adjacent double bond. In bonding arrangements where tautomerization is possible, a chemical equilibrium of the tautomers will exist. All tautomeric forms of the compounds disclosed herein are contemplated. The exact ratio of the tautomers depends on several factors, including temperature, solvent, and pH. Some examples of tautomeric interconversions include:
- “Pharmaceutically acceptable salt” includes both acid and base addition salts.
- a pharmaceutically acceptable salt of any one of the kallikrein inhibitory compounds described herein is intended to encompass any and all pharmaceutically suitable salt forms.
- Preferred pharmaceutically acceptable salts of the compounds disclosed herein, are pharmaceutically acceptable acid addition salts and
- pharmaceutically acceptable carrier refers to a pharmaceutically acceptable carrier
- pharmaceutically acceptable excipient refers to a pharmaceutically acceptable carrier
- each component is "pharmaceutically acceptable" in the sense of being compatible with other ingredients of a pharmaceutical formulation, and suitable for use in contact with the tissue or organ of humans and animals without excessive toxicity, irritation, allergic response, immunogenicity, or other problems or complications, commensurate with a reasonable benefit/risk ratio.
- the term “about” or “approximately” means an acceptable error for a particular value as determined by one of ordinary skill in the art, which depends in part on how the value is measured or determined. In certain embodiments, the term “about” or “approximately” means within 1, 2, 3, or 4 standard deviations. In certain embodiments, the term “about” or “approximately” means within 50%, 20%, 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, or 0.05% of a given value or range.
- each X 1 , X 2 , X 3 , X 4 and X 5 is independently N, S, O or CR 4 ; provided that at least one X 1 , X 2 , X 3 , X 4 and X 5 is N, S, C or O;
- each R a is selected from the group consisting of hydrogen, halogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted alkoxy, optionally substituted heterocycloalkyl, haloalkyl, haloalkoxy, optionally substituted aryl, and optionally substituted heteroaryl;
- p 0-3;
- Z is N or C
- Y is N or C
- W is N or C
- R 1 is selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, haloalkyl, optionally substituted aryl, and optionally substituted heteroaryl;
- n 0-4;
- n 0-4;
- t 0-4;
- v 0-2;
- R 2 and R 3 are taken together to form a ring selected from the group consisting of an optionally substituted carbocycle, optionally substituted heterocycle, optionally substituted aryl, and optionally substituted heteroaryl;
- each R 4 and R 5 is independently selected from the group consisting of hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, or R 4 and R 5 together with the nitrogen or carbon atom to which they are attached form an optionally substituted carbocycle or heterocycle;
- R 3 and R 6 are taken together to form a ring selected from the group consisting of an optionally substituted carbocycle, optionally substituted heterocycle, optionally substituted aryl, and optionally substituted heteroaryl; Ring C is a five membered heteroaryl or a six membered heteroaryl substituted with -(R b ) q ;
- each X 6 , X 7 , X 8 , X 9 and X 10 is independently N, S, O or CR 4 ; provided that at least one X 6 , X 7 , X 8 , X 9 and X 10 is N, S, C or O;
- R b is selected from the group consisting of hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted alkoxy, optionally substituted heterocycloalkyl, haloalkyl, haloalkoxy, optionally substituted aryl, and optionally substituted heteroaryl;
- Ring A is and bound to the 6' position of the pyridine, Ring B is
- Ring C is and bound para to Y
- Y is C
- Z is C
- R 1 is H, then R 2 and R 3 are taken together to form a ring selected from the group consisting of an optionally substituted carbocycle, optionally substituted heterocycle, optionally substituted aryl, and . optionally substituted heteroaryl;
- the compound is not 5-(4-cyclopropyl-lH-imidazol-l-yl)-2-fluoro-N-(6-(4-isopropyl-4H-l,2,4- triazol-3-yl)pyridin-2-yl)-4-methylbenzamide.
- each Ring A and Ring C is optionally substituted and independently selected from the group consisting of furan, thiophene, pyrrole, pyrroline, pyrolidine, dioxolane, oxoazole, thiazole, imidazole, imidazoline, imidazolidine, pyrazole, pyrazoline, pyrazolidine, isozole, isothiazole, oxadiazole, triazole, thiadiazole, tetrazole, oxatriazole, and thiatriazole.
- Ring C is imidazole, pyrazole, triazole, or thiophene.
- Ring C is imidazole. In some embodiments of Formula (I), Ring C is pyridine, pyrimidine, pyrazine, or pyridazine.In some embodiments of Formula (I), Ring C is pyridine.
- Ring A is triazole, tetrazole, or isoxazole. In some embodiments of a compound of Formula (I), Ring A is triazole. [0045] In some embodiments of Formula (I), Ring A and Ring B are connected to the 2' and 6' position of the pyridine ring.
- Ring C is positioned para to Y.
- each R a is selected from the group consisting of hydrogen, optionally substituted alkyl, and optionally substituted cycloalkyl. In some embodiments of a compound of Formula (I), R a is optionally substituted cycloalkyl.
- each R b is selected from the group consisting of hydrogen, optionally substituted alkyl, and optionally substituted cycloalkyl. In some embodiments of a compound of Formula (I), R b is optionally substituted alkyl.
- p is 1. In some embodiments of a compound of Formula (I), p is 2. In some embodiments of a compound of Formula (I), p is 3. In some embodiments of a compound of Formula (I), p is 4.
- q is 1. In some embodiments of a compound of Formula (I), q is 2. In some embodiments of a compound of Formula (I), q is 3. In some embodiments of a compound of Formula (I), q is 4.
- between W and CR 6 is a double bond
- between CR 6 and Z is a single bond
- between Z and Y is a double bond
- W is C.
- Z is N and R 3 is absent. In some embodiments of a compound of Formula (I), Z is C.
- Y is N and R 2 is absent. In some embodiments of a compound of Formula (I), Y is C.
- R' is selected from the group consisting of hydrogen and optionally substituted alkyl.
- R 2 when present, is selected from the group consisting of hydrogen, halogen, and optionally substituted alkyl.
- n is 1. In some embodiments of a compound of Formula (I), n is 2. In some embodiments of a compound of Formula (I), n is 3. In some embodiments of a compound of Formula (I), n is 4.
- m is 1. In some embodiments of a compound of Formula (I), m is 2. In some embodiments of a compound of Formula (I), m is 3. In some embodiments of a compound of Formula (I), m is 4.
- R 3 whenpresent, is selected from the group consisting of hydrogen, halogen, and optionally substituted alkyl.
- R 2 and R 3 are taken together to form an optionally substituted carbocycle.
- R 2 and R 3 are taken together to form an optionally substituted heterocycle.
- R 2 and R 3 are taken together to form an optionally substituted aryl.
- R 2 and R 3 are taken together to form an optionally substituted heteroaryl.
- R 6 is selected from the group consisting of hydrogen, halogen, and optionally substituted alkyl.
- R 7 is selected from the group consisting of hydrogen, halogen, and optionally substituted alkyl.
- R 3 and R 6 are taken together to form an optionally substituted carbocycle. In some embodiments of a compound of Formula (I), R 3 and R 6 are taken together to form an optionally substituted heterocycle. In some embodiments of a compound of Formula (I), R 3 and R 6 are taken together to form an optionally substituted aryl. In some embodiments of a compound of Formula (I), R 3 and R 6 are taken together to form an optionally substituted heteroaryl.
- each X 1 , X 2 , X 3 and X 4 is independently N, S, O or CR 4 ;
- X 5 is N or C
- X 1 , X 2 , X 3 , X 4 and X 5 is N, S or O;
- R a is selected from the group consisting of hydrogen, halogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted alkoxy, optionally substituted heterocycloalkyl, haloalkyl, haloalkoxy, optionally substituted aryl, and optionally substituted heteroaryl;
- p 0-3;
- Z is N or C
- Y is N or C
- W is N or C
- R 1 is selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, haloalkyl, optionally substituted aryl, and optionally substituted heteroaryl;
- n 0-4;
- n 0-4;
- t 0-4;
- v 0-2;
- R 2 and R 3 are taken together to form a ring selected from the group consisting of an optionally substituted carbocycle, optionally substituted heterocycle, optionally substituted aryl, and optionally substituted heteroaryl;
- each R 4 and R 5 is independently selected from the group consisting of hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, or R 4 and R 5 together with the nitrogen or carbon atom to which they are attached form an optionally substituted carbocycle or heterocycle;
- R 3 and R 6 are taken together to form a ring selected from the group consisting of an optionally substituted carbocycle, optionally substituted heterocycle, optionally substituted aryl, and optionally substituted heteroaryl; each X 6 , X 7 , X 9 and X 10 is each independently N, S, O or CR 4 ;
- X s is N or C
- X 6 , X 7 , X 8 , X 9 and X 10 is N, S or O;
- R b is selected from the group consisting of hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted alkoxy, optionally substituted heterocycloalkyl, haloalkyl, haloalkoxy, optionally substituted aryl, and optionally substituted heteroaryl;
- p is 1, and R a is bonded to X 4 . In another embodiment, q is 1 and R b is bonded to X 10 . In some embodiments of Formula (II), p is 2. In some embodiments of Formula (II), p is 3.
- X 1 is N, X 2 , X 3 and X 4 is CR 4 and X 5 is C.
- X 2 is N, X 1 , X 3 and X 4 is CR 4 and X 5 is C.
- X 3 is N, X 1 , X 2 and X 4 is CR 4 and X 5 is C.
- X 4 is N, X 1 , X 2 and X 3 is CR 4 and X 5 is C.
- X 5 is N, X 1 , X 2 , X 3 , and X 4 is CR 4 .
- X 1 and X 2 is N, and X 3 , X 4 is CR 4 and X 5 is C.
- X 1 and X 3 is N, and X 2 , X 4 is CR 4 and X 5 is C.
- X 1 and X 4 is N, and X 2 , X 3 is CR 4 and X 5 is C.
- X 1 and X 5 is N, and X 2 , X 3 and X 4 is CR 4 .
- X 2 and X 3 is N, X 1 and X 4 is CR 4 and X 5 is C.
- X 2 and X 4 is N, X 1 and X 3 is CR 4 and X 5 is C. In another embodiment, X 2 and X 5 is N, and ⁇ ', X 3 and X 4 is CR 4 . In another embodiment, X 3 and X 4 is N, X 1 and X 2 is CR 4 and X 5 is C. In another embodiment, X 3 and X 5 is N, and X 1 , X 2 and X 4 is CR 4 . In another embodiment, X 4 and X 5 is N, and X 1 , X 2 and X 3 is CR 4 . In another embodiment, X 4 and X 5 is N, and X 1 , X 2 and X 3 is CR 4 .
- X 1 , X 2 and X 3 is N, X 4 is CR 4 and X 5 is C.
- X 1 , X 2 and X 4 is N
- X 3 is CR 4 and X 5 is C.
- X 1 , X 2 and X 5 is N
- X 3 and X 4 is CR 4 .
- X 1 , X 3 and X 4 is N
- X 2 is CR 4 and X 5 is C.
- X 1 , X 3 and X 5 is N, and X 2 and X 4 is CR 4 .
- X 1 , X 4 and X 5 is N, and X 2 and X 3 is CR 4 .
- X 2 , X 3 and X 4 is N, X 1 is CR 4 and X 5 is C.
- X 2 , X 3 and X 5 is N, and X 1 and X 4 is CR 4 .
- X 2 , X 4 and X 5 is N, and X 1 and X 3 is CR 4 .
- X 3 , X 4 and X 5 is N, and X 1 and X 2 is CR 4 .
- X 1 , X 2 , X 3 and X 4 is N, and X 5 is C.
- X 1 , X 2 , X 3 and X 5 is N, and X 4 is CR 4 .
- X 2 , X 3 , X 4 and X 5 is N, and X 1 is CR 4 .
- X 1 , X 3 , X 4 and X 5 is N, and X 2 is CR 4 .
- X 1 , X 2 , X 4 and X 5 is N, and X 3 is CR 4 .
- X 1 is O, X 2 is N, X 3 and X 4 is CR 4 and X 5 is C.
- X 1 is O, X 3 is N, X 2 and X 4 is CR 4 and X 5 is C.
- X 1 is O, X 4 is N, X 2 and X 3 is CR 4 and X 5 is C.
- X 1 is O, X 5 is N, and X 2 , X 3 and X 4 is CR 4 .
- X 1 is O, X 2 and X 3 is N, X 4 is CR 4 and X 5 is C.
- X 1 is O, X 2 and X 4 is N, X 3 is CR 4 and X 5 is C. In another embodiment, X 1 is O, X 2 and X 5 is N, and X 3 and X 4 is CR 4 . In another embodiment, X 1 is O, X 3 and X 4 is N, X 2 is CR 4 and X s is C. In another embodiment, X 1 is O, X 3 and X 5 is N, and X 2 and X 4 is CR 4 .In another embodiment, X 1 is O, X 4 and X 5 is N, and X 2 and X 3 is CR 4 .
- X 2 is O, X 1 is N, X 3 and X 4 is CR 4 and X 5 is C. In another embodiment, X 2 is O, X 3 is N, X 1 and X 4 is CR 4 and X 5 is C. In another embodiment, X 2 is O, X 4 is N, X 1 and X 3 is CR 4 and X 5 is C. In another embodiment, X 2 is O, X 5 is N, and X 1 , X 3 and X 4 is CR 4 . In another embodiment, X 2 is O, X 1 and X 3 is N, X 4 is CR 4 and X 5 is C.
- X 2 is O, X 1 and X 4 is N, X 3 is CR 4 and X 5 is C. In another embodiment, X 2 is O, X 1 and X 5 is N, and X 3 and X 4 is CR 4 . In another embodiment, X 2 is O, X 3 and X 4 is N, X 1 is CR 4 and X 5 is C. In another embodiment, X 2 is O, X 3 and X 5 is N, and X 1 and X 4 is CR 4 . In another embodiment, X 2 is O, X 4 and X 5 is N, and X 1 and X 3 is CR 4 . In another embodiment, X 2 is O, X 4 and X 5 is N, and X 1 and X 3 is CR 4 .
- X 3 is O, X 1 is N, X 2 and X 4 is CR 4 and X 5 is C. In another embodiment, X 3 is O, X 2 is N, X 1 and X 4 is CR 4 and X 5 is C. In another embodiment, X 3 is O, X 4 is N, X 1 and X 2 is CR 4 and X 5 is C. In another embodiment, X 3 is O, X 5 is N, and X 1 , X 2 and X 4 is CR 4 . In another embodiment, X 3 is O, X 1 and X 2 is N, X 4 is CR 4 and X 5 is C.
- X 3 is O, X 1 and X 4 is N, X 2 is CR 4 and X 5 is C. In another embodiment, X 3 is O, X 1 and X 5 is N, and X 2 and X 4 is CR 4 . In another embodiment, X 3 is O, X 2 and X 4 is N, X 1 is CR 4 and X 5 is C. In another embodiment, X 3 is O, X 2 and X 5 is N, and X 1 and X 4 is CR 4 . In another embodiment, X 3 is O, X 4 and X s is N, and X 1 and X 2 is CR 4 .
- X 4 is O, X 1 is N, X 2 and X 3 is CR 4 and X 5 is C. In another embodiment, X 4 is O, X 2 is N, X 1 and X 3 is CR 4 and X 5 is C. In another embodiment, X 4 is O, X 3 is N, X 1 and X 2 is CR 4 and X 5 is C. In another embodiment, X 4 is O, X 5 is N, and X 1 , X 2 and X 3 is CR 4 . In another embodiment, X 4 is O, X 1 and X 2 is N, X 3 is CR 4 and X 5 is C.
- X 4 is O, X 1 and X 3 is N, X 2 is CR 4 and X 5 is C. In another embodiment, X 4 is O, X 1 and X 5 is N, and X 2 and X 3 is CR 4 . In another embodiment, X 4 is O, X 2 and X 3 is N, X 1 is CR 4 and X 5 is C. In another embodiment, X 4 is O, X 2 and X 5 is N, and X 1 and X 3 is CR 4 . In another embodiment, X 4 is O, X 3 and X 5 is N, and X 1 and X 2 is CR 4 .
- X 1 is S, X 2 is N, X 3 and X 4 is CR 4 and X 5 is C.
- X 1 is S, X 3 is N, X 2 and X 4 is CR 4 and X 5 is C.
- X 1 is S, X 4 is N, X 2 and X 3 is CR 4 and X 5 is C.
- X 1 is S, X 5 is N, and X 2 , X 3 and X 4 is CR 4 .
- X 1 is S, X 2 and X 3 is N, X 4 is CR 4 and X 5 is C.
- X 1 is S, X 2 and X 4 is N, X 3 is CR 4 and X 5 is C. In another embodiment, X 1 is S, X 2 and X 5 is N, and X 3 and X 4 is CR 4 . In another embodiment, X 1 is S, X 3 and X 4 is N, X 2 is CR 4 and X 5 is C. In another embodiment, X 1 is S, X 3 and X 5 is N, and X 2 and X 4 is CR 4 . In another embodiment, X 1 is S, X 4 and X 5 is N, and X 2 and X 3 is CR 4 . In another embodiment, X 1 is S, X 4 and X 5 is N, and X 2 and X 3 is CR 4 .
- X 2 is S, X 1 is N, X 3 and X 4 is CR 4 and X 5 is C. In another embodiment, X 2 is S, X 3 is N, X 1 and X 4 is CR 4 and X 5 is C. In another embodiment, X 2 is S, X 4 is N, X 1 and X 3 is CR 4 and X 5 is C. In another embodiment, X 2 is S, X 5 is N, and X 1 , X 3 and X 4 is CR 4 . In another embodiment, X 2 is S, X 1 and X 3 is N, X 4 is CR 4 and X 5 is C.
- X 2 is S, X 1 and X 4 is N, X 3 is CR 4 and X 5 is C. In another embodiment, X 2 is S, X 1 and X 5 is N, and X 3 and X 4 is CR 4 . In another embodiment, X 2 is S, X 3 and X 4 is N, X 1 is CR 4 and X 5 is C. In another embodiment, X 2 is S, X 3 and X 5 is N, and X 1 and X 4 is CR 4 . In another embodiment, X 2 is S, X 4 and X 5 is N, and X 1 and X 3 is CR 4 . In another embodiment, X 2 is S, X 4 and X 5 is N, and X 1 and X 3 is CR 4 .
- X 3 is S, X 1 is N, X 2 and X 4 is CR 4 and X 5 is C. In another embodiment, X 3 is S, X 2 is N, X 1 and X 4 is CR 4 and X 5 is C. In another embodiment, X 3 is S, X 4 is N, X 1 and X 2 is CR 4 and X 5 is C. In another embodiment, X 3 is S, X 5 is N, and X 1 , X 2 and X 4 is CR 4 . In another embodiment, X 3 is S, X 1 and X 2 is N, X 4 is CR 4 and X 5 is C.
- X 3 is S, X 1 and X 4 is N, X 2 is CR 4 and X 5 is C. In another embodiment, X 3 is S, X 1 and X 5 is N, and X 2 and X 4 is CR 4 . In another embodiment, X 3 is S, X 2 and X 4 is N, X 1 is CR 4 and X 5 is C. In another embodiment, X 3 is S, X 2 and X 5 is N, and X 1 and X 4 is CR 4 . In another embodiment, X 3 is S, X 4 and X 5 is N, and X 1 and X 2 is CR 4 . In another embodiment, X 3 is S, X 4 and X 5 is N, and X 1 and X 2 is CR 4 .
- X 4 is S, X 1 is N, X 2 and X 3 is CR 4 and X 5 is C. In another embodiment, X 4 is S, X 2 is N, X 1 and X 3 is CR 4 and X 5 is C. In another embodiment, X 4 is S, X 3 is N, X 1 and X 2 is CR 4 and X 5 is C. In another embodiment, X 4 is S, X 5 is N, and X 1 , X 2 and X 3 is CR 4 . In another embodiment, X 4 is S, X 1 and X 2 is N, X 3 is CR 4 and X 5 is C.
- X 4 is S, X 1 and X 3 is N, X 2 is CR 4 and X 5 is C. In another embodiment, X 4 is S, X 1 and X 5 is N, and X 2 and X 3 is CR 4 . In another embodiment, X 4 is S, X 2 and X 3 is N, X 1 is CR 4 and X 5 is C. In another embodiment, X 4 is S, X 2 and X 5 is N, and X 1 and X 3 is CR 4 . In another embodiment, X 4 is S, X 3 and X 5 is N, and X 1 and X 2 is CR 4 .
- X 6 is N, X 7 , X 10 and X 9 is CR 4 and X 8 is C.
- X 7 is N
- X 6 , X 10 and X 9 is CR 4 and X 8 is C.
- X 10 is N, X 6 , X 7 and X 9 is CR 4 and X 8 is C.
- X 9 is N, X 6 , X 7 and X 10 is CR 4 and X s is C.
- X 8 is N, X 6 , X 7 , X 10 , and X 9 is CR 4 .
- X 6 and X 7 is N, and X 10 , X 9 is CR 4 and X 8 is C.
- X 6 and X 10 is N, and X 7 , X 9 is CR 4 and X 8 is C.
- X 6 and X 9 is N, and X 7 , X 9 is CR 4 and X 8 is C.
- X 6 and X 8 is N, and X 7 , X 9 and X 10 is CR 4 .
- X 7 and X 10 is N, X 6 and X 9 is CR 4 and X 8 is C.
- X 7 and X 9 is N, X 6 and X 10 is CR 4 and X 8 is C. In another embodiment, X 7 and X 10 is N, and X 6 , X 8 and X 9 is CR 4 . In another embodiment, X 10 and X 9 is N, X 6 and X 7 is CR 4 and X 8 is C. In another embodiment, X 10 and X 8 is N, and X 6 , X 7 and X 9 is CR 4 . In another embodiment, X 9 and X 10 is N, and X 6 , X 7 and X 8 is CR 4 . In another embodiment, X 9 and X 10 is N, and X 6 , X 7 and X 8 is CR 4 .
- X 6 , X 7 and X 10 is N, X 9 is CR 4 and X 8 is C.
- X 6 , X 7 and X 9 is N
- X 10 is CR 4 and X 8 is C.
- X 6 , X 7 and X 8 is N
- X 10 and X 9 is CR 4 .
- X 6 , X 10 and X 9 is N
- X 6 , X 10 and X 8 is N, and X 7 and X 9 is CR 4 .
- X 6 , X 9 and X 8 is N, and X 7 and X 10 is CR 4 .
- X 7 , X 10 and X 9 is N
- X 6 is CR 4 and X 8 is C.
- X 7 , X 10 and X 8 is N
- X 6 and X 9 is CR 4 .
- X 7 , X 8 and X 9 is N
- X 6 and X 10 is CR 4 .
- X 10 , X 9 and X 8 is N, and X 6 and X 7 is CR 4 .
- X 6 , X 7 , X 10 and X 9 is N, and X 8 is C.
- X 6 , X 7 , X 10 and X 8 is N, and X 9 is CR 4 .
- X 7 , X 10 , X 9 and X 8 is N, and X 6 is CR 4 .
- X 6 , X 10 , X 9 and X 8 is N, and X 7 is CR 4 .
- X 6 , X 7 , X 9 and X s is N, and X 10 is CR 4 .
- X 6 is O, X 7 is N, X 10 and X 9 is CR 4 and X 8 is C.
- X 6 is O, X 10 is N, X 7 and X 9 is CR 4 and X 8 is C.
- X 6 is O, X 9 is N, X 7 and X 10 is CR 4 and X 8 is C.
- X 6 is O, X 8 is N, and X 7 , X 10 and X 9 is CR 4 .
- X 6 is O, X 7 and X 10 is N, X 9 is CR 4 and X 8 is C.
- X 6 is O, X 7 and X 9 is N, X 10 is CR 4 and X 8 is C. In another embodiment, X 6 is O, X 7 and X 8 is N, and X 10 and X 9 is CR 4 . In another embodiment, X 6 is O, X 10 and X 9 is N, X 7 is CR 4 and X 8 is C. In another embodiment, X 6 is O, X 8 and X 10 is N, and X 7 and X 9 is CR 4 . In another embodiment, X 6 is O, X 9 and X 8 is N, and X 7 and X 10 is CR 4 .
- X 7 is O, X 6 is N, X 10 and X 9 is CR 4 and X 8 is C. In another embodiment, X 7 is O, X 10 is N, X 6 and X 9 is CR 4 and X 8 is C. In another embodiment, X 7 is O, X 9 is N, X 6 and X 10 is CR 4 and X 8 is C. In another embodiment, X 7 is O, X 8 is N, and X 6 , X 10 and X 9 is CR 4 . In another embodiment, X 7 is O, X 6 and X 10 is N, X 9 is CR 4 and X 8 is C.
- X 7 is O, X 6 and X 9 is N, X 10 is CR 4 and X 8 is C. In another embodiment, X 7 is O, X 6 and X 8 is N, and X 10 and X 9 is CR 4 . In another embodiment, X 7 is O, X 10 and X 9 is N, X 6 is CR 4 and X 8 is C. In another embodiment, X 7 is O, X 8 and X 10 is N, and X 6 and X 9 is CR 4 . In another embodiment, X 7 is O, X 9 and X 8 is N, and X 6 and X 10 is CR 4 . In another embodiment, X 7 is O, X 9 and X 8 is N, and X 6 and X 10 is CR 4 .
- X 10 is O, X 6 is N, X 7 and X 9 is CR 4 and X s is C. In another embodiment, X 10 is O, X 7 is N, X 6 and X 9 is CR 4 and X 8 is C. In another embodiment, X 10 is O, X 9 is N, X 6 and X 7 is CR 4 and X 8 is C. In another embodiment, X 10 is O, X 8 is N, and X 6 , X 7 and X 9 is CR 4 . In another embodiment, X 10 is O, X 6 and X 7 is N, X 9 is CR 4 and X 8 is C.
- X 10 is O, X 6 and X 9 is N, X 7 is CR 4 and X 8 is C. In another embodiment, X 10 is O, X 6 and X 8 is N, and X 7 and X 9 is CR 4 . In another embodiment, X 10 is O, X 7 and X 9 is N, X 6 is CR 4 and X 8 is C. In another embodiment, X 10 is O, X 7 and X 8 is N, and X 6 and X 9 is CR 4 . In another embodiment, X 10 is O, X 9 and X 8 is N, and X 6 and X 7 is CR 4 . In another embodiment, X 10 is O, X 9 and X 8 is N, and X 6 and X 7 is CR 4 .
- X 9 is O, X 6 is N, X 7 and X 10 is CR 4 and X 8 is C. In another embodiment, X 9 is O, X 7 is N, X 6 and X 10 is CR 4 and X 8 is C. In another embodiment, X 9 is O, X 10 is N, X 6 and X 7 is CR 4 and X 8 is C. In another embodiment, X 9 is O, X 8 is N, and X 6 , X 7 and X 10 is CR 4 . In another embodiment, X 9 is O, X 6 and X 7 is N, X 10 is CR 4 and X 8 is C.
- X 9 is O, X 6 and X 10 is N, X 7 is CR 4 and X 8 is C. In another embodiment, X 9 is O, X 6 and X 8 is N, and X 7 and X 10 is CR 4 . In another embodiment, X 9 is O, X 7 and X 10 is N, X 6 is CR 4 and X 8 is C. In another embodiment, X 9 is O, X 7 and X 8 is N, and X 6 and X 10 is CR 4 . In another embodiment, X 9 is O, X 8 and X 10 is N, and X 6 and X 7 is CR 4 .
- X 6 is S, X 7 is N, X 10 and X 9 is CR 4 and X 8 is C.
- X 6 is S, X 10 is N, X 7 and X 9 is CR 4 and X 8 is C.
- X 6 is S, X 9 is N, X 7 and X 10 is CR 4 and X 8 is C.
- X 6 is S, X 8 is N, and X 7 , X 10 and X 9 is CR 4 .
- X 6 is S, X 7 and X 10 is N, X 9 is CR 4 and X s is C.
- X 6 is S, X 7 and X 9 is N, X 10 is CR 4 and X 8 is C. In another embodiment, X 6 is S, X 7 and X s is N, and X 10 and X 9 is CR 4 . In another embodiment, X 6 is S, X 10 and X 9 is N, X 7 is CR 4 and X s is C. In another embodiment, X 6 is S, X 8 and X 10 is N, and X 7 and X 9 is CR 4 . In another embodiment, X 6 is S, X 9 and X 8 is N, and X 7 and X 10 is CR 4 .
- X 7 is S, X 6 is N, X 10 and X 9 is CR 4 and X 8 is C.
- X 7 is S, X 10 is N, X 6 and X 9 is CR 4 and X 8 is C.
- X 7 is S, X 9 is N, X 6 and X 10 is CR 4 and X 8 is C.
- X 7 is S, X 8 is N, and X 6 , X 10 and X 9 is CR 4 .
- X 7 is S, X 6 and X 10 is N, X 9 is CR 4 and X 8 is C.
- X 7 is S, X 6 and X 9 is N, X 10 is CR 4 and X s is C. In another embodiment, X 7 is S, X 6 and X 8 is N, and X 10 and X 9 is CR 4 . In another embodiment, X 7 is S, X 10 and X 9 is N, X 6 is CR 4 and X 8 is C. In another embodiment, X 7 is S, X s and X 10 is N, and X 6 and X 9 is CR 4 . In another embodiment, X 7 is S, X 9 and X 8 is N, and X 6 and X 10 is CR 4 .
- X 10 is S, X 6 is N, X 7 and X 9 is CR 4 and X 8 is C. In another embodiment, X 10 is S, X 7 is N, X 6 and X 9 is CR 4 and X 8 is C. In another embodiment, X 10 is S, X 9 is N, X 6 and X 7 is CR 4 and X 8 is C. In another embodiment, X 10 is S, X 8 is N, and X 6 , X 7 and X 9 is CR 4 . In another embodiment, X 10 is S, X 6 and X 7 is N, X 9 is CR 4 and X 8 is C.
- X 10 is S, X 6 and X 9 is N, X 7 is CR 4 and X 8 is C. In another embodiment, X 10 is S, X 6 and X 8 is N, and X 7 and X 9 is CR 4 . In another embodiment, X 10 is S, X 7 and X 9 is N, X 6 is CR 4 and X 8 is C. In another embodiment, X 10 is S, X 7 and X 8 is N, and X 6 and X 9 is CR 4 . In another embodiment, X 10 is S, X 9 and X 8 is N, and X 6 and X 7 is CR 4 . In another embodiment, X 10 is S, X 9 and X 8 is N, and X 6 and X 7 is CR 4 .
- X 9 is S, X 6 is N, X 7 and X 10 is CR 4 and X 8 is C. In another embodiment, X 9 is S, X 7 is N, X 6 and X 10 is CR 4 and X 8 is C. In another embodiment, X 9 is S, X 10 is N, X 6 and X 7 is CR 4 and X 8 is C. In another embodiment, X 9 is S, X 8 is N, and X 6 , X 7 and X 10 is CR 4 . In another embodiment, X 9 is S, X 6 and X 7 is N, X 10 is CR 4 and X 8 is C.
- X 9 is S, X 6 and X 10 is N, X 7 is CR 4 and X 8 is C. In another embodiment, X 9 is S, X 6 and X 8 is N, and X 7 and X 10 is CR 4 . In another embodiment, X 9 is S, X 7 and X 10 is N, X 6 is CR 4 and X 8 is C. In another embodiment, X 9 is S, X 7 and X 8 is N, and X 6 and X 10 is CR 4 . In another embodiment, X 9 is S, X s and X 10 is N, and X 6 and X 7 is CR 4 .
- each X 1 , X 2 and X 3 is independently N, S, O or CR 4 ;
- each X 4 and X 5 is independently N or C;
- R a is selected from the group consisting of hydrogen, halogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted alkoxy, optionally substituted heterocycloalkyl, haloalkyl, haloalkoxy, optionally substituted aryl, and optionally substituted heteroaryl;
- Z is N or C
- Y is N or C
- W is N or C
- R 1 is selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, haloalkyl, optionally substituted aryl, and optionally substituted heteroaryl;
- n 0-4;
- n 0-4;
- t 0-4;
- v 0-2;
- R 2 and R 3 are taken together to form a ring selected from the group consisting of an optionally substituted carbocycle, optionally substituted heterocycle, optionally substituted aryl, and optionally substituted heteroaryl; each R 4 and R 5 is independently selected from the group consisting of hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, or R 4 and R 5 together with the nitrogen or carbon atom to which they are attached form an optionally substituted carbocycle or heterocycle;
- R 3 and R 6 are taken together to form a ring selected from the group consisting of an optionally substituted carbocycle, optionally substituted heterocycle, optionally substituted aryl, and optionally substituted heteroaryl;
- X 6 , X 7 and X 9 is each independently N, S, O or CR 4 ;
- X s and X 10 is each independently N or C;
- X 6 , X 7 , X 8 , X 9 and X 10 is N, S or O;
- R b is selected from the group consisting of hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted alkoxy, optionally substituted heterocycloalkyl, haloalkyl, haloalkoxy, optionally substituted aryl, and optionally substituted heteroaryl;
- the compound is not 5-(4-cyclopropyl-lH-imidazol-l-yl)-2-fluoro-N-(6-(4-isopropyl-4H-l ,2,4- triazol-3-yl)pyridin-2-yl)-4-methylbenzamide.
- R 7 is H, between Y and Z is a double bond, Y is C,
- R 1 is H
- between Y and Z is a single bond
- Y is C
- between Y and Z is a double bond
- Y is C
- R 1 and R 2 are taken together to form - R c -.
- each X 1 , X 2 and X 3 is independently N, S, O or CR 4 ;
- each X 4 and X 5 is independently N or C;
- X 1 , X 2 , X 3 , X 4 and X 5 is N, S or O;
- R a is selected from the group consisting of hydrogen, halogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted alkoxy, optionally substituted heterocycloalkyl, haloalkyl, haloalkoxy, optionally substituted aryl, and optionally substituted heteroaryl;
- R 1 is selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, haloalkyl, optionally substituted aryl, and optionally substituted heteroaryl;
- R 2 and R 3 are taken together to form a ring selected from the group consisting of an optionally substituted carbocycle, optionally substituted heterocycle, optionally substituted aryl, and optionally substituted heteroaryl;
- v 0-2;
- each R 4 and R 5 is independently selected from the group consisting of hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, or R 4 and R 5 together with the nitrogen or carbon atom to which they are attached form an optionally substituted carbocycle or heterocycle;
- R 3 and R 6 are taken together to form a ring selected from the group consisting of an optionally substituted carbocycle, optionally substituted heterocycle, optionally substituted aryl, and optionally substituted heteroaryl;
- each X 6 , X 7 and X 9 is independently N, S, O or CR 4 ;
- each X 8 and X 10 is independently N or C;
- X 6 , X 7 , X s , X 9 and X 10 is N, S or O;
- R b is selected from the group consisting of hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted alkoxy, optionally substituted heterocycloalkyl, haloalkyl, haloalkoxy, optionally substituted aryl, and optionally substituted heteroaryl;
- R 2 is not hydrogen or methyl
- the compound is not 5-(4-cyclopropyl-lH-irnidazol-l-yl)-2-fluoro-N-(6-(4-isopropyl-4H-l,2,4- triazol-3-yl)pyridin-2-yl)-4-methylbenzamide.
- R 2 and R 3 are taken together to form a ring selected from the group consisting of an optionally substituted carbocycle, optionally substituted heterocycle, optionally substituted aryl, and optionally substituted heteroaryl. In another embodiment, R 2 and R 3 are taken together to form an optionally substituted heterocycle. In an additional embodiment, R 6 is hydrogen or an optionally substituted alkyl.
- each X 1 , X 2 and X 3 is independently N, S, O or CR 4 ;
- each X 4 and X 5 is independently N or C;
- R a is selected from the group consisting of hydrogen, halogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted alkoxy, optionally substituted heterocycloalkyl, haloalkyl, haloalkoxy, optionally substituted aryl, and optionally substituted heteroaryl;
- R 4 is selected from the group consisting of hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, and optionally substituted aryl;
- each X 6 , X 7 and X 9 is independently N, S, O or CR 4 ;
- each X 8 and X 10 is independently N or C;
- X 6 , X 7 , X 8 , X 9 and X 10 is N, S or O;
- R b is selected from the group consisting of hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted alkoxy, optionally substituted heterocycloalkyl, haloalkyl, haloalkoxy, optionally substituted aryl, and optionally substituted heteroaryl; and
- the compound is not 5-(4-cyclopropyl-lH-imidazol-l-yl)-2-fluoro-N-(6-(4-isopropyl-4H-l,2,4- triazol-3-yl)pyridin-2-yl)-4-methylbenzamide.
- R a is isopropyl.
- R a is an alkyl substituted with at least one hydroxyl group.
- R b is an alkyl substituted with at least one hydroxyl group.
- X 1 , X 2 , X 3 and X 4 is N, and X 5 is C.
- X 1 , X 2 , X 3 and X 5 is N, and X 4 is C.
- X 1 , X 2 and X 5 is N, and X 3 , X 4 is C.
- X 2 , X 3 and X 5 is N, and X 1 , X 4 is C. In another embodiment, X 2 , X 3 and X 4 is N, and X 1 , X 5 is C. In another embodiment, X 2 is N, X 3 , X 4 and X 5 is C, and X 1 is O. In another embodiment, X 2 is N, X 3 , X 4 and X 5 is C, and X 1 is S.
- Z is C or N
- R 2 and R 3 are taken together to form a ring selected from the group consisting of an optionally substituted carbocycle, optionally substituted heterocycle, optionally substituted aryl, and optionally substituted heteroaryl;
- v 0-2;
- each R 4 and R 5 is independently selected from the group consisting of hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, or R 4 and R 5 together with the nitrogen or carbon atom to which they are attached form an optionally substituted carbocycle or heterocycle;
- R 3 and R 6 are taken together to form a ring selected from the group consisting of an optionally substituted carbocycle, optionally substituted heterocycle, optionally substituted aryl, and optionally substituted heteroaryl;
- each X 6 , X 7 and X 9 is independently N, S, O or CR 4 ;
- each X 8 and X 10 is independently N or C;
- X 6 , X 7 , X 8 , X 9 and X 10 is N, S or O;
- R b is selected from the group consisting of hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted alkoxy, optionally substituted heterocycloalkyl, haloalkyl, haloalkoxy, optionally substituted aryl, and optionally substituted heteroaryl; and
- the compound is not 5-(4-cyclopropyl-lH-imidazol-l-yl)-2-fluoro-N-(6-(4-isopropyl-4H-l,2,4- triazol-3-yl)pyridin-2-yl)-4-methylbenzamide
- R 2 and R 3 are taken together to form a ring selected from the group consisting of an optionally substituted carbocycle, optionally substituted heterocycle, optionally substituted aryl, and optionally substituted heteroaryl. In another embodiment, R 2 and R 3 are taken together to form an optionally substituted heterocycle.
- R 6 is hydrogen or an optionally substituted alkyl.
- X 9 and X 10 is N, and X 6 , X 7 and X 8 is C.
- R b is an alkyl substituted with at least one hydroxyl group.
- Z is C or N
- each X 1 , X 2 and X 3 is independently N, S, O or CR 4 ;
- each X 4 and X 5 is independently N or C;
- X 1 , X 2 , X 3 , X 4 and X 5 is N, S or O;
- R a is selected from the group consisting of hydrogen, halogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted alkoxy, optionally substituted heterocycloalkyl, haloalkyl, haloalkoxy, optionally substituted aryl, and optionally substituted heteroaryl;
- R 2 and R 3 are taken together to form a ring selected from the group consisting of an optionally substituted carbocycle, optionally substituted heterocycle, optionally substituted aryl, and optionally substituted heteroaryl;
- v 0-2;
- each R 4 and R 5 is independently selected from the group consisting of hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, or R 4 and R 5 together with the nitrogen or carbon atom to which they are attached form an optionally substituted carbocycle or heterocycle;
- R 2 is not hydrogen or methyl
- the compound is not 5-(4-cyclopropyl-lH-imidazol-l-yl)-2-fluoro-N-(6-(4-isopropyl-4H-l,2,4- triazol-3-yl)pyridin-2-yl)-4-methylbenzamide.
- R a is isopropyl. In another embodiment, R a is an alkyl substituted with at least one hydroxyl group. In another embodiment, X 1 , X 2 , X 3 and X 4 is N, and X 5 is C. In another embodiment, X 1 , X 2 , X 3 and X 5 is N, and X 4 is C. In another embodiment, X 1 , X 2 and X 5 is N, and X 3 , X 4 is C. In another embodiment, wherein X 2 , X 3 and X 5 is N, and X 1 , X 4 is C.
- X 2 , X 3 and X 4 is N, and X 1 , X 5 is C.
- X 2 is N, X 3 , X 4 and X 5 is C, and X 1 is O.
- X 2 is N, X 3 , X 4 and X 5 is C, and X 1 is S.
- R 2 and R 3 are taken together to form a ring selected from the group consisting of an optionally substituted carbocycle, optionally substituted heterocycle, optionally substituted aryl, and optionally substituted heteroaryl. In another embodiment, R 2 and R 3 are taken together to form an optionally substituted heterocycle. In another embodiment, R 6 is hydrogen or an optionally substituted alkyl.
- each X 1 , X 2 and X 3 is independently N, S, O or CR 4 ;
- each X 4 and X 5 is independently N or C;
- X 1 , X 2 , X 3 , X 4 and X 5 is N, S or O;
- R a is selected from the group consisting of hydrogen, halogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted alkoxy, optionally substituted heterocycloalkyl, haloalkyl, haloalkoxy, optionally substituted aryl, and optionally substituted heteroaryl;
- Z is N or C
- W is N or C
- each R 4 and R 5 is independently selected from the group consisting of hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, or R 4 and R 5 together with the nitrogen or carbon atom to which they are attached form an optionally substituted carbocycle or heterocycle;
- R 3 and R 6 are taken together to form a ring selected from the group consisting of an optionally substituted carbocycle, optionally substituted heterocycle, optionally substituted aryl, and optionally substituted heteroaryl;
- each X 6 , X 7 and X 9 is independently N, S, O or CR 4 ;
- each X 8 and X 10 is independently N or C;
- X 6 , X 7 , X 8 , X 9 and X 10 is N, S or O;
- R b is selected from the group consisting of hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted alkoxy, optionally substituted heterocycloalkyl, haloalkyl, haloalkoxy, optionally substituted aryl, and optionally substituted heteroaryl.
- X a is O.
- Z is N.
- X 6 and X 10 is N, and X 7 , X 8 and X 9 is C.
- X 6 and X 8 is N, and X 7 , X 9 and X 10 is C.
- Rb is cyclopropyl.
- W is N or C; each X 1 , X 2 and X 3 is independently N, S, O or CR 4 ;
- each X 4 and X 5 is independently N or C;
- X 1 , X 2 , X 3 , X 4 and X 5 is N, S or O;
- R a is selected from the group consisting of hydrogen, halogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted alkoxy, optionally substituted heterocycloalkyl, haloalkyl, haloalkoxy, optionally substituted aryl, and optionally substituted heteroaryl;
- each R 4 and R 5 is independently selected from the group consisting of hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, or R 4 and R 5 together with the nitrogen or carbon atom to which they are attached form an optionally substituted carbocycle or heterocycle;
- R 3 and R 6 are taken together to form a ring selected from the group consisting of an optionally substituted carbocycle, optionally substituted heterocycle, optionally substituted aryl, and optionally substituted heteroaryl;
- each X 6 , X 7 and X 9 is independently N, S, O or CR 4 ;
- each X s and X 10 is independently N or C;
- X 6 , X 7 , X 8 , X 9 and X 10 is N, S or O;
- R b is selected from the group consisting of hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted alkoxy, optionally substituted heterocycloalkyl, haloalkyl, haloalkoxy, optionally substituted aryl, and optionally substituted heteroaryl.
- R 3 is methyl, and R 6 , R 7 is hydrogen.
- X 6 and X 10 is N, and X 7 , X 8 and X 9 is C.
- X 6 and X 8 is N, and X 7 , X 9 and X 10 is C.
- R b is cyclopropyl.
- W is N or C
- each R 4 and R 5 is independently selected from the group consisting of hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, or R 4 and R 5 together with the nitrogen or carbon atom to which they are attached form an optionally substituted carbocycle or heterocycle;
- R 3 and R 6 are taken together to form a ring selected from the group consisting of an optionally substituted carbocycle, optionally substituted heterocycle, optionally substituted aryl, and optionally substituted heteroaryl;
- each X 6 , X 7 and X 9 is independently N, S, O or CR 4 ;
- each X s and X 10 is independently N or C;
- X 6 , X 7 , X 8 , X 9 and X 10 is N, S or O;
- R b is selected from the group consisting of hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted alkoxy, optionally substituted heterocycloalkyl, haloalkyl, haloalkoxy, optionally substituted aryl, and optionally substituted heteroaryl.
- R 3 is methyl, and R 6 , R 7 is hydrogen.
- X 6 and X 10 is N, and X 7 , X s and X 9 is C.
- X 6 and X 8 is N, and X 7 , X 9 and X 10 is C.
- R b is cyclopropyl.
- W is N or C
- each X 1 , X 2 and X 3 is independently N, S, O or CR 4 ;
- each X 4 and X 5 is independently N or C;
- X 1 , X 2 , X 3 , X 4 and X 5 is N, S or O;
- R a is selected from the group consisting of hydrogen, halogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted alkoxy, optionally substituted heterocycloalkyl, haloalkyl, haloalkoxy, optionally substituted aryl, and optionally substituted heteroaryl;
- each R 4 and R 5 is independently selected from the group consisting of hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, or R 4 and R 5 together with the nitrogen or carbon atom to which they are attached form an optionally substituted carbocycle or heterocycle;
- R 3 and R 6 are taken together to form a ring selected from the group consisting of an optionally substituted carbocycle, optionally substituted heterocycle, optionally substituted aryl, and optionally substituted heteroaryl.
- R 3 is methyl, and R 6 , R 7 is hydrogen.
- each X 1 , X 2 and X 3 is independently N, S, O or CR 4 ;
- each X 4 and X 5 is independently N or C;
- X 1 , X 2 , X 3 , X 4 and X 5 is N, S or O;
- R a is selected from the group consisting of hydrogen, halogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted alkoxy, optionally substituted heterocycloalkyl, haloalkyl, haloalkoxy, optionally substituted aryl, and optionally substituted heteroaryl;
- Z is N or C
- W is C
- n 0-4;
- t 0-4;
- v 0-2;
- each R 4 and R 5 is independently selected from the group consisting of hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, or R 4 and R 5 together with the nitrogen or carbon atom to which they are attached form an optionally substituted carbocycle or heterocycle;
- R 3 and R 6 are taken together to form a ring selected from the group consisting of an optionally substituted carbocycle, optionally substituted heterocycle, optionally substituted aryl, and optionally substituted heteroaryl;
- X 6 , X 7 and X 9 is each independently N, S, O or CR 4 ;
- X 8 and X 10 is each independently N or C;
- X 6 , X 7 , X 8 , X 9 and X 10 is N, S or O;
- R b is selected from the group consisting of hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted alkoxy, optionally substituted heterocycloalkyl, haloalkyl, haloalkoxy, optionally substituted aryl, and optionally substituted heteroaryl.
- each X 1 , X 2 and X 3 is independently N, S, O or CR 4 ;
- each X 4 and X 5 is independently N or C;
- X 1 , X 2 , X 3 , X 4 and X 5 is N, S or O;
- R a is selected from the group consisting of hydrogen, halogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted alkoxy, optionally substituted heterocycloalkyl, haloalkyl, haloalkoxy, optionally substituted aryl, and optionally substituted heteroaryl;
- Z is N or C
- W is C
- n 0-4;
- v 0-2;
- each R 4 and R 5 is independently selected from the group consisting of hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, or R 4 and R 5 together with the nitrogen or carbon atom to which they are attached form an optionally substituted carbocycle or heterocycle;
- R 3 and R 6 are taken together to form a ring selected from the group consisting of an optionally substituted carbocycle, optionally substituted heterocycle, optionally substituted aryl, and optionally substituted heteroaryl;
- each X 6 , X 7 and X 9 is independently N, S, O or CR 4 ;
- each X 8 and X 10 is independently N or C;
- X 6 , X 7 , X 8 , X 9 and X 10 is N, S or O;
- R b is selected from the group consisting of hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted alkoxy, optionally substituted heterocycloalkyl, haloalkyl, haloalkoxy, optionally substituted aryl, and optionally substituted heteroaryl.
- n is 1 or 2 and R 4 and R 5 is hydrogen.
- Z is N or C
- W is C
- n 0-4;
- t 0-4;
- v 0-2;
- each R 4 and R 5 is independently selected from the group consisting of hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, or R 4 and R 5 together with the nitrogen or carbon atom to which they are attached form an optionally substituted carbocycle or heterocycle;
- R 3 and R 6 are taken together to form a ring selected from the group consisting of an optionally substituted carbocycle, optionally substituted heterocycle, optionally substituted aryl, and optionally substituted heteroaryl;
- each X 6 , X 7 and X 9 is independently N, S, O or CR 4 ;
- each X 8 and X 10 is independently N or C;
- X d , X 7 , X s , X 9 and X 10 is N, S or O;
- R b is selected from the group consisting of hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted alkoxy, optionally substituted heterocycloalkyl, haloalkyl, haloalkoxy, optionally substituted aryl, and optionally substituted heteroaryl.
- -R c - is -CH 2 CH 2 - or -CH 2 -.
- each X 1 , X 2 and X 3 is independently N, S, O or CR 4 ;
- each X 4 and X 5 is independently N or C;
- X 1 , X 2 , X 3 , X 4 and X 5 is N, S or O;
- R a is selected from the group consisting of hydrogen, halogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted alkoxy, optionally substituted heterocycloalkyl, haloalkyl, haloalkoxy, optionally substituted aryl, and optionally substituted heteroaryl;
- Z is N or C
- W is C
- n 0-4;
- t 0-4;
- v 0-2;
- each R 4 and R 5 is independently selected from the group consisting of hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, or R 4 and R 5 together with the nitrogen or carbon atom to which they are attached form an optionally substituted carbocycle or heterocycle; and
- R 3 and R 6 are taken together to form a ring selected from the group consisting of an optionally substituted carbocycle, optionally substituted heterocycle, optionally substituted aryl, and optionally substituted heteroaryl.
- VIE Formula (VIE), or a pharmaceutically acce table salt, tautomer, stereoisomer, or solvate thereof:
- each X 1 , X 2 and X 3 is independently N, S, O or CR 4 ;
- each X 4 and X 5 is independently N or C;
- X 1 , X 2 , X 3 , X 4 and X 5 is N, S or O;
- R" is selected from the group consisting of hydrogen, halogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted alkoxy, optionally substituted heterocycloalkyl, haloalkyl, haloalkoxy, optionally substituted aryl, and optionally substituted heteroaryl;
- Z is N or C
- W is C
- X b is CR 4 or N
- X c is CR 4 or N
- R 3 and R 6 are taken together to form a ring selected from the group consisting of an optionally substituted carbocycle, optionally substituted heterocycle, optionally substituted aryl, and optionally substituted heteroaryl;
- each X 6 , X 7 and X 9 is independently N, S, O or CR 4 ;
- each X 8 and X 10 is independently N or C;
- X 6 , X 7 , X 8 , X 9 and X 10 is N, S or O;
- R b is selected from the group consisting of hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted alkoxy, optionally substituted heterocycloalkyl, haloalkyl, haloalkoxy, optionally substituted aryl, and optionally substituted heteroaryl.
- X b is CR 4 and X c is CR 4 .
- X b is CH and X c is CH.
- X b is CR 4 and X c is N.
- X b is CH and X c is N.
- X b is N and X c is CR 4 .
- X b is N and X c is CH.
- Z is N or C
- W is C
- X b is CR 4 or N
- X c is CR 4 or N
- v 0-2;
- R 4 and R 5 together with the nitrogen or carbon atom to which they are attached form an optionally substituted carbocycle or heterocycle;
- each R 6 and R 7 is independently selected from the group consisting of hydrogen, halogen, -CN, -
- R 3 and R 6 are taken together to form a ring selected from the group consisting of an optionally substituted carbocycle, optionally substituted heterocycle, optionally substituted aryl, and optionally substituted heteroaryl;
- each X 6 , X 7 and X 9 is independently N, S, O or CR 4 ;
- each X s and X 10 is independently N or C;
- X 6 , X 7 , X 8 , X 9 and X 10 is N, S or O;
- R b is selected from the group consisting of hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted alkoxy, optionally substituted heterocycloalkyl, haloalkyl, haloalkoxy, optionally substituted aryl, and optionally substituted heteroaryl.
- X b is CR 4 and X c is CR 4 .
- X b is CH and X° is CH.
- X b is CR 4 and X c is N.
- X b is CH and X c is N.
- X b is N and X c is CR 4 .
- X b is N and X c is CH.
- each X 1 , X 2 and X 3 is independently N, S, O or CR 4 ;
- each X 4 and X 5 is independently N or C;
- X 1 , X 2 , X 3 , X 4 and X 5 is N, S or O;
- R a is selected from the group consisting of hydrogen, halogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted alkoxy, optionally substituted heterocycloalkyl, haloalkyl, haloalkoxy, optionally substituted aryl, and optionally substituted heteroaryl;
- Z is N or C; W is C;
- X b is CR 4 or N
- X c is CR 4 or N
- v 0-2;
- each R 4 and R 5 is independently selected from the group consisting of hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, or R 4 and R 5 together with the nitrogen or carbon atom to which they are attached form an optionally substituted carbocycle or heterocycle;
- R 3 and R 6 are taken together to form a ring selected from the group consisting of an optionally substituted carbocycle, optionally substituted heterocycle, optionally substituted aryl, and optionally substituted heteroaryl.
- X b is CR 4 and X is CR 4 .
- X b is CH and X° is CH.
- X b is CR 4 and X° is N.
- X b is CH and X c is N.
- X b is N and X° is CR 4 .
- X b is N and X c is CH.
- X 1 is N, X 2 , X 3 and X 4 is CR 4 and X 5 is C.
- X 2 is N, X 1 , X 3 and X 4 and X 5 is C.
- X 3 is N, X 1 , X 2 is CR 4 , and X 4 and X s is C.
- X 4 is N, X 1 , X 2 and X 3 is CR 4 and X 5 is C.
- X 5 is N, X 1 , X 2 and X 3 is CR 4 , and X 4 is C.
- X 1 and X 2 is N, X 3 is CR 4 , and X 4 and X 5 is C.
- X 1 and X 3 is N, X 2 is CR 4 , and X 4 and X 5 is C.
- X 1 and X 4 is N, and X 2 , X 3 is CR 4 and X 5 is C.
- X 1 and X 5 is N, X 2 , X 3 is CR 4 and X 5 is C.
- X 1 and X 5 is N, X 2 , X 3 is CR 4 , and X 4 is C.
- X 2 and X 3 is N, X 1 is CR 4 , and X 4 and X s is C.
- X 2 and X 4 is N, X 1 and X 3 is CR 4 , and X 5 is C.
- X 2 and X 5 is N, and X 1 , X 3 is CR 4 , and X 4 is C.
- X 3 and X 4 is N, X 1 and X 2 is CR 4 , and X 5 is C.
- X 3 and X 5 is N, and X 1 , X 2 is CR 4 , and X 4 is C.
- X 4 and X 5 is N, and X 1 , X 2 and X 3 is CR 4 .
- X 1 , X 2 and X 3 is N
- X 4 is CR 4 and X 5 is C
- X 1 , X 2 and X 4 is N
- X 3 is CR 4 and X 5 is C
- X 1 , X 2 and X 5 is N
- X 3 is CR 4 and X 4 is C.
- X 1 , X 3 and X 4 is N, X 2 is CR 4 and X s is C. In another embodiment, X 1 , X 3 and X 5 is N, X 2 is CR 4 and X 4 is C. In another embodiment, X 1 , X 4 and X 5 is N, and X 2 and X 3 is CR 4 . In another embodiment, X 2 , X 3 and X 4 is N, X 1 is CR 4 and X s is C. In another embodiment, X 2 , X 3 and X 5 is N, X 1 is CR 4 and X 4 is C.
- X 2 , X 4 and X 5 is N, and X 1 and X 3 is CR 4 .
- X 3 , X 4 and X 5 is N, and X 1 and X 2 is CR 4 .
- X 1 , X 2 , X 3 and X 4 is N, and X 5 is C.
- X 1 , X 2 , X 3 and X 5 is N, and X 4 is C.
- X 2 , X 3 , X 4 and X 5 is N, and X 1 is CR 4 .
- X 1 , X 3 , X 4 and X s is N, and X 2 is CR 4 .
- X 1 , X 2 , X 4 and X 5 is N, and X 3 is CR 4 .
- X 1 is O, X 2 is N, X 3 is CR 4 and X 4 and X 5 is C. In another embodiment, X 1 is O, X 3 is N, X 2 is CR 4 and X 4 and X 5 is C. In another embodiment, X 1 is O, X 4 is N, X 2 and X 3 is CR 4 and X 5 is C. In another embodiment, X 1 is O, X 4 is N, X 2 and X 3 is CR 4 and X 5 is C. In another embodiment, X 1 is O, X 5 is N, X 2 , X 3 is CR 4 and X 4 is C.
- X 1 is O, X 2 and X 3 is N, X 4 and X 5 is C. In another embodiment, X 1 is O, X 2 and X 4 is N, X 3 is CR 4 and X 5 is C. In another embodiment, X 1 is O, X 2 and X 5 is N, X 3 is CR 4 , and X 4 is C. In another embodiment, X 1 is O, X 3 and X 4 is N, X 2 is CR 4 and X 5 is C. In another embodiment, X 1 is O, X 3 and X 5 is N, and X 2 is CR 4 and X 4 is C.
- X 1 is O, X 4 and X 5 is N, and X 2 and X 3 is CR 4 .
- X 2 is O, X 1 is N, X 3 is CR 4 and X 4 and X 5 is C.
- X 2 is O, X 3 is N, X 1 is CR 4 and X 4 and X 3 is C.
- X 2 is O, X 4 is N, X 1 and X 3 is CR 4 and X 5 is C.
- X 2 is O, X 5 is N, X 1 , X 3 is CR 4 and X 4 is C.
- X 2 is O, X 1 and X 3 is N, and X 4 and X 5 is C.
- X 2 is O, X 1 and X 4 is N, X 3 is CR 4 and X 5 is C.
- X 2 is O, X 1 and X 5 is N, X 3 is CR 4 and X 4 is C.
- X 2 is O, X 3 and X 4 is N, X 1 is CR 4 and X 5 is C.
- X 2 is O, X 3 and X 5 is N, X 1 is CR 4 and X 5 is C.
- X 2 is O, X 3 and X 5 is N, X 1 is CR 4 and X 4 is C.
- X 2 is O, X 4 and X 5 is N, and X 1 and X 3 is CR 4 .
- X 3 is O, X 1 is N, X 2 is CR 4 and X 4 and X 5 is C.
- X 3 is O, X 2 is N, X 1 is CR 4 and X 4 and X 5 is C.
- X 3 is O, X 4 is N, X 1 and X 2 is CR 4 and X 5 is C.
- X 3 is O, X 5 is N, and X 1 , X 2 is CR 4 and X 4 is C.
- X 3 is O, X 1 and X 2 is N, X 4 and X 5 is C. In another embodiment, X 3 is O, X 1 and X 4 is N, X 2 is CR 4 and X 5 is C. In another embodiment, X 3 is O, X 1 and X 5 is N, X 2 is CR 4 and X 4 is C. In another embodiment, X 3 is O, X 2 and X 4 is N, X 1 is CR 4 and X 5 is C. In another embodiment, X 3 is O, X 2 and X 5 is N, X 1 is CR 4 and X 4 is C. In another embodiment, X 3 is O, X 4 and X 5 is N, X 1 is CR 4 and X 4 is C. In another embodiment, X 3 is O, X 4 and X 5 is N, and X 1 and X 2 is CR 4 .
- X 1 is S, X 2 is N, X 3 is CR 4 and X 4 and X 5 is C.
- X 1 is S, X 3 is N, X 2 is CR 4 and X 4 and X 5 is C.
- X 1 is S, X 4 is N, X 2 and X 3 is CR 4 and X 5 is C.
- X 1 is S, X 5 is N, X 2 , X 3 is CR 4 and X 4 is C.
- X 1 is S, X 2 and X 3 is N, X 4 and X 5 is C. In another embodiment, X 1 is S, X 2 and X 4 is N, X 3 is CR 4 and X 5 is C. In another embodiment, X 1 is S, X 2 and X 5 is N, X 3 is CR 4 , and X 4 is C. In another embodiment, X 1 is S, X 3 and X 4 is N, X 2 is CR 4 and X 5 is C. In another embodiment, X 1 is S, X 3 and X 5 is N, and X 2 is CR 4 and X 4 is C.
- X 1 is S, X 4 and X 5 is N, and X 2 and X 3 is CR 4 .
- X 2 is S, X 1 is N, X 3 is CR 4 and X 4 and X 5 is C.
- X 2 is S, X 3 is N, X 1 is CR 4 and X 4 and X 5 is C.
- X 2 is S, X 4 is N, X 1 and X 3 is CR 4 and X 5 is C.
- X 2 is S, X 5 is N, X 1 , X 3 is CR 4 and X 4 is C.
- X 2 is S, X 1 and X 3 is N, and X 4 and X 5 is C.
- X 2 is S, X 1 and X 4 is N, X 3 is CR 4 and X 5 is C.
- X 2 is S, X 1 and X 5 is N, X 3 is CR 4 and X 4 is C.
- X 2 is S, X 3 and X 4 is N, X 1 is CR 4 and X 5 is C.
- X 2 is S, X 3 and X 5 is N, X 1 is CR 4 and X 5 is C.
- X 2 is S, X 3 and X 5 is N, X 1 is CR 4 and X 4 is C.
- X 2 is S, X 4 and X 5 is N, and X 1 and X 3 is CR 4 .
- X 3 is S, X 1 is N, X 2 is CR 4 and X 4 and X s is C.
- X 3 is S, X 2 is N, X 1 is CR 4 and X 4 and X 5 is C.
- X 3 is S, X 4 is N, X 1 and X 2 is CR 4 and X 3 is C.
- X 3 is S, X 5 is N, and X 1 , X 2 is CR 4 and X 4 is C.
- X 3 is S, X 1 and X 2 is N, X 4 and X 5 is C. In another embodiment, X 3 is S, X 1 and X 4 is N, X 2 is CR 4 and X 5 is C. In another embodiment, X 3 is S, X 1 and X 5 is N, X 2 is CR 4 and X 4 is C. In another embodiment, X 3 is S, X 2 and X 4 is N, X 1 is CR 4 and X 5 is C. In another embodiment, X 3 is S, X 2 and X 5 is N, X 1 is CR 4 and X 4 is C. In another embodiment, X 3 is S, X 4 and X 5 is N, X 1 is CR 4 and X 4 is C. In another embodiment, X 3 is S, X 4 and X 5 is N, and X 1 and X 2 is CR 4 .
- X 6 is N, X 7 , X 9 and X 10 is CR 4 and X 8 is C.
- X 7 is N
- X 6 , X 9 is CR 4 and X 10 and X 8 is C.
- X 9 is N
- X 6 , X 7 is CR 4 and X 10 and X s is C.
- X 10 is N, X 6 , X 7 and X 9 is CR 4 and X 8 is C.
- X 8 is N, X 6 , X 7 and X 9 is CR 4 , and X 10 is C.
- X 6 and X 7 is N, X 9 is CR 4 , and X 10 and X 8 is C.
- X 6 and X 9 is N, X 7 is CR 4 , and X 10 and X 8 is C.
- X 6 and X 10 is N, and X 7 , X 9 is CR 4 and X 8 is C.
- X 6 and X 8 is N, X 7 , X 9 is CR 4 , and X 10 is C.
- X 7 and X 9 is N, X 6 is CR 4 , and X 10 and X 8 is C.
- X 7 and X 10 is N, X 6 and X 9 is CR 4 , and X 8 is C.
- X 7 and X 8 is N, and X 6 , X 9 is CR 4 , and X 10 is C.
- X 9 and X 10 is N, X 6 and X 7 is CR 4 , and X 8 is C.
- X 9 and X 8 is N, and X 6 , X 7 is CR 4 , and X 10 is C.
- X 10 and X 8 is N, and X 6 , X 7 and X 9 is CR 4 .
- X 6 , X 7 and X 9 is N, and X 10 and X 8 is C.
- X 6 , X 7 and X 10 is N, X 9 is CR 4 and X 8 is C.
- X 6 , X 7 and X 8 is N, X 9 is CR 4 and X 10 is C.
- X 6 , X 9 and X 10 is N, X 7 is CR 4 and X 8 is C.
- X 6 , X 9 and X 10 is N, X 7 is CR 4 and X 8 is C.
- X 6 , X 9 and X 8 is N, X 7 is CR 4 and X 10 is C. In another embodiment, X 6 , X 10 and X 8 is N, and X 7 and X 9 is CR 4 . In another embodiment, X 7 , X 9 and X 10 is N, X 6 is CR 4 and X 8 is C. In another embodiment, X 7 , X 9 and X 8 is N, X 6 is CR 4 and X 10 is C. In another embodiment, X 7 , X 10 and X s is N, and X 6 and X 9 is CR 4 . In another embodiment, X 9 , X 10 and X 8 is N, and X 6 and X 7 is CR 4 .
- X 6 , X 7 , X 9 and X 10 is N, and X 8 is C.
- X 6 , X 7 , X 9 and X 8 is N, and X 10 is C.
- X 7 , X 9 , X 10 and X 8 is N, and X 6 is CR 4 .
- X 6 , X 9 , X 10 and X 8 is N, and X 7 is CR 4 .
- X 6 , X 7 , X 10 and X 8 is N, and X 9 is CR 4 .
- X 6 is O, X 7 is N, X 9 is CR 4 and X 10 and X 8 is C. In another embodiment, X 6 is O, X 9 is N, X 7 is CR 4 and X 10 and X 8 is C. In another embodiment, X 6 is O, X 10 is N, X 7 and X 9 is CR 4 and X 8 is C. In another embodiment, X 6 is O, X 8 is N, X 7 , X 9 is CR 4 and X 10 is C.
- X 6 is O, X 7 and X 9 is N, X 10 and X 8 is C. In another embodiment, X 6 is O, X 7 and X 10 is N, X 9 is CR 4 and X s is C.In another embodiment, X 6 is O, X 7 and X 8 is N, X 9 is CR 4 , and X 10 is C. In another embodiment, X 6 is O, X 9 and X 10 is N, X 7 is CR 4 and X 8 is C. In another embodiment, X 6 is O, X 9 and X 8 is N, and X 7 is CR 4 and X 10 is C.
- X 6 is O, X 10 and X 8 is N, and X 7 and X 9 is CR 4 .
- X 7 is O, X 6 is N, X 9 is CR 4 and X 10 and X 8 is C.
- X 7 is O, X 9 is N, X 6 is CR 4 and X 10 and X 8 is C.
- X 7 is O, X 10 is N, X 6 and X 9 is CR 4 and X s is C.
- X 7 is O, X 8 is N, X 6 , X 9 is CR 4 and X 10 is C.
- X 7 is O, X 6 and X 9 is N, and X 10 and X 8 is C.
- X 7 is O, X 6 and X 10 is N, X 9 is CR 4 and X 8 is C.
- X 7 is O, X 6 and X 8 is N, X 9 is CR 4 and X 10 is C.
- X 7 is O, X 9 and X 10 is N, X 6 is CR 4 and X 8 is C.
- X 7 is O, X 9 and X 8 is N, X 6 is CR 4 and X 10 is C.
- X 7 is O, X 10 and X 8 is N, and X 6 and X 9 is CR 4 .
- X 9 is O, X 6 is N, X 7 is CR 4 and X 10 and X 8 is C.
- X 9 is O, X 7 is N, X 6 is CR 4 and X 10 and X 8 is C.
- X 9 is O, X 10 is N, X 6 and X 7 is CR 4 and X s is C.
- X 9 is O, X 8 is N, and X 6 , X 7 is CR 4 and X 10 is C.
- X 9 is O, X 6 and X 7 is N, X 10 and X 8 is C. In another embodiment, X 9 is O, X 6 and X 10 is N, X 7 is CR 4 and X 8 is C. In another embodiment, X 9 is O, X 6 and X s is N, X 7 is CR 4 and X 10 is C. In another embodiment, X 9 is O, X 7 and X 10 is N, X 6 is CR 4 and X 8 is C. In another embodiment, X 9 is O, X 7 and X 8 is N, X 6 is CR 4 and X 10 is C. In another embodiment, X 9 is O, X 10 and X 8 is N, and X 6 and X 7 is CR 4 .
- X 6 is S, X 7 is N, X 9 is CR 4 and X 10 and X 8 is C.
- X 6 is S, X 9 is N, X 7 is CR 4 and X 10 and X 8 is C.
- X 6 is S, X 10 is N, X 7 and X 9 is CR 4 and X 8 is C.
- X 6 is S, X 8 is N, X 7 , X 9 is CR 4 and X 10 is C.
- X 6 is S, X 7 and X 9 is N, X 10 and X 8 is C. In another embodiment, X 6 is S, X 7 and X 10 is N, X 9 is CR 4 and X 8 is C. In another embodiment, X 6 is S, X 7 and X 8 is N, X 9 is CR 4 , and X 10 is C. In another embodiment, X 6 is S, X 9 and X 10 is N, X 7 is CR 4 and X 8 is C. In another embodiment, X 6 is S, X 9 and X 8 is N, and X 7 is CR 4 and X 10 is C.
- X 6 is S, X 10 and X 8 is N, and X 7 and X 9 is CR 4 .
- X 7 is S, X 6 is N, X 9 is CR 4 and X 10 and X 8 is C.
- X 7 is S, X 9 is N, X 6 is CR 4 and X 10 and X 8 is C.
- X 7 is S, X 10 is N, X 6 and X 9 is CR 4 and X 8 is C.
- X 7 is S, X 8 is N, X 6 , X 9 is CR 4 and X 10 is C.
- X 7 is S, X 6 and X 9 is N, and X 10 and X 8 is C.
- X 7 is S, X 6 and X 10 is N, X 9 is CR 4 and X s is C.
- X 7 is S, X 6 and X 8 is N, X 9 is CR 4 and X 10 is C.
- X 7 is S, X 9 and X 10 is N, X 6 is CR 4 and X 8 is C.
- X 7 is S, X 9 and X 8 is N, X 6 is CR 4 and X 10 is C.
- X 7 is S, X 10 and X 8 is N, and X 6 and X 9 is CR 4 .
- X 9 is S, X 6 is N, X 7 is CR 4 and X 10 and X 8 is C.
- X 9 is S, X 7 is N, X 6 is CR 4 and X 10 and X 8 is C.
- X 9 is S, X 10 is N, X 6 and X 7 is CR 4 and X 8 is C.
- X 9 is S, X 8 is N, and X 6 , X 7 is CR 4 and X 10 is C.
- X 9 is S, X 6 and X 7 is N, X 10 and X 8 is C. In another embodiment, X 9 is S, X 6 and X 10 is N, X 7 is CR 4 and X 8 is C. In another embodiment, X 9 is S, X 6 and X 8 is N, X 7 is CR 4 and X 10 is C. In another embodiment, X 9 is S, X 7 and X 10 is N, X 6 is CR 4 and X 8 is C. In another embodiment, X 9 is S, X 7 and X 8 is N, X 6 is CR 4 and X 10 is C.
- X 9 is S, X 10 and X 8 is N, and X 6 and X 7 is CR 4 .
- X 9 is S, X 8 and X 10 is N, and X 6 and X 7 is CR 4 .
- R 1 is selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, haloalkyl, optionally substituted aryl, and optionally substituted heteroaryl. In another embodiment, R 1 is selected from the group consisting of optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl and optionally substituted heteroaryl.
- R 1 is selected from the group consisting of hydrogen, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, haloalkyl, optionally substituted aryl, and optionally substituted heteroaryl. In another embodiment, R 1 is selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted heterocycloalkyl and optionally substituted heteroaryl. In another embodiment, R 1 is selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted heterocycloalkyl and optionally substituted heteroaryl. In another embodiment, R 1 is selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl and optionally substituted heteroaryl.
- R 1 is selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, and optionally substituted heterocycloalkyl. In another embodiment, R 1 is selected from the group consisting of hydrogen, optionally substituted alkyl and optionally substituted cycloalkyl. In another embodiment, R 1 is selected from the group consisting of hydrogen, optionally substituted heterocycloalkyl and optionally substituted heteroaryl.
- R 1 is selected from the group consisting of hydrogen, substituted alkyl, substituted cycloalkyl, substituted heterocycloalkyl, haloalkyl, substituted aryl, and substituted heteroaryl. In another embodiment, R 1 is selected from the group consisting of substituted alkyl, substituted cycloalkyl, substituted
- R 1 is selected from the group consisting of hydrogen, substituted cycloalkyl, substituted heterocycloalkyl, haloalkyl, substituted aryl, and substituted heteroaryl. In another embodiment, R 1 is selected from the group consisting of hydrogen, substituted alkyl, substituted heterocycloalkyl and substituted heteroaryl. In another embodiment, R 1 is selected from the group consisting of hydrogen, substituted alkyl, substituted heterocycloalkyl and substituted heteroaryl. In another embodiment, R 1 is selected from the group consisting of hydrogen, substituted alkyl, substituted cycloalkyl and substituted heteroaryl.
- R 1 is selected from the group consisting of hydrogen, substituted alkyl, substituted cycloalkyl, and substituted heterocycloalkyl. In another embodiment, R 1 is selected from the group consisting of hydrogen, substituted alkyl and substituted cycloalkyl. In another embodiment, R 1 is selected from the group consisting of hydrogen, substituted heterocycloalkyl and substituted heteroaryl.
- R 1 is selected from the group consisting of hydrogen, unsubstituted alkyl, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, haloalkyl, unsubstituted aryl, and unsubstituted heteroaryl. In another embodiment, R 1 is selected from the group consisting of unsubstituted alkyl, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl and unsubstituted heteroaryl.
- R 1 is selected from the group consisting of hydrogen, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, haloalkyl, unsubstituted aryl, and unsubstituted heteroaryl. In another embodiment, R 1 is selected from the group consisting of hydrogen, unsubstituted alkyl, unsubstituted heterocycloalkyl and unsubstituted heteroaryl. In another embodiment, R 1 is selected from the group consisting of hydrogen, unsubstituted alkyl, unsubstituted heterocycloalkyl and unsubstituted heteroaryl.
- R 1 is selected from the group consisting of hydrogen, unsubstituted alkyl, unsubstituted cycloalkyl and unsubstituted heteroaryl. In another embodiment, R 1 is selected from the group consisting of hydrogen, unsubstituted alkyl, unsubstituted cycloalkyl, and unsubstituted heterocycloalkyl. In another embodiment, R 1 is selected from the group consisting of hydrogen, unsubstituted alkyl and unsubstituted cycloalkyl. In another embodiment, R 1 is selected from the group consisting of hydrogen, unsubstituted
- heterocycloalkyl and unsubstituted heteroaryl.
- R 2 is selected from the group consisting of hydrogen, halogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, haloalkyl, optionally substituted aryl, and optionally substituted heteroaryl. In another embodiment, R 2 is selected from the group consisting of optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl and optionally substituted heteroaryl.
- R 2 is absent or selected from the group consisting of hydrogen, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, haloalkyl, optionally substituted aryl, and optionally substituted heteroaryl.
- R 2 is selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted heterocycloalkyl and optionally substituted heteroaryl.
- R 2 is selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted heterocycloalkyl and optionally substituted heteroaryl.
- R 2 is selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl and optionally substituted heteroaryl. In another embodiment, R 2 is selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, and optionally substituted heterocycloalkyl. In another embodiment, R 2 is selected from the group consisting of hydrogen, optionally substituted alkyl and optionally substituted cycloalkyl. In another embodiment, R 2 is selected from the group consisting of hydrogen, optionally substituted heterocycloalkyl and optionally substituted heteroaryl.
- R 2 is selected from the group consisting of hydrogen, halogen, substituted alkyl, substituted cycloalkyl, substituted heterocycloalkyl, haloalkyl, substituted aryl, and substituted heteroaryl. In another embodiment, R 2 is selected from the group consisting of substituted alkyl, substituted cycloalkyl, substituted heterocycloalkyl and substituted heteroaryl.
- R 2 is selected from the group consisting of hydrogen, substituted cycloalkyl, substituted heterocycloalkyl, haloalkyl, substituted aryl, and substituted heteroaryl. In another embodiment, R 2 is selected from the group consisting of hydrogen, substituted alkyl, substituted heterocycloalkyl and substituted heteroaryl. In another embodiment, R 2 is selected from the group consisting of hydrogen, substituted alkyl, substituted heterocycloalkyl and substituted heteroaryl. In another embodiment, R 2 is selected from the group consisting of hydrogen, substituted alkyl, substituted cycloalkyl and substituted heteroaryl.
- R 2 is selected from the group consisting of hydrogen, substituted alkyl, substituted cycloalkyl, and substituted heterocycloalkyl. In another embodiment, R 2 is selected from the group consisting of hydrogen, substituted alkyl and substituted cycloalkyl. In another embodiment, R 2 is selected from the group consisting of hydrogen, substituted heterocycloalkyl and substituted heteroaryl.
- R 2 is selected from the group consisting of hydrogen, halogen, unsubstituted alkyl, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, haloalkyl, unsubstituted aryl, and unsubstituted heteroaryl. In another embodiment, R 2 is selected from the group consisting of unsubstituted alkyl, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl and unsubstituted heteroaryl.
- R 2 is selected from the group consisting of hydrogen, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, haloalkyl, unsubstituted aryl, and unsubstituted heteroaryl. In another embodiment, R 2 is selected from the group consisting of hydrogen, unsubstituted alkyl, unsubstituted heterocycloalkyl and unsubstituted heteroaryl. In another embodiment, R 2 is selected from the group consisting of hydrogen, unsubstituted alkyl, unsubstituted heterocycloalkyl and unsubstituted heteroaryl.
- R 2 is selected from the group consisting of hydrogen, unsubstituted alkyl, unsubstituted cycloalkyl and unsubstituted heteroaryl. In another embodiment, R 2 is selected from the group consisting of hydrogen, unsubstituted alkyl, unsubstituted cycloalkyl, and unsubstituted heterocycloalkyl. In another embodiment, R 2 is selected from the group consisting of hydrogen, unsubstituted alkyl and unsubstituted cycloalkyl. In another embodiment, R 2 is selected from the group consisting of hydrogen, unsubstituted
- heterocycloalkyl and unsubstituted heteroaryl.
- R 3 is selected from the group consisting of hydrogen, halogen, optionally substituted alkyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, haloalkyl, optionally substituted aryl, and optionally substituted heteroaryl.
- R is selected from the group consisting of optionally substituted alkyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl and optionally substituted heteroaryl.
- R 3 is selected from the group consisting of hydrogen, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, haloalkyl, optionally substituted aryl, and optionally substituted heteroaryl. In another embodiment, R 3 is selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkynyl, optionally substituted heterocycloalkyl and optionally substituted heteroaryl. In another embodiment, R 3 is selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkynyl, optionally substituted
- R 3 is selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkynyl, optionally substituted cycloalkyl and optionally substituted heteroaryl.
- R 3 is selected from the group consisting bf hydrogen, optionally substituted alkyl, optionally substituted alkynyl, optionally substituted cycloalkyl, and optionally substituted heterocycloalkyl.
- R 3 is selected from the group consisting of hydrogen, optionally substituted alkyl and optionally substituted cycloalkyl.
- R 3 is selected from the group consisting of hydrogen, optionally substituted heterocycloalkyl and optionally substituted heteroaryl.
- R 3 is selected from the group consisting of hydrogen, halogen, substituted alkyl, substituted cycloalkyl, substituted heterocycloalkyl, haloalkyl, substituted aryl, and substituted heteroaryl. In another embodiment, R 3 is selected from the group consisting of substituted alkyl, substituted cycloalkyl, substituted heterocycloalkyl and substituted heteroaryl.
- R 3 is selected from the group consisting of hydrogen, substituted cycloalkyl, substituted heterocycloalkyl, haloalkyl, substituted aryl, and substituted heteroaryl. In another embodiment, R 3 is selected from the group consisting of hydrogen, substituted alkyl, substituted heterocycloalkyl and substituted heteroaryl. In another embodiment, R 3 is selected from the group consisting of hydrogen, substituted alkyl, substituted heterocycloalkyl and substituted heteroaryl. In another embodiment, R 3 is selected from the group consisting of hydrogen, substituted alkyl, substituted cycloalkyl and substituted heteroaryl.
- R 3 is selected from the group consisting of hydrogen, substituted alkyl, substituted cycloalkyl, and substituted heterocycloalkyl. In another embodiment, R 3 is selected from the group consisting of hydrogen, substituted alkyl and substituted cycloalkyl. In another embodiment, R 3 is selected from the group consisting of hydrogen, substituted heterocycloalkyl and substituted heteroaryl.
- R 3 is selected from the group consisting of hydrogen, halogen, unsubstituted alkyl, unsubstituted alkynyl, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, haloalkyl, unsubstituted aryl, and unsubstituted heteroaryl.
- R 3 is selected from the group consisting of unsubstituted alkyl, unsubstituted alkynyl, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl and unsubstituted heteroaryl. In another embodiment, R 3 is selected from the group consisting of hydrogen, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, haloalkyl, unsubstituted aryl, and unsubstituted heteroaryl.
- R 3 is selected from the group consisting of hydrogen, unsubstituted alkyl, unsubstituted alkynyl, unsubstituted heterocycloalkyl and unsubstituted heteroaryl. In another embodiment, R 3 is selected from the group consisting of hydrogen, unsubstituted alkyl, unsubstituted alkynyl, unsubstituted heterocycloalkyl and unsubstituted heteroaryl. In another embodiment, R 3 is selected from the group consisting of hydrogen, unsubstituted alkyl, unsubstituted alkynyl, unsubstituted cycloalkyl and unsubstituted heteroaryl.
- R 3 is selected from the group consisting of hydrogen, unsubstituted alkyl, unsubstituted alkynyl, unsubstituted cycloalkyl, and unsubstituted heterocycloalkyl. In another embodiment, R 3 is selected from the group consisting of hydrogen, unsubstituted alkyl and unsubstituted cycloalkyl. In another embodiment, R 3 is selected from the group consisting of hydrogen, unsubstituted heterocycloalkyl and unsubstituted heteroaryl.
- R 4 is selected from the group consisting of hydrogen, halogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, haloalkyl, optionally substituted aryl, and optionally substituted heteroaryl. In another embodiment, R 4 is selected from the group consisting of optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl and optionally substituted heteroaryl.
- R 4 is selected from the group consisting of hydrogen, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, haloalkyl, optionally substituted aryl, and optionally substituted heteroaryl. In another embodiment, R 4 is selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted heterocycloalkyl and optionally substituted heteroaryl. In another embodiment, R 4 is selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted heterocycloalkyl and optionally substituted heteroaryl. In another embodiment, R 4 is selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl and optionally substituted heteroaryl.
- R 4 is selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, and optionally substituted heterocycloalkyl. In another embodiment, R 4 is selected from the group consisting of hydrogen, optionally substituted alkyl and optionally substituted cycloalkyl. In another embodiment, R 4 is selected from the group consisting of hydrogen, optionally substituted heterocycloalkyl and optionally substituted heteroaryl.
- R 4 is selected from the group consisting of hydrogen, halogen, substituted alkyl, substituted cycloalkyl, substituted heterocycloalkyl, haloalkyl, substituted aryl, and substituted heteroaryl. In another embodiment, R 4 is selected from the group consisting of substituted alkyl, substituted cycloalkyl, substituted heterocycloalkyl and substituted heteroaryl.
- R 4 is selected from the group consisting of hydrogen, substituted cycloalkyl, substituted heterocycloalkyl, haloalkyl, substituted aryl, and substituted heteroaryl. In another embodiment, R 4 is selected from the group consisting of hydrogen, substituted alkyl, substituted heterocycloalkyl and substituted heteroaryl. In another embodiment, R 4 is selected from the group consisting of hydrogen, substituted alkyl, substituted heterocycloalkyl and substituted heteroaryl. In another embodiment, R 4 is selected from the group consisting of hydrogen, substituted alkyl, substituted cycloalkyl and substituted heteroaryl.
- R 4 is selected from the group consisting of hydrogen, substituted alkyl, substituted cycloalkyl, and substituted heterocycloalkyl. In another embodiment, R 4 is selected from the group consisting of hydrogen, substituted alkyl and substituted cycloalkyl. In another embodiment, R 4 is selected from the group consisting of hydrogen, substituted heterocycloalkyl and substituted heteroaryl.
- R 4 is selected from the group consisting of hydrogen, halogen, unsubstituted alkyl, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, haloalkyl, unsubstituted aryl, and unsubstituted heteroaryl. In another embodiment, R 4 is selected from the group consisting of unsubstituted alkyl, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl and unsubstituted heteroaryl.
- R 4 is selected from the group consisting of hydrogen, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, haloalkyl, unsubstituted aryl, and unsubstituted heteroaryl. In another embodiment, R 4 is selected from the group consisting of hydrogen, unsubstituted alkyl, unsubstituted heterocycloalkyl and unsubstituted heteroaryl. In another embodiment, R 4 is selected from the group consisting of hydrogen, unsubstituted alkyl, unsubstituted heterocycloalkyl and unsubstituted heteroaryl.
- R 4 is selected from the group consisting of hydrogen, unsubstituted alkyl, unsubstituted cycloalkyl and unsubstituted heteroaryl. In another embodiment, R 4 is selected from the group consisting of hydrogen, unsubstituted alkyl, unsubstituted cycloalkyl, and unsubstituted heterocycloalkyl. In another embodiment, R 4 is selected from the group consisting of hydrogen, unsubstituted alkyl and unsubstituted cycloalkyl. In another embodiment, R 4 is selected from the group consisting of hydrogen, unsubstituted
- heterocycloalkyl and unsubstituted heteroaryl.
- R 5 is selected from the group consisting of hydrogen, halogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, haloalkyl, optionally substituted aryl, and optionally substituted heteroaryl. In another embodiment, R 5 is selected from the group consisting of optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl and optionally substituted heteroaryl.
- R 5 is selected from the group consisting of hydrogen, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, haloalkyl, optionally substituted aryl, and optionally substituted heteroaryl.
- R 5 is selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted heterocycloalkyl and optionally substituted heteroaryl.
- R 5 is selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted heterocycloalkyl and optionally substituted heteroaryl.
- R 5 is selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl and optionally substituted heteroaryl.
- R 5 is selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, and optionally substituted heterocycloalkyl. In another embodiment, R 5 is selected from the group consisting of hydrogen, optionally substituted alkyl and optionally substituted cycloalkyl. In another embodiment, R 5 is selected from the group consisting of hydrogen, optionally substituted heterocycloalkyl and optionally substituted heteroaryl.
- R 5 is selected from the group consisting of hydrogen, halogen, substituted alkyl, substituted cycloalkyl, substituted heterocycloalkyl, haloalkyl, substituted aryl, and substituted heteroaryl. In another embodiment, R 5 is selected from the group consisting of substituted alkyl, substituted cycloalkyl, substituted heterocycloalkyl and substituted heteroaryl.
- R 5 is selected from the group consisting of hydrogen, substituted cycloalkyl, substituted heterocycloalkyl, haloalkyl, substituted aryl, and substituted heteroaryl. In another embodiment, R 5 is selected from the group consisting of hydrogen, substituted alkyl, substituted heterocycloalkyl and substituted heteroaryl. In another embodiment, R 5 is selected from the group consisting of hydrogen, substituted alkyl, substituted heterocycloalkyl and substituted heteroaryl. In another embodiment, R 5 is selected from the group consisting of hydrogen, substituted alkyl, substituted cycloalkyl and substituted heteroaryl.
- R 5 is selected from the group consisting of hydrogen, substituted alkyl, substituted cycloalkyl, and substituted heterocycloalkyl. In another embodiment, R 5 is selected from the group consisting of hydrogen, substituted alkyl and substituted cycloalkyl. In another embodiment, R 5 is selected from the group consisting of hydrogen, substituted heterocycloalkyl and substituted heteroaryl.
- R 5 is selected from the group consisting of hydrogen, halogen, unsubstituted alkyl, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, haloalkyl, unsubstituted aryl, and unsubstituted heteroaryl. In another embodiment, R 5 is selected from the group consisting of unsubstituted alkyl, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl and unsubstituted heteroaryl.
- R 5 is selected from the group consisting of hydrogen, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, haloalkyl, unsubstituted aryl, and unsubstituted heteroaryl. In another embodiment, R 5 is selected from the group consisting of hydrogen, unsubstituted alkyl, unsubstituted heterocycloalkyl and unsubstituted heteroaryl. In another embodiment, R 5 is selected from the group consisting of hydrogen, unsubstituted alkyl, unsubstituted heterocycloalkyl and unsubstituted heteroaryl.
- R 5 is selected from the group consisting of hydrogen, unsubstituted alkyl, unsubstituted cycloalkyl and unsubstituted heteroaryl. In another embodiment, R 5 is selected from the group consisting of hydrogen, unsubstituted alkyl, unsubstituted cycloalkyl, and unsubstituted heterocycloalkyl. In another embodiment, R 5 is selected from the group consisting of hydrogen, unsubstituted alkyl and unsubstituted cycloalkyl. In another embodiment, R 5 is selected from the group consisting of hydrogen, unsubstituted
- heterocycloalkyl and unsubstituted heteroaryl.
- R 6 is selected from the group consisting of hydrogen, halogen, optionally substituted alkyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, haloalkyl, optionally substituted aryl, and optionally substituted heteroaryl. In another embodiment, R 6 is selected from the group consisting of optionally substituted alkyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl and optionally substituted heteroaryl.
- R 6 is selected from the group consisting of hydrogen, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, haloalkyl, optionally substituted aryl, and optionally substituted heteroaryl. In another embodiment, R 6 is selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkynyl, optionally substituted heterocycloalkyl and optionally substituted heteroaryl. In another embodiment, R 6 is selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkynyl, optionally substituted
- R 6 is selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkynyl, optionally substituted cycloalkyl and optionally substituted heteroaryl. In another embodiment, R 6 is selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkynyl, optionally substituted cycloalkyl, and optionally substituted heterocycloalkyl. In another embodiment, R 6 is selected from the group consisting of hydrogen, optionally substituted alkyl and optionally substituted cycloalkyl. In another embodiment, R 6 is selected from the group consisting of hydrogen, optionally substituted heterocycloalkyl and optionally substituted heteroaryl.
- R 6 is selected from the group consisting of hydrogen, halogen, substituted alkyl, substituted cycloalkyl, substituted heterocycloalkyl, haloalkyl, substituted aryl, and substituted heteroaryl. In another embodiment, R 6 is selected from the group consisting of substituted alkyl, substituted cycloalkyl, substituted heterocycloalkyl and substituted heteroaryl.
- R 6 is selected from the group consisting of hydrogen, substituted cycloalkyl, substituted heterocycloalkyl, haloalkyl, substituted aryl, and substituted heteroaryl. In another embodiment, R 6 is selected from the group consisting of hydrogen, substituted alkyl, substituted heterocycloalkyl and substituted heteroaryl. In another embodiment, R 6 is selected from the group consisting of hydrogen, substituted alkyl, substituted heterocycloalkyl and substituted heteroaryl. In another embodiment, R 6 is selected from the group consisting of hydrogen, substituted alkyl, substituted cycloalkyl and substituted heteroaryl.
- R 6 is selected from the group consisting of hydrogen, substituted alkyl, substituted cycloalkyl, and substituted heterocycloalkyl. In another embodiment, R 6 is selected from the group consisting of hydrogen, substituted alkyl and substituted cycloalkyl. In another embodiment, R 6 is selected from the group consisting of hydrogen, substituted heterocycloalkyl and substituted heteroaryl.
- R 6 is selected from the group consisting of hydrogen, halogen, unsubstituted alkyl, unsubstituted alkynyl, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, haloalkyl, unsubstituted aryl, and unsubstituted heteroaryl.
- R 6 is selected from the group consisting of unsubstituted alkyl, unsubstituted alkynyl, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl and unsubstituted heteroaryl. In another embodiment, R 6 is selected from the group consisting of hydrogen, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, haloalkyl, unsubstituted aryl, and unsubstituted heteroaryl.
- R 6 is selected from the group consisting of hydrogen, unsubstituted alkyl, unsubstituted alkynyl, unsubstituted heterocycloalkyl and unsubstituted heteroaryl. In another embodiment, R 6 is selected from the group consisting of hydrogen, unsubstituted alkyl, unsubstituted alkynyl, unsubstituted heterocycloalkyl and unsubstituted heteroaryl. In another embodiment, R 6 is selected from the group consisting of hydrogen, unsubstituted alkyl, unsubstituted alkynyl, unsubstituted cycloalkyl and unsubstituted heteroaryl.
- R 6 is selected from the group consisting of hydrogen, unsubstituted alkyl, unsubstituted alkynyl, unsubstituted cycloalkyl, and unsubstituted heterocycloalkyl. In another embodiment, R 6 is selected from the group consisting of hydrogen, unsubstituted alkyl and unsubstituted cycloalkyl. In another embodiment, R 6 is selected from the group consisting of hydrogen, unsubstituted heterocycloalkyl and unsubstituted heteroaryl.
- R 7 is selected from the group consisting of hydrogen, halogen, optionally substituted alkyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, haloalkyl, optionally substituted aryl, and optionally substituted heteroaryl. In another embodiment, R 7 is selected from the group consisting of optionally substituted alkyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl and optionally substituted heteroaryl.
- R 7 is selected from the group consisting of hydrogen, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, haloalkyl, optionally substituted aryl, and optionally substituted heteroaryl. In another embodiment, R 7 is selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkynyl, optionally substituted heterocycloalkyl and optionally substituted heteroaryl. In another embodiment, R 7 is selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkynyl, optionally substituted
- R 7 is selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkynyl, optionally substituted cycloalkyl and optionally substituted heteroaryl. In another embodiment, R 7 is selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkynyl, optionally substituted cycloalkyl, and optionally substituted heterocycloalkyl. In another embodiment, R 7 is selected from the group consisting of hydrogen, optionally substituted alkyl and optionally substituted cycloalkyl. In another embodiment, R 7 is selected from the group consisting of hydrogen, optionally substituted heterocycloalkyl and optionally substituted heteroaryl.
- R 7 is selected from the group consisting of hydrogen, halogen, substituted alkyl, substituted cycloalkyl, substituted heterocycloalkyl, haloalkyl, substituted aryl, and substituted heteroaryl. In another embodiment, R 7 is selected from the group consisting of substituted alkyl, substituted cycloalkyl, substituted heterocycloalkyl and substituted heteroaryl.
- R 7 is selected from the group consisting of hydrogen, substituted cycloalkyl, substituted heterocycloalkyl, haloalkyl, substituted aryl, and substituted heteroaryl. In another embodiment, R 7 is selected from the group consisting of hydrogen, substituted alkyl, substituted heterocycloalkyl and substituted heteroaryl. In another embodiment, R 7 is selected from the group consisting of hydrogen, substituted alkyl, substituted heterocycloalkyl and substituted heteroaryl. In another embodiment, R 7 is selected from the group consisting of hydrogen, substituted alkyl, substituted cycloalkyl and substituted heteroaryl.
- R 7 is selected from the group consisting of hydrogen, substituted alkyl, substituted cycloalkyl, and substituted heterocycloalkyl. In another embodiment, R 7 is selected from the group consisting of hydrogen, substituted alkyl and substituted cycloalkyl. In another embodiment, R 7 is selected from the group consisting of hydrogen, substituted heterocycloalkyl and substituted heteroaryl.
- R 7 is selected from the group consisting of hydrogen, halogen, unsubstituted alkyl, ubsubstituted alkynyl, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, haloalkyl, unsubstituted aryl, and unsubstituted heteroaryl.
- R 7 is selected from the group consisting of unsubstituted alkyl, ubsubstituted alkynyl, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl and unsubstituted heteroaryl. In another embodiment, R 7 is selected from the group consisting of hydrogen, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, haloalkyl, unsubstituted aryl, and unsubstituted heteroaryl.
- R 7 is selected from the group consisting of hydrogen, unsubstituted alkyl, ubsubstituted alkynyl, unsubstituted heterocycloalkyl and unsubstituted heteroaryl. In another embodiment, R 7 is selected from the group consisting of hydrogen, unsubstituted alkyl, ubsubstituted alkynyl, unsubstituted heterocycloalkyl and unsubstituted heteroaryl. In another embodiment, R 7 is selected from the group consisting of hydrogen, unsubstituted alkyl, ubsubstituted alkynyl, unsubstituted cycloalkyl and unsubstituted heteroaryl.
- R 7 is selected from the group consisting of hydrogen, unsubstituted alkyl, ubsubstituted alkynyl, unsubstituted cycloalkyl, and unsubstituted heterocycloalkyl. In another embodiment, R 7 is selected from the group consisting of hydrogen, unsubstituted alkyl and unsubstituted cycloalkyl. In another embodiment, R 7 is selected from the group consisting of hydrogen, unsubstituted heterocycloalkyl and unsubstituted heteroaryl.
- R a is selected from the group consisting of hydrogen, halogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted alkoxy, optionally substituted heterocycloalkyl, haloalkyl, haloalkoxy, optionally substituted aryl, and optionally substituted heteroaryl.
- R 1 is optionally selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, haloalkyl, optionally substituted aryl, and optionally substituted heteroaryl.
- R 2 is halogen.
- Y is C and between Y and Z is a single bond.
- R 3 is optionally selected from the group consisting of hydrogen, halogen, optionally substituted alkyl, and optionally substituted alkynyl.
- R 2 and R 3 are taken together to form a ring selected from the group consisting of an optionally substituted carbocycle, optionally substituted heterocycle, optionally substituted aryl, and optionally substituted heteroaryl.
- each R 4 and R 5 is independently selected from the group consisting of hydrogen, halogen, optionally substituted alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, or R 4 and R 5 together with the nitrogen or carbon atom to which they are attached form an optionally substituted carbocycle or heterocycle.
- R b is selected from the group consisting of hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted alkoxy, optionally substituted heterocycloalkyl, haloalkyl, haloalkoxy, optionally substituted aryl, and optionally substituted heteroaryl.
- R b is selected from the group consisting of optionally substituted alkyl, optionally substituted alkynyl, and optionally substituted cycloalkyl.
- the compound is not 5-(4-cyclopropyl-lH-irnidazol-l-yl)-2-fluoro-N-(6-(4-isopropyl-4H-l,2,4-triazol-3- yl)pyridin-2-yl)-4-methylbenzamide.
- the compound is not (R)-5-(4-cyclopropyl- 1 H-imidazol- 1 -yl)-2-fiuoro-4-methyl-N-(6-(4-( 1 -phenylethyl)- 4H-l,2,4-triazol-3-yl)pyridin-2-yl)benzamide.
- the compound is not (S)-5-(4-cyclopropyl-l H-imidazol- l-yl)-2-fluoro-4-methyl-N-(6-(4-( 1,1,1 - trifluoropropan-2-yl)-4H- 1 ,2,4-triazol-3-yl)pyridin-2-yl)benzamide.
- the compound is not (S)-5-(4-cyclopropyl-l H-imidazol- l-yl)-2-fluoro-4-methyl-N-(6-(4-( 1,1,1 - trifluoropropan-2-yl)-4H-l,2,4-triazol-3-yl)pyridin-2-yl)benzamide.
- the compound is not 5-(4-cyclopropyl-lH-imidazol-l-yl)-2-fluoro-N-(6-(4-isopropyl-4H-l,2,4-triazol-3- yl)pyridin-2-yl)-4-methylbenzamide.
- R is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted heteroalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl;
- R 23 and R 22 are taken together with the atoms to which they are attached to form an optionally substituted heterocycloalkyl or optionally substituted heteroaryl;
- R 24 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted heteroalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl;
- R 25 is optionally substituted heterocycloalkyl or optionally substituted heteroaryl
- each R 27 and R 28 is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted heteroalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl;
- R 27 and R 28 together with the nitrogen atom to which they are attached, form an optionally substituted heterocycloalkyl or optionally substituted heteroaryl;
- R 29 is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted heteroalkyl, optionally substituted cycloalkyl, optionally substituted
- heterocycloalkyl optionally substituted aryl, or optionally substituted heteroaryl
- s is 0-3.
- the compound of Formula (VII) is of Formula (VIla)
- the compound of Formula (VII) is of Formula (Vllb)
- Ring D is a heterocycloalkyl
- u is 0-4.
- each R 30 is independently hydrogen, halogen, -CN, -OR 27 , -NR 2 'R 28 , or optionally substituted alkyl. In one embodiment of Formula (Vllb), each R 30 is
- each R 30 is hydrogen.
- u is 0.
- u is 1.
- u is 2.
- the compound of Formula (VII) is of Formula (VIIc)
- w is 0-2.
- each R 31 is independently hydrogen, halogen, -CN, -OR 27 , -NR 27 R 28 , or optionally substituted alkyl. In one embodiment of Formula (VIIc), each R 31 is
- each R 31 is hydrogen.
- w is 0.
- w is 1.
- w is 2.
- R 21 is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl.
- R 21 is an optionally substituted aryl.
- R 21 is an optionally substituted phenyl.
- R 21 is an optionally substituted heteroaryl.
- R 21 is an optionally substituted 5-membered heteroaryl selected from imidazole, pyrazole, pyrrole, triazole, tetrazole, thiophene, furan, thiazole, isothiazole, oxazole, and isoxazole.
- R 21 is an optionally substituted 5-membered heteroaryl selected from imidazole, pyrazole, triazole, and thiophene. In one embodiment of Formula (VII), (VIla), (Vllb), or (VIIc), R 21 is an optionally substituted imidazole. In one embodiment of Formula (VII), (VIla), (Vllb), or (VIIc), R 21 is an optionally substituted 6-membered heteroaryl selected from pyridine, pyrimidine, pyrazine, and pyridazine.
- R 21 is an optionally substituted pyridine. In one embodiment of Formula (VII), (VIla), (Vllb), or (VIIc), R 21 is an optionally substituted heteroaryl selected from imidazole, pyrazole, triazole, thiophene, and pyridine.
- R 2 ' is optionally substituted with 1 or 2 R b ; and R b is halogen, - CN, -OR 27 , -NR 27 R 28 , optionally substituted alkyl, optionally substituted alkynyl, optionally substituted cycloalkyl, or optionally substituted heterocycloalkyl.
- R 21 is optionally substituted with 1 or 2 R b ; and R b is halogen, -CN, -OH, -NH 2 , alkyl, haloalkyl, hydroxyalkyl, or cycloalkyl.
- R 21 is optionally substituted with 1 R b ; and R b is cycloalkyl.
- R 25 is an optionally substituted heteroaryl.
- R 23 is an optionally substituted 5-membered heteroaryl selected from imidazole, pyrazole, pyrrole, triazole, tetrazole, thiophene, furan, thiazole, isothiazole, oxazole, and isoxazole.
- R 25 is optionally substituted 5-membered heteroaryl selected from triazole, tetrazole, and isoxazole. In one embodiment of Formula (VII), (VIla), (Vllb), or (VIIc), R 25 is an optionally substituted triazole.
- R 25 is an optionally substituted 5/5 fused bicyclic heteroaryl. In one embodiment of Formula (VII), (VIla), (Vllb), or (VIIc), R 25 is an optionally nuhstitutcd 5/6 fu3cd bieyclic heteroaryl.
- R 25 is optionally substituted with 1 or 2 R a ; and each R a is independently halogen, -CN, -OR 27 , -NR 27 R 28 , optionally substituted alkyl, optionally substituted alkynyl, optionally substituted cycloalkyl, or optionally substituted
- R 25 is optionally substituted with 1 or 2 R a ; and each R a is independently halogen, -CN, -OH, -NH 2 , alkyl, haloalkyl, hydroxyalkyl, or cycloalkyl; or two R a form an optionally substituted cycloalkyl or an optionally substituted heterocycloalkyl.
- R is optionally substituted with 1 R a ; and R a is alkyl.
- R is wherein: each X is independently N or CR a ;
- Ring E is a 5- to 6-membered heterocycloalkyl or 5- to 6-membered heteroaryl
- alkyl optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted heteroalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl;
- R a form an optionally substituted cycloalkyl or an optionally substituted heterocycloalkyl; and s4 is 0-4.
- Ring E is a 5- to 6-membered heterocycloalkyl comprising 0-2 additional heteroatoms selected from N, O, and S.
- Ring E is a 5-membered heterocycloalkyl comprising 0-2 additional heteroatoms selected from N, O, and S.
- Ring E is a 5-membered heterocycloalkyl.
- Ring E is a 6-membered heterocycloalkyl comprising 0-2 additional heteroatoms selected from N, O, and S.
- E is a 6-membered heterocycloalkyl.
- Ring E is a 5- to 6- membered heteroaryl comprising 0-2 additional heteroatoms selected from N, O, and S.
- Ring E is a 5-membered heteroaryl comprising 0-2 additional heteroatoms selected from N, O, and S. In one embodiment of Formula (VII), (VIla), (Vllb), or (VIIc), Ring E is a 6-membered heteroaryl comprising 0-2 additional heteroatoms selected from N.
- Ring E is a 6-membered heteroaryl.
- R is
- R a form an optionally substituted cycloalkyl or an optionally substituted heterocycloalkyl; and s4 is 0-2.
- s4 is 0 or 1. In one embodiment of Formula (VII), (VIla), (Vllb), or (VIIc), s4 is 1. In one embodiment of Formula (VII), (VIla), (Vllb), or (VIIc), s4 is 2. In one embodiment of Formula (VII), (VIla), (Vllb), or (VIIc), s4 is 3. In one embodiment of Formula (VII), (VIla), (Vllb), or (VIIc), s4 is 0-2. In one embodiment of Formula (VII), (VIla), (Vllb), or (VIIc), s4 is 1 or 2.
- X are both N. In one embodiment of Formula (VII), (VIla), (Vllb), or (VIIc), one X is N and the other is CR a . In one embodiment of Formula (VII), (VIla), (Vllb), or (VIIc), X are both CR a .
- each R a is independently hydrogen, halogen, -CN, -OR , -NR R , optionally substituted alkyl, optionally substituted alkynyl, optionally substituted cycloalkyl, or optionally substituted heterocycloalkyl.
- each R a is independently hydrogen, halogen, - CN, -OH, -NH 2 , alkyl, haloalkyl, hydroxyalkyl, or cycloalkyl.
- each R a is independently hydrogen, halogen, or alkyl. In one embodiment of Formula (VII), (VIla), (Vllb), or (VIIc), each R a is independently hydrogen or alkyl.
- two R a on the same carbon form an optionally substituted cycloalkyl or an optionally substituted heterocycloalkyl.
- R is
- R is hydrogen, halogen, -CN, - OR 27 , -NR 27 R 28 , optionally substituted alkyl, optionally substituted alkynyl, optionally substituted heteroalkyl, optionally substituted cycloalkyl, or optionally substituted heterocycloalkyl.
- R 20 is hydrogen, halogen, or alkyl.
- R 20 is hydrogen.
- R 20 is hydrogen or alkyl. In one embodiment of Formula (VII), (VIla), (Vllb), or (VIIc), R 20 is halogen, or alkyl. In one embodiment of Formula (VII), (VIla), (Vllb), or (VIIc), R 20 is hydrogen or halogen.
- R 22 is hydrogen, halogen, -CN, - OR 27 , -NR 27 R 28 , optionally substituted alkyl, optionally substituted alkynyl, optionally substituted heteroalkyl, optionally substituted cycloalkyl, or optionally substituted heterocycloalkyl.
- R 22 is hydrogen, halogen, or alkyl.
- R 22 is hydrogen or alkyl.
- R 22 is hydrogen.
- R 22 is alkyl.
- R 24 is hydrogen or alkyl. In one embodiment of Formula (VII), (VIla), (Vllb), or (VIIc), R 24 is hydrogen. [0182] In one embodiment of Formula (VII), (VIla), (Vllb), or (VIIc), s is 0 or 1. In one embodiment of Formula (VII), (VIla), (Vllb), or (VIIc), s is 0. In one embodiment of Formula (VII), (VIla), (Vllb), or (VIIc), s is 1. In one embodiment of Formula (VII), (VIla), (Vllb), or (VIIc), s is 0, 1, or 2. In one embodiment of Formula (VII), (VIla), (Vllb), or (VIIc), s is 2.
- R 26 is halogen or alkyl.
- R 27 and R 28 are independently hydrogen or optionally substituted alkyl. In one embodiment of Formula (VII), (VIla), (Vllb), or (VIIc), R 27 and R 28 are hydrogen. In one embodiment of Formula (VII), (VIla), (Vllb), or (VUc), R 29 is optionally substituted alkyl.
- Y 1 is N or CR Y1 ;
- R 43 and R 44 are taken together with the atoms to which they are attached to form an optionally substituted heterocycloalkyl or an optionally substituted heteroaryl;
- R 41 is optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl;
- R 45 is optionally substituted heterocycloalkyl or optionally substituted heteroaryl
- each R 47 and R 4S is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted heteroalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl; or R and R , together with the nitrogen atom to which they are attached, form an optionally substituted heterocycloalkyl or optionally substituted heteroaryl;
- R 49 is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted heteroalkyl, optionally substituted cycloalkyl, optionally substituted
- heterocycloalkyl optionally substituted aryl, or optionally substituted heteroaryl
- si is 0-3.
- R 43 and R 44 are taken together with the atom to which they are attached to form an optionally substituted 5- or 6-membered heterocycloalkyl.
- R 43 and R 44 are taken together with the atom to which they are attached to form a 5- membered heterocycloalkyl optionally substituted with oxo, halogen, -CN, -OR 47 , -NR 47 R 48 , -C0 2 R 47 , optionally substituted alkyl, or optionally substituted heteroalkyl.
- R ⁇ and R 44 are taken together with the atom to which they are attached to form a 5-membered heterocycloalkyl optionally substituted with oxo, halogen, or optionally substituted alkyl.
- R 43 and R 44 are taken together with the atom to which they are attached to form a 6-membered heterocycloalkyl optionally substituted with oxo, halogen, -CN, -OR 47 , -NR 47 R 48 , - C0 2 R 47 , optionally substituted alkyl, or optionally substituted heteroalkyl.
- R 43 and R 44 are taken together with the atom to which they are attached to form a 6- membered heterocycloalkyl optionally substituted with oxo, halogen, or optionally substituted alkyl.
- R 43 and R 44 are taken together with the atom to which they are attached to form an optionally substituted 6-membered heteroaryl.
- R 43 and R 44 are taken together with the atom to which they are attached to form a 6-membered heteroaryl optionally substituted with halogen, -CN, -OR 47 , -NR 47 R 48 , -C0 2 R 47 , optionally substituted alkyl, or optionally substituted heteroalkyl.
- R 43 and R 44 are taken together with the atom to which they are attached to form a 6-membered heteroaryl optionally substituted with halogen, or optionally substituted alkyl.
- the compound of Formula (VIII) is of Formula (VIlla)
- R 50 and R 51 are taken together with the atom to which they are attached to form an oxo.
- R 50 and R 51 are independently hydrogen, halogen, -CN, - OR 47 , -NR 47 R 48 , or optionally substituted alkyl.
- R 50 and R 51 are independently hydrogen, halogen, -CN, -OH, -OMe, -NH 2 , alkyl, or haloalkyl.
- R 50 and R 51 are hydrogen.
- R 50 and R 51 are are taken together with the atom to which they are attached to form an oxo.
- the compound of Formula (VIII) is of Formula (Vlllb)
- R 50 and R 51 are taken together with the atom to which they are attached to form an oxo; or or R 52 and R 53 are taken together with the atom to which they are attached to form an oxo.
- R 50 and R 51 are independently hydrogen, halogen, -CN, - OR 47 , -NR 47 R 48 , or optionally substituted alkyl.
- R 50 and R 51 are independently hydrogen, halogen, -CN, -OH, -OMe, -NH 2 , alkyl, or haloalkyl.
- R 50 and R 51 are hydrogen.
- R 50 and R 51 are are taken together with the atom to which they are attached to form an oxo.
- R 52 and R 53 are independently hydrogen, halogen, -CN, - OR 47 , -NR 47 R 48 , or optionally substituted alkyl.
- R 52 and R 53 are independently hydrogen, halogen, -CN, -OH, -OMe, -NH 2 , alkyl, or haloalkyl.
- R 52 and R 53 are hydrogen.
- R 52 and R 53 are are taken together with the atom to which they are attached to form an oxo.
- the compound of Formula (VIII) is of Formula (VIIIc)
- s2 is 0-2.
- each R 54 is independently hydrogen, halogen, -CN, - OR 47 , -NR 47 R 48 , or optionally substituted alkyl. In one embodiment of Formula (VIIIc), each R 54 is independently hydrogen, halogen, -CN, -OH, -OMe, -NH 2 , alkyl, or haloalkyl. In one embodiment of Formula (VIIIc), each R 54 is hydrogen. In one embodiment of Formula (VIIIc), s2 is 0. In one embodiment of Formula (VIIIc), s2 is 1. In one embodiment of Formula (VIIIc), s2 is 2.
- the compound of Formula (VIII) is of Formula (Vllld)
- R 55 is hydrogen, halogen, -CN, -OR 47 , -NR 47 R 48 , or optionally substituted alkyl. In one embodiment of Formula (VHId), R 55 is hydrogen, halogen, -CN, -OH, -OMe, -NH 2 , alkyl, or haloalkyl. In one embodiment of Formula (VHId), R 55 is hydrogen.
- R 4 ' is optionally substituted monocyclic optionally substituted aryl or optionally substituted monocyclic heteroaryl.
- R 41 is an optionally substituted aryl.
- R 41 is an optionally substituted phenyl.
- R 41 is an optionally substituted heteroaryl.
- R 41 is an optionally substituted 5- membered heteroaryl selected from imidazole, pyrazole, pyrrole, triazole, tetrazole, thiophene, furan, thiazole, isothiazole, oxazole, and isoxazole.
- R 41 is an optionally substituted 5-membered heteroaryl selected from imidazole, pyrazole, triazole, and thiophene.
- R 41 is an optionally substituted imidazole. In one embodiment of Formula (VIII), (VIlla), (Vlllb), or (VIIIc), R 41 is an optionally substituted 6-membered heteroaryl selected from pyridine, pyrimidine, pyrazine, and pyridazine. In one embodiment of Formula (VIII), (VIlla), (Vlllb), or (VIIIc), R 41 is an optionally substituted pyridine.
- R 41 is an optionally substituted heteroaryl selected from imidazole, pyrazole, triazole, thiophene, and pyridine.
- R 41 is optionally substituted with 1 or 2 R b ; and R b is halogen, -CN, -OR 47 , -NR 47 R 48 , optionally substituted alkyl, optionally substituted alkynyl, optionally substituted cycloalkyl, or optionally substituted heterocycloalkyl.
- R 41 is optionally substituted with 1 or 2 R b ; and R b is halogen, -CN, -OH, -NH 2 , alkyl, haloalkyl, hydroxyalkyl, or cycloalkyl.
- R 41 is optionally substituted with 1 R b ; and R b is cycloalkyl.
- R is an optionally substituted heteroaryl.
- R 45 is optionally substituted monocyclic heteroaryl. In one embodiment of Formula (VIII), (VIlla), (Vlllb), or (VIIIc), R 45 is an optionally substituted 5-membered heteroaryl selected from imidazole, pyrazole, pyrrole, triazole, tetrazole, thiophene, furan, thiazole, isothiazole, oxazole, and isoxazole.
- R 45 is optionally substituted 5-membered heteroaryl selected from triazole, tetrazole, and isoxazole. In one embodiment of Formula (VIII), (VIlla), (Vlllb), or (VIIIc), R 45 is an optionally substituted triazole.
- R 45 is optionally substituted with 1 or 2 R a ; and R a is halogen, -CN, -OR 47 , -NR 47 R 48 , optionally substituted alkyl, optionally substituted alkynyl, optionally substituted cycloalkyl, or optionally substituted heterocycloalkyl.
- R 45 is optionally substituted with 1 or 2 R a ; and R a is halogen, -CN, -OH, -NH 2 , alkyl, haloalkyl, hydroxyalkyl, or cycloalkyl.
- R 45 is optionally substituted with 1 R a ; and R a is alkyl.
- Y 1 is N.
- Y 1 is CR Y1 and R Y1 is hydrogen, halogen, -CN, -OR 47 , - NR 47 R 48 , optionally substituted alkyl, optionally substituted alkynyl, optionally substituted heteroalkyl, optionally substituted cycloalkyl, or optionally substituted heterocycloalkyl.
- Y 1 is CR YI and R Yl is hydrogen, halogen, or alkyl.
- Y l is CR Y1 and R Y1 is hydrogen.
- Y 1 is CR Y1 and R Y1 is hydrogen or alkyl.
- Y 1 is CR YI and R Y1 is halogen or alkyl.
- Y 1 is CR YI and R Y1 is hydrogen or halogen.
- R 40 is hydrogen, halogen, - CN, -OR 47 , -NR 47 R 48 , optionally substituted alkyl, optionally substituted alkynyl, optionally substituted heteroalkyl, optionally substituted cycloalkyl, or optionally substituted heterocycloalkyl.
- R 40 is hydrogen, halogen, or alkyl.
- R 40 is hydrogen.
- R 40 is hydrogen or alkyl. In one embodiment of Formula (VIII), (VIlla), (Vlllb), or (VIIIc), R 40 is halogen or alkyl. In one embodiment of Formula (VIII), (VIlla), (VIIIb), or (VIIIc), R 40 is hydrogen or halogen.
- R is hydrogen, halogen, - CN, -OR 47 , -NR 47 R 48 , optionally substituted alkyl, optionally substituted alkynyl, optionally substituted heteroalkyl, optionally substituted cycloalkyl, or optionally substituted heterocycloalkyl.
- R 42 is hydrogen, halogen, or alkyl.
- R 42 is hydrogen or alkyl.
- R 42 is hydrogen. In one embodiment of Formula (VIII), (Vina), (Vlllb), or (VIIIc), R 42 is alkyl.
- si is 0 or 1. In one embodiment of Formula (VIII), (VIlla), (Vlllb), or (VIIIc), si is 0. In one embodiment of Formula (VIII), (VIlla), (Vlllb), or (VIIIc), si is 1. In one embodiment of Formula (VIII), (VIlla), (Vlllb), or (Vine), si is 0, 1, or 2. In one embodiment of Formula (VIII), (VIlla), (Vlllb), or (VIIIc), si is 2.
- R 46 is halogen or alkyl.
- R 47 and R 48 are independently hydrogen or optionally substituted alkyl. In one embodiment of Formula (VIII), (VIlla), (Vlllb), or (Vine), R 47 and R 48 are hydrogen. In one embodiment of Formula (VIII), (VIlla), (VIIIb), or (VIUc), R 49 is optionally substituted alkyl.
- Y 2 is N or CR Y2 ;
- Y 2 is NR Y3 ;
- R 63 is O or S
- R Y3 is hydrogen or optionally substituted alkyl
- R 64 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted heteroalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, . optionally substituted aryl, or optionally substituted heteroaryl;
- R 63 and R 64 are taken together with the atoms to which they are attached to form an optionally substituted heterocycloalkyl or an optionally substituted heteroaryl;
- R 65 is optionally substituted fused bicyclic heterocycloalkyl or optionally substituted fused bicyclic heteroaryl;
- each R 67 and R 68 is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted heteroalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl;
- R 67 and R 68 together with the nitrogen atom to which they are attached, form an optionally substituted heterocycloalkyl or optionally substituted heteroaryl;
- R 69 is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted heteroalkyl, optionally substituted cycloalkyl, optionally substituted
- heterocycloalkyl optionally substituted aryl, or optionally substituted heteroaryl
- s3 is 0-3. [0206] In one embodiment of Formula (IX), In one embodiment of
- Formula (IX), and Y 2 is In one embodiment of Formula (IX),
- R63 is hydrogen, halogen, -CN, -OR 67 , -NR 67 R 68 , optionally substituted
- alkyl optionally substituted alkynyl, optionally substituted heteroalkyl, optionally substituted cycloalkyl,
- Formula (IX) Y is NR Y3 ; and R is optionally substituted alkyl. In one 63
- R 63 is S.
- R 61 is -OR 67 , optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl.
- R 61 is an optionally substituted aryl.
- R 61 is an optionally substituted phenyl.
- R 61 is an optionally substituted heteroaryl.
- R 61 is an optionally substituted 5-membered heteroaryl selected from imidazole, pyrazole, pyrrole, triazole, tetrazole, thiophene, furan, thiazole, isothiazole, oxazole, or isoxazole.
- R 61 is an optionally substituted 5- membered heteroaryl selected from imidazole, pyrazole, triazole, and thiophene.
- R is an optionally substituted imidazole.
- R is an optionally substituted 6-membered heteroaryl selected from pyridine, pyrimidine, pyrazine, and pyridazine.
- R 61 is an optionally substituted pyridine.
- R 61 is optionally substituted with 1 or 2 R b ; and each R b is independently halogen, -CN, -OR 67 , -NR 67 R 68 , optionally substituted alkyl, optionally substituted alkynyl, optionally substituted cycloalkyl, or optionally substituted heterocycloalkyl.
- R 61 is optionally substituted with 1 or 2 R b ; and each R b is independently halogen, -CN, -OH, -NH 2 , alkyl, haloalkyl, hydroxyalkyl, or cycloalkyl.
- R 61 is optionally substituted with 1 R b ; and R b is cycloalkyl.
- R 60 is hydrogen, halogen, -CN, -OR 67 , -NR 67 R 68 , optionally substituted alkyl, optionally substituted alkynyl, optionally substituted heteroalkyl, optionally substituted cycloalkyl, or optionally substituted heterocycloalkyl.
- R 60 is hydrogen, halogen, or alkyl. The compound of any one of claims 1-27, wherein R 60 is hydrogen.
- R 62 is hydrogen, halogen, -CN, -OR 67 , -NR 67 R 68 , optionally substituted alkyl, optionally substituted alkynyl, optionally substituted heteroalkyl, optionally substituted cycloalkyl, or optionally substituted heterocycloalkyl.
- R 62 is hydrogen, halogen, or alkyl.
- R 62 is hydrogen or alkyl.
- R 62 is alkyl.
- R 64 is hydrogen or alkyl.
- R 63 and R 64 are taken together with the atom to which they are attached to form an optionally substituted 5- or 6-membered heterocycloalkyl.
- R 63 and R 64 are taken together with the atom to which they are attached to form a 5- membered heterocycloalkyl optionally substituted with oxo, halogen, -CN, -OR 67 , -NR 67 R 68 , -C0 2 R 67 , optionally substituted alkyl, or optionally substituted heteroalkyl.
- R 63 and R 64 are taken together with the atom to which they are attached to form a 6-membered heterocycloalkyl optionally substituted with oxo, halogen, -CN, -OR , -NR R , -C0 2 R , optionally substituted alkyl, or optionally substituted heteroalkyl.
- R 63 and R 64 are taken together with the atom to which they are attached to form a 6-membered heteroaryl optionally substituted with halogen, -CN, - OR 67 , -NR 67 R 68 , -C0 2 R 67 , optionally substituted alkyl, or optionally substituted heteroalkyl.
- s3 is 0 or 1. In one embodiment of Formula (IX), s3 is 0. In one embodiment of Formula (IX), s3 is 1. In one embodiment of Formula (IX), s3 is 2. In one embodiment of Formula (IX), s3 is 3.
- R 66 is hydrogen, halogen, or alkyl. In one embodiment of Formula (IX), R 66 is hydrogen.
- R 65 is an optionally substituted 5/5 fused bicyclic heteroaryl. In one embodiment of Formula (IX), R 65 is an optionally substituted 5/6 fused bicyclic heteroaryl.
- R 65 is optionally substituted with 1 or 2 R a ; and each R a is independently halogen, -CN, -OR 67 , -NR 67 R 68 , optionally substituted alkyl, optionally substituted alkynyl, optionally substituted cycloalkyl, or optionally substituted heterocycloalkyl; or two R a form an optionally substituted cycloalkyl or an optionally substituted heterocycloalkyl.
- R 65 is optionally substituted with 1 or 2 R a ; and each R a is independently halogen, -CN, - OH, -NH 2 , alkyl, haloalkyl, hydroxyalkyl, or cycloalkyl; or two R a form an optionally substituted cycloalkyl or an optionally substituted heterocycloalkyl.
- R 65 is optionally substituted with 1 R a ; and R a is alkyl.
- R is wherein:
- each X is independently N or CR a ;
- Ring E is a 5- to 6-membered heterocycloalkyl or 5- to 6-membered heteroaryl
- R a form an optionally substituted cycloalkyl or an optionally substituted heterocycloalkyl; and s4 is 0-4.
- Ring E is a 5- to 6-membered heterocycloalkyl comprising 0-2 additional heteroatoms selected from N, O, and S. In one embodiment of Formula (IX), Ring E is a 5- membered heterocycloalkyl comprising 0-2 additional heteroatoms selected from N, O, and S. In one embodiment of Formula (IX), Ring E is a 5-membered heterocycloalkyl. In one embodiment of Formula (IX), Ring E is a 6-membered heterocycloalkyl comprising 0-2 additional heteroatoms selected from N, O, and S. In one embodiment of Formula (IX), E is a 6-membered heterocycloalkyl.
- Ring E is a 5- to 6-membered heteroaryl comprising 0-2 additional heteroatoms selected from N, O, and S. In one embodiment of Formula (IX), Ring E is a 5-membered heteroaryl comprising 0- 2 additional heteroatoms selected from N, O, and S. In one embodiment of Formula (IX), Ring E is a 6- membered heteroaryl comprising 0-2 additional heteroatoms selected from N.
- Ring E is a 6-membered heteroaryl.
- R is
- s4 is 0 or 1. In one embodiment of Formula (IX), s4 is 1. In one embodiment of Formula (IX), s4 is 2. In one embodiment of Formula (IX), s4 is 3. In one embodiment of Formula (IX), s4 is 0-2. In one embodiment of Formula (IX), s4 is 1 or 2.
- X are both N. In one embodiment of Formula (IX), one X is N and the other is CR a . In one embodiment of Formula (IX), X are both CR a .
- each R a is independently hydrogen, halogen, -CN, -OR 67 , -NR 67 R 68 , optionally substituted alkyl, optionally substituted alkynyl, optionally substituted cycloalkyl, or optionally substituted heterocycloalkyl.
- each R a is independently hydrogen, halogen, -CN, -OH, -NH 2 , alkyl, haloalkyl, hydroxyalkyl, or cycloalkyl.
- each R a is independently hydrogen, halogen, or alkyl.
- each R a is independently hydrogen or alkyl.
- two R a on the same carbon form an optionally substituted cycloalkyl or an optionally substituted heterocycloalkyl.
- R is
- R and R are independently hydrogen or optionally substituted alkyl. In one embodiment of Formula (IX), R 67 and R 68 are hydrogen. In one embodiment of Formula (IX), R 69 is optionally substituted alkyl.
- the compound is selected from the following compounds:
- the compound is selected from the following compounds:
- composition refers to a preparation of one or more of the components described herein, or pharmaceutically acceptable salts thereof, with other chemical components such as physiologically suitable carriers and excipients.
- the purpose of a pharmaceutical composition is to facilitate administration of a compound to a patient or subject.
- excipient refers to an inert or inactive substance added to a pharmaceutical composition to further facilitate administration of a compound.
- excipients include calcium carbonate, calcium phosphate, various sugars and types of starch, cellulose derivatives, gelatin, vegetable oils and polyethylene glycols.
- the present teachings further comprise pharmaceutical compositions comprising one or more of the compounds of the present disclosure.
- a pharmaceutical composition comprises one or more of the compounds of the present disclosure and at least one pharmaceutically acceptable excipient.
- the pharmaceutical composition comprises a therapeutically effective amount of a compound of disclosed herein and at least one pharmaceutically acceptable carrier.
- compositions are administered to humans, human patients or subjects.
- active ingredient generally refers to a compound to be delivered as a compound described herein.
- the pharmaceutical composition is a tablet, a pill, a capsule, a liquid, an inhalant, a nasal spray solution, a suppository, a suspension, a gel, a colloid, a dispersion, a suspension, a solution, an emulsion, an ointment, a lotion, eye drop or an ear drop.
- compositions are principally directed to pharmaceutical compositions which are suitable for administration to humans, it will be understood by the skilled artisan that such compositions are generally suitable for administration to any other animal, e.g., to non-human animals, e.g. non-human mammals.
- Subjects to which administration of the pharmaceutical compositions is contemplated include, but are not limited to, non-human mammals, including cattle, pigs, cats, dogs, mice, and rats.
- the compounds described herein are formulated into pharmaceutical compositions.
- pharmaceutical compositions are formulated in a conventional manner using one or more physiologically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen. Any pharmaceutically acceptable techniques, carriers, and excipients are used as suitable to formulate the pharmaceutical compositions described herein: Remington: The Science and Practice of Pharmacy, Nineteenth Ed (Easton, Pa.: Mack Publishing Company, 1995); Hoover, John E., Remington 's
- compositions comprising a compound described herein, and a pharmaceutically acceptable diluent(s), excipient(s), or carrier(s).
- the compounds described are administered as pharmaceutical compositions in which compounds described herein, are mixed with other active ingredients, as in combination therapy.
- the pharmaceutical compositions include one or more compounds described herein.
- one or more compounds described herein is formulated in an aqueous solutions.
- the aqueous solution is selected from, by way of example only, a physiologically compatible buffer, such as Hank's solution, Ringer's solution, or physiological saline buffer.
- one or more compound described herein is formulated for transmucosal administration.
- transmucosal formulations include penetrants that are appropriate to the barrier to be permeated.
- appropriate formulations include aqueous or nonaqueous solutions.
- such solutions include physiologically compatible buffers and/or excipients.
- compounds described herein are formulated for oral administration.
- Compounds described herein, including compounds described herein are formulated by combining the active compounds with, e.g., pharmaceutically acceptable carriers or excipients.
- the compounds described herein are formulated in oral dosage forms that include, by way of example only, tablets, powders, pills, dragees, capsules, liquids, gels, syrups, elixirs, slurries, suspensions and the like.
- pharmaceutical preparations for oral use are obtained by mixing one or more solid excipient with one or more of the compounds described herein, optionally grinding the resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores.
- Suitable excipients are, in particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as: for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methylcellulose, microcrystalline cellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose; or others such as: polyvinylpyrrolidone (PVP or povidone) or calcium phosphate.
- disintegrating agents are optionally added. Disintegrating agents include, by way of example only, cross-linked croscarmellose sodium, polyvinylpyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate.
- dosage forms such as dragee cores and tablets, are provided with one or more suitable coating.
- concentrated sugar solutions are used for coating the dosage form.
- the sugar solutions optionally contain additional components, such as by way of example only, gum arabic, talc, polyvinylpyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures.
- Dyestuffs and/or pigments are also optionally added to the coatings for identification purposes. Additionally, the dyestuffs and/or pigments are optionally utilized to characterize different combinations of active compound doses.
- Oral dosage forms include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol.
- push-fit capsules contain the active ingredients in admixture with one or more filler.
- Fillers include, by way of example only, lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers.
- soft capsules contain one or more active compound that is dissolved or suspended in a suitable liquid. Suitable liquids include, by way of example only, one or more fatty oil, liquid paraffin, or liquid polyethylene glycol.
- stabilizers are optionally added.
- therapeutically effective amounts of at least one of the compounds described herein are formulated for buccal or sublingual administration.
- Formulations suitable for buccal or sublingual administration include, by way of example only, tablets, lozenges, or gels.
- the compounds described herein are formulated for parental injection, including formulations suitable for bolus injection or continuous infusion.
- formulations for injection are presented in unit dosage form (e.g., in ampoules) or in multi-dose containers.
- Preservatives are, optionally, added to the injection formulations.
- the pharmaceutical compositions comprising a compound described herein are formulated in a form suitable for parenteral injection as a sterile suspensions, solutions or emulsions in oily or aqueous vehicles.
- Parenteral injection formulations optionally contain formulatory agents such as suspending, stabilizing and/or dispersing agents.
- pharmaceutical formulations for parenteral administration include aqueous solutions of the active compounds in water-soluble form.
- suspensions of the active compounds are prepared as appropriate oily injection suspensions.
- Suitable lipophilic solvents or vehicles for use in the pharmaceutical compositions described herein include, by way of example only, fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes.
- aqueous injection suspensions contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran.
- the suspension contains suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.
- the active ingredient is in powder form for constitution with a suitable vehicle, e.g. , sterile pyrogen-free water, before use.
- the compounds described herein are administered topically.
- the compounds described herein are formulated into a variety of topically administrable compositions, such as solutions, suspensions, lotions, gels, pastes, medicated sticks, balms, creams or ointments.
- Such pharmaceutical compositions optionally contain solubilizers, stabilizers, tonicity enhancing agents, buffers and preservatives.
- transdermal formulations employ transdermal delivery devices and transdermal delivery patches and can be lipophilic emulsions or buffered, aqueous solutions, dissolved and/or dispersed in a polymer or an adhesive.
- patches are constructed for continuous, pulsatile, or on demand delivery of pharmaceutical agents.
- the transdermal delivery of the compounds described herein is accomplished by means of iontophoretic patches and the like.
- transdermal patches provide controlled delivery of the compounds described herein.
- the rate of absorption is slowed by using rate-controlling membranes or by trapping the compound within a polymer matrix or gel.
- absorption enhancers are used to increase absorption.
- Absorption enhancers or carriers include absorbable pharmaceutically acceptable solvents that assist passage through the skin.
- transdermal devices are in the form of a bandage comprising a backing member, a reservoir containing the compound optionally with carriers, optionally a rate controlling barrier to deliver the compound to the skin of the host at a controlled and predetermined rate over a prolonged period of time, and means to secure the device to the skin.
- the compounds described herein are formulated for administration by inhalation.
- Various forms suitable for administration by inhalation include, but are not limited to, aerosols, mists or powders.
- Pharmaceutical compositions comprising a compound described herein are conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebulizer, with the use of a suitable propellant (e.g. , dichlorodifluoromethane, trichlorofluoromethane,
- the dosage unit of a pressurized aerosol is determined by providing a valve to deliver a metered amount.
- capsules and cartridges of, such as, by way of example only, gelatin for use in an inhaler or insufflator are formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.
- the compounds described herein are formulated in rectal
- compositions such as enemas, rectal gels, rectal foams, rectal aerosols, suppositories, jelly suppositories, or retention enemas, containing conventional suppository bases such as cocoa butter or other glycerides, as well as synthetic polymers such as polyvinylpyrrolidone, PEG, and the like.
- a low-melting wax such as, but not limited to, a mixture of fatty acid glycerides, optionally in combination with cocoa butter is first melted.
- pharmaceutical compositions are formulated in any conventional manner using one or more physiologically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used
- compositions comprising a compound described herein are manufactured in a conventional manner, such as, by way of example only, by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or compression processes.
- compositions include at least one pharmaceutically acceptable. carrier, diluent or excipient and at least one compound described herein as an active ingredient.
- the active ingredient is in free-acid or free-base form, or in a pharmaceutically acceptable salt form.
- the methods and pharmaceutical compositions described herein include the use of N-oxides, crystalline forms (also known as polymorphs), as well as active metabolites of these compounds having the same type of activity. All tautomers of the compounds described herein are included within the scope of the compounds presented herein.
- the compounds described herein encompass unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like. The solvated forms of the compounds presented herein are also considered to be disclosed herein.
- compositions optionally include other medicinal or pharmaceutical agents, carriers, adjuvants, such as preserving, stabilizing, wetting or emulsifying agents, solution promoters, salts for regulating the osmotic pressure, buffers, and/or other therapeutically valuable substances.
- adjuvants such as preserving, stabilizing, wetting or emulsifying agents, solution promoters, salts for regulating the osmotic pressure, buffers, and/or other therapeutically valuable substances.
- compositions comprising the compounds described herein include formulating the compounds with one or more inert, pharmaceutically acceptable excipients or carriers to form a solid, semi-solid or liquid.
- Solid compositions include, but are not limited to, powders, tablets, dispersible granules, capsules, cachets, and suppositories.
- Liquid compositions include solutions in which a compound is dissolved, emulsions comprising a compound, or a solution containing liposomes, micelles, or nanoparticles comprising a compound as disclosed herein.
- Semi-solid compositions include, but are not limited to, gels, suspensions and creams.
- compositions described herein include liquid solutions or suspensions, solid forms suitable for solution or suspension in a liquid prior to use, or as emulsions. These compositions also optionally contain minor amounts of nontoxic, auxiliary substances, such as wetting or emulsifying agents, pH buffering agents, and so forth.
- composition comprising at least one compound described herein, illustratively takes the form of a liquid where the agents are present in solution, in suspension or both. Typically when the composition is administered as a solution or suspension a first portion of the agent is present in solution and a second portion of the agent is present in particulate form, in suspension in a liquid matrix.
- a liquid composition includes a gel formulation. In other embodiments, the liquid composition is aqueous.
- useful aqueous suspension contain one or more polymers as suspending agents.
- Useful polymers include water-soluble polymers such as cellulosic polymers, e.g., hydroxypropyl methylcellulose, and water-insoluble polymers such as cross-linked carboxyl-containing polymers.
- Certain pharmaceutical compositions described herein comprise a mucoadhesive polymer, selected for example from carboxymethylcellulose, carbomer (acrylic acid polymer), poly(methylmethacrylate), polyacrylamide, polycarbophil, acrylic acid/butyl acrylate copolymer, sodium alginate and dextran.
- Useful pharmaceutical compositions also, optionally, include solubilizing agents to aid in the solubility of a compound described herein.
- the term "solubilizing agent” generally includes agents that result in formation of a micellar solution or a true solution of the agent.
- Certain acceptable nonionic surfactants for example polysorbate 80, are useful as solubilizing agents, as can ophthalmically acceptable glycols, polyglycols, e.g., polyethylene glycol 400, and glycol ethers.
- useful pharmaceutical compositions optionally include one or more pH adjusting agents or buffering agents, including acids such as acetic, boric, citric, lactic, phosphoric and hydrochloric acids; bases such as sodium hydroxide, sodium phosphate, sodium borate, sodium citrate, sodium acetate, sodium lactate and tris-hydroxymethylaminomethane; and buffers such as
- citrate/dextrose sodium bicarbonate and ammonium chloride.
- Such acids, bases and buffers are included in an amount required to maintain pH of the composition in an acceptable range.
- useful compositions also, optionally, include one or more salts in an amount required to bring osmolality of the composition into an acceptable range.
- salts include those having sodium, potassium or ammonium cations and chloride, citrate, ascorbate, borate, phosphate, bicarbonate, sulfate, thiosulfate or bisulfite anions; suitable salts include sodium chloride, potassium chloride, sodium thiosulfate, sodium bisulfite and ammonium sulfate.
- compositions optionally include one or more preservatives to inhibit microbial activity.
- Suitable preservatives include mercury-containing substances such as merfen and thiomersal; stabilized chlorine dioxide; and quaternary ammonium compounds such as benzalkonium chloride, cetyltrimethylammonium bromide and cetylpyridinium chloride.
- compositions include one or more surfactants to enhance physical stability or for other purposes.
- Suitable nonionic surfactants include polyoxyethylene fatty acid glycerides and vegetable oils, e.g. , polyoxyethylene (60) hydrogenated castor oil; and polyoxyethylene alkylethers and alkylphenyl ethers, e.g., octoxynol 10, octoxynol 40.
- compositions include one or more antioxidants to enhance chemical stability where required.
- Suitable antioxidants include, by way of example only, ascorbic acid and sodium metabisulfite.
- aqueous suspension compositions are packaged in single-dose non- reclosable containers.
- multiple-dose reclosable containers are used, in which case it is typical to include a preservative in the composition.
- hydrophobic pharmaceutical compounds are employed. Liposomes and emulsions are examples of delivery vehicles or carriers useful herein. In certain embodiments, organic solvents such as N-methylpyrrolidone are also employed. In additional embodiments, the compounds described herein are delivered using a sustained-release system, such as semipermeable matrices of solid hydrophobic polymers containing the therapeutic agent. Various sustained-release materials are useful herein. In some embodiments, sustained-release capsules release the compounds for a few weeks up to over 100 days. Depending on the chemical nature and the biological stability of the therapeutic reagent, additional strategies for protein stabilization are employed.
- the formulations described herein comprise one or more antioxidants, metal chelating agents, thiol containing compounds and/or other general stabilizing agents.
- stabilizing agents include, but are not limited to: (a) about 0.5% to about 2% w/v glycerol, (b) about 0.1% to about 1% w/v methionine, (c) about 0.1% to about 2% w/v monothioglycerol, (d) about 1 mM to about 10 mM EDTA, (e) about 0.01% to about 2% w/v ascorbic acid, (f) 0.003% to about 0.02% w/v polysorbate 80, (g) 0.001% to about 0.05% w/v.
- polysorbate 20 (h) arginine, (i) heparin, (j) dextran sulfate, (k) cyclodextrins, (1) pentosan polysulfate and other heparinoids, (m) divalent cations such as magnesium and zinc; or (n) combinations thereof.
- the present disclosure provides methods comprising administering compounds of the disclosure to a subject in need thereof.
- Compounds as described herein may be administered to a subject using any amount and any route of administration effective for treating a disease, a disorder, or a condition (e.g., a disease, a disorder, or a condition relating to gram-negative bacterial infections).
- compositions in accordance with the disclosure are typically formulated in dosage unit form for ease of administration and uniformity of dosage. It will be understood, however, that the total daily usage of the compositions of the present disclosure may be decided by the attending physician within the scope of sound medical judgment.
- the specific therapeutically effective or prophylactically effective dose level for any particular subject will depend upon a variety of factors including the species, age, body weight, general health, sex and diet of the subject; the disorder or disease being treated and the severity of the disorder or disease; the activity of the specific compound employed; the specific composition employed; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific compound employed; and like factors well known in the medical arts.
- described herein is a method for treating a disease in a mammal comprising administering to the mammal a therapeutically effective amount of a compound described herein.
- the disease is selected from the group consisting of a blood disease, an autoimmune disorder, a pulmonary disorder, hypertension, an inflammatory disease, a fibrotic disease, diabetes, diabetic nephropathy, a renal disease, a respiratory disease, a cardiovascular disease, acute lung injury, acute or chronic liver disease, and a neurodegenerative disease.
- the liver disease is selected from the group consisting of fascioliasis, hepatitis, non-alcoholic steatohepatitis (NASH) with or without fibrosis, hepatic steatosis, fatty liver disease (FLD), non-alcoholic fatty liver disease (NAFLD), alcoholic liver disease, Alagille syndrome, biliary atresia, galactosemia, gallstones, hemochromatosis, liver cancer, lysosomal acid lipase deficiency (LALD), porphyria, acetaminophen hepatotoxicity, Reye's syndrome, sarcoidosis, tyrosinemia, Wilson disease, Gilbert's syndrome, cirrhosis and primary sclerosing cholangitis.
- fascioliasis hepatitis
- NASH non-alcoholic steatohepatitis
- NASH non-alcoholic steatohepatitis
- fatty liver disease FLD
- the liver disease is non-alcoholic steatohepatitis (NASH).
- NASH non-alcoholic steatohepatitis
- the liver disease is acute liver injury.
- the liver disease is hepatic steatosis.
- the pulmonary disorder is selected from the group consisting of chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), asthma, bronchitis, emphysema, lung cancer, pneumonia, cystic fibrosis, pulmonary embolism, pulmonary arterial hypertension, pulmonary edema and pulmonary hemorrhage.
- COPD chronic obstructive pulmonary disease
- IPF idiopathic pulmonary fibrosis
- asthma bronchitis
- emphysema emphysema
- lung cancer pneumonia
- cystic fibrosis pulmonary embolism
- pulmonary arterial hypertension pulmonary edema
- pulmonary hemorrhage
- the autoimmune disorder is selected from the group consisting of alopecia areata, autoimmune hemolytic anemia, autoimmune hepatitis, dermatomyositis, diabetes (type 1), idiopathic arthritis, glomerulonephritis, Graves' disease, Guillain-Barre syndrome, idiopathic thrombocytopenic purpura, myasthenia gravis, myocarditis, multiple sclerosis, pemphigus/pemphigoid, pernicious anemia, polyarteritis nodosa, polymyositis, primary biliary cirrhosis, psoriasis, rheumatoid arthritis, scleroderma/systemic sclerosis, Sjogren's syndrome, systemic lupus erythematosus, thyroiditis, uveitis, vitiligo, granulomatosis with polyangiitis (Wegener's).
- the inflammatory disease is selected from the group consisting of Alzheimer's, ankylosing spondylitis, arthritis (osteoarthritis, rheumatoid arthritis (RA), psoriatic arthritis), atherosclerosis, arteriosclerosis, cholestasis, Crohn's disease, colitis, dermatitis, diverticulitis, fibromyalgia, irritable bowel syndrome (IBS), systemic lupus erythematous (SLE), nephritis, Parkinson's disease, cardiac inflammation, and ulcerative colitis.
- arthritis osteoarthritis, rheumatoid arthritis (RA), psoriatic arthritis
- atherosclerosis arteriosclerosis
- cholestasis cholestasis
- Crohn's disease colitis
- dermatitis diverticulitis
- fibromyalgia irritable bowel syndrome
- SLE systemic lupus erythematous
- nephritis Parkinson
- the renal disease is selected from the group consisting of Alport syndrome, renal fibrosis, kidney disease, diabetic nephropathy, fabry disease, diabetic kidney disease, diabetic nephropathy, renal inflammation, renal fibrosis focal segmental glomerulosclerosis, glomerulonephritis, IgA nephropathy (Berger's disease), kidney stones, minimal change disease, nephrotic syndrome, and polycystic kidney disease (PKD).
- Alport syndrome renal fibrosis
- kidney disease diabetic nephropathy
- fabry disease diabetic kidney disease
- diabetic nephropathy diabetic nephropathy
- renal inflammation renal fibrosis focal segmental glomerulosclerosis
- glomerulonephritis IgA nephropathy (Berger's disease)
- kidney stones minimal change disease
- nephrotic syndrome nephrotic syndrome
- PPD polycystic kidney disease
- the neurodegenerative disease is selected from the group consisting of Alzheimer's disease, dementia, multiple sclerosis, optical neuritis, amyotrophic lateral sclerosis, Friedreich's ataxia, amyotrophic lateral sclerosis (ALS), Huntington's disease, Lewy body disease, Parkinson's disease and spinal muscular atrophy.
- the neurodegenerative disease is multiple sclerosis.
- the neurodegenerative disease is amyotrophic lateral sclerosis.
- the neurodegenerative disease is Alzheimer's disease.
- the neurodegenerative disease is Parkinson's disease.
- the cardiovascular disease is selected from the group consisting of endothelial dysfunction, metabolic syndrome, atherosclerosis, coronary artery disease, heart failure, peripheral artery disease, cardiac inflammation, cardiac fibrosis, cerebrovascular disease and coronary syndrome.
- the blood disease is sickle cell disease.
- described herein is a method for reducing neuronal cell death following ischemic injury in a mammal comprising administering to the mammal a therapeutically effective amount of a compound described herein.
- described herein is a method for modulating platelets in a mammal comprising administering to the mammal a therapeutically effective amount of a compound described herein.
- the compound modulates platelet activation, platelet granule secretion, thromboxane A2 generation, or thrombosis modulation.
- described herein is a method for modulating the level of a reactive oxidative species in a mammal comprising administering to the mammal a therapeutically effective amount of a compound described herein.
- the oxidative species is a reactive oxygen species. In another embodiment, the oxidative species contains a radical on the oxygen atom.
- the disease is a cancer. In one embodiment, the disease is a Sickle cell disease. In one embodiment, the disease is a renal fibrosis. In one embodiment, the disease is a kidney disease. In one embodiment, the disease is a function of oxidative stress. In one embodiment, the disease is liver ischemia.
- the compounds disclosed herein are prepared as a pharmaceutically acceptable acid addition salt (which is a type of a pharmaceutically acceptable salt) by reacting the free base form of the compound with a pharmaceutically acceptable inorganic or organic acid, including, but not limited to, inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid metaphosphoric acid, and the like; and organic acids such as acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, p-toluenesulfonic acid, tartaric acid, trifluoroacetic acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, arylsulfonic acid, methane
- inorganic acids such as
- pharmaceutically acceptable refers a material, such as a carrier or diluent, which does not abrogate the biological activity or properties of the compound, and is relatively nontoxic, i.e., the material may be administered to an individual without causing undesirable biological effects or interacting in a deleterious manner with any of the components of the composition in which it is contained.
- pharmaceutically acceptable salt refers to a formulation of a compound that does not cause significant irritation to an organism to which it is administered and does not abrogate the biological activity and properties of the compound.
- pharmaceutically acceptable salts are obtained by reacting a compound the compounds disclosed herein with acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid and the like.
- salts are also obtained by reacting a compound the compounds disclosed herein with a base to form a salt such as an ammonium salt, an alkali metal salt, such as a sodium or a potassium salt, an alkaline earth metal salt, such as a calcium or a magnesium salt, a salt of organic bases such as dicyclohexylamine, N-methyl-D-glucamine, tris(hydroxymethyl)methylamine, and salts with amino acids such as arginine, lysine, and the like.
- a salt such as an ammonium salt, an alkali metal salt, such as a sodium or a potassium salt, an alkaline earth metal salt, such as a calcium or a magnesium salt, a salt of organic bases such as dicyclohexylamine, N-methyl-D-glucamine, tris(hydroxymethyl)methylamine, and salts with amino acids such as arginine, lysine, and the like.
- the compounds disclosed herein are prepared as a pharmaceutically acceptable salts by reacting the free acid form of the compound with a pharmaceutically acceptable inorganic or organic base, including, but not limited to organic bases such as ethanolamine,
- diethanolamine triethanolamine, tromethamine, N-methylglucamine, and the like, or with an inorganic base such as aluminum hydroxide, calcium hydroxide, potassium hydroxide, sodium carbonate, sodium hydroxide, and the like.
- an inorganic base such as aluminum hydroxide, calcium hydroxide, potassium hydroxide, sodium carbonate, sodium hydroxide, and the like.
- a reference to a pharmaceutically acceptable salt includes the solvent addition forms or crystal forms thereof, particularly solvates or polymorphs.
- Solvates contain either stoichiometric or non-stoichiometric amounts of a solvent, and are optionally formed during the process of crystallization with pharmaceutically acceptable solvents such as water, ethanol, and the like. Hydrates are formed when the solvent is water, or alcoholates are formed when the solvent is alcohol. Solvates of compounds described herein are conveniently prepared or formed during the processes described herein.
- hydrates of compounds described herein are conveniently prepared by recrystallization from an aqueous/organic solvent mixture, using organic solvents including, but not limited to, dioxane, tetrahydrofuran, ethanol, or methanol.
- organic solvents including, but not limited to, dioxane, tetrahydrofuran, ethanol, or methanol.
- the compounds provided herein can exist in unsolvated as well as solvated forms. In general, the solvated forms are considered equivalent to the unsolvated forms for the purposes of the compounds and methods provided herein.
- the compounds disclosed herein are prepared in various forms, including but not limited to, amorphous forms, milled forms and nano-particulate forms.
- compounds the compounds disclosed herein include crystalline forms, also known as polymorphs.
- Polymorphs include the different crystal packing arrangements of the same elemental composition of a compound. Polymorphs usually have different X-ray diffraction patterns, infrared spectra, melting points, density, hardness, crystal shape, optical and electrical properties, stability, and solubility. Various factors such as the recrystallization solvent, rate of crystallization, and storage temperature may cause a single crystal form to dominate.
- the compounds disclosed herein are prepared as prodrugs.
- a "prodrug” refers to an agent that is converted into the parent drug in vivo. Prodrugs are often useful because, in some situations, they are easier to administer than the parent drug. They are, for instance, be bioavailable by oral administration whereas the parent is not. The prodrug may also have improved solubility in pharmaceutical compositions over the parent drug.
- prodrug a compound disclosed herein, which is administered as an ester (the "prodrug") to facilitate transmittal across a cell membrane where water solubility is detrimental to mobility but which then is metabolically hydrolyzed to the carboxylic acid, the active entity, once inside the cell where water-solubility is beneficial.
- prodrug a short peptide (polyaminoacid) bonded to an acid group where the peptide is metabolized to reveal the active moiety.
- Prodrugs are generally drug precursors that, following administration to a subject and subsequent absorption, are converted to an active, or a more active species via some process, such as conversion by a metabolic pathway. Some prodrugs have a chemical group present on the prodrug that renders it less active and/or confers solubility or some other property to the drug. Once the chemical group has been cleaved and/or modified from the prodrug the active drug is generated. Prodrugs are often useful because, in some situations, they are easier to administer than the parent drug. In certain embodiments, the prodrug of a compound described herein is bioavailable by oral administration whereas the parent is not. Furthermore, in some embodiments, the prodrug of a compound described herein has improved solubility in pharmaceutical compositions over the parent drug.
- prodrugs are designed as reversible drug derivatives, for use as modifiers to enhance drug transport to site-specific tissues.
- the design of prodrugs to date is to increase the effective water solubility of the therapeutic compound for targeting to regions where water is the principal solvent.
- appropriate prodrugs are prepared by reacting a non- derivatized compounds disclosed herein with a suitable carbamylating agent, such as, but not limited to,
- sites on the aromatic ring portion of any compounds disclosed herein are susceptible to various metabolic reactions Therefore incorporation of appropriate substituents on the aromatic ring structures will reduce, minimize or eliminate this metabolic pathway.
- the appropriate substituent to decrease or eliminate the susceptibility of the aromatic ring to metabolic reactions is, by way of example only, a halogen, or an alkyl group.
- the compounds described herein are labeled isotopically (e.g. with a radioisotope) or by another other means, including, but not limited to, the use of chromophores or fluorescent moieties, bioluminescent labels, or chemiluminescent labels.
- the compounds disclosed herein possess one or more stereocenters and each center exists independently in either the R or S configuration.
- the compounds presented herein include all diastereomeric, enantiomeric, and epimeric forms as well as the appropriate mixtures thereof.
- compounds disclosed herein are prepared as their individual stereoisomers.
- compounds disclosed herein are prepared as their individual stereoisomers by reacting a racemic mixture of the compound with an optically active resolving agent to form a pair of diastereoisomeric compounds, separating the diastereomers and recovering the optically pure enantiomers.
- resolution of enantiomers is carried out using covalent
- dissociable complexes are utilized (e.g., crystalline diastereomeric salts).
- Diastereomers have distinct physical properties (e.g., melting points, boiling points, solubilities, reactivity, etc.) and are, in specific embodiments, separated by taking advantage of these dissimilarities.
- the diastereomers are separated by chiral chromatography or by separation/resolution techniques based upon differences in solubility.
- the optically pure enantiomer is then recovered, along with the resolving agent, by any practical means that does not result in racemization. Jean Jacques, Andre Collet, Samuel H. Wilen, "Enantiomers, Racemates and Resolutions", John Wiley And Sons, Inc., 1981.
- the compounds provided herein exist as geometric isomers.
- the compounds and methods provided herein include all cis, trans, syn, anti,
- E
- Z
- the compounds described herein exist as tautomers. All tautomers are intended to be within the scope of the molecular formulas described herein.
- mixtures of enantiomers and/or diastereoisomers, resulting from a single preparative step, combination, or interconversion are envisioned.
- Example la (10.0 g, 71.87 mmol) and NIS (21.0 g, 93.43 mmol) in DMF (125 mL) was stirred at room temperature for 1 h and at 50°C for 20 h. Most of DMF was removed in vacuo and water (150 mL) was added to the mixture. The mixture was stirred at 0°C for 1 h and filtered. The cake was washed with water (30 mL*3). The solid was suspended in MeOH (100 mL) and stirred at room temperature for 2 h, filtered, washed with MeOH (15 mL) and dried in vacuo to afford the desired product Example lb (16.7 g, 88% yield) as a yellow solid.
- LC-MS [M+H] + 265.9
- Example lb (1.00 g, 3.77 mmol)
- Example lc (0.51 g, 4.72 mmol) and Cs 2 C0 3 (3.69 g, 11.32 mmol) in DMF (12.5 mL)
- Cul 72 mg, 0.37 mmol
- (1R,2S)-N',N 2 - dimethylcyclohexane-l,2-diamine 107 mg, 0.75 mmol
- the reaction mixture was heated to 130°C and stirred for 16 h.
- the reaction mixture was cooled to room temperature and diluted with MeOH and filtered.
- the cake was washed with MeOH and the filtrate was concentrated to afford crude product Example Id (1.00 g, containing DMF, crude yield >100%), which was used for the next step without further purification.
- LC-MS [M+H] + 246.0
- Example lg (282 mg, 1.39 mmol), DIEA (996 mg, 7.70 mmol), DMAP (19 mg, 0.15 mmol) and HATU (880 mg, 2.31 mmol) in DMF (15 mL) was heated to 40°C and stirred for 16 h.
- Example 2a To a solution of Example 2a (2.0 g, 11.5 mmol) in DCM (50 mL) was added TEA dropwise (4.8mL, 34.4 mmol) at 5 °C. Thenisobutyryl chloride (1.4 mL,13.4mmol)was added dropwise. The reaction mixture was stirred at room temperature for 2 hours. TLC showed the starting materiall was consumed, and a new point was formed. The mixture was diluted with EtOAc (150 mL), washed with aq. NH 4 C1, brine, dried over anhydrous Na 2 SC> 4 . The solvent was removed under reduced pressure. The residue was purified by biotage-flash to afford 2.1 g of the title compound. Yield: 75.1%.
- Example 2b (1.85 g, 7.6 mmol) was dissolved in CH 3 CN (20 mL), and SiCL, (9.2 mL, 80.1 mmol) was added dropwise, followed by NaN 3 (8.17g, 125.7mmol). Then the reaction mixture was stirred at room temperature for 2 days. The reaction mixture was added to a solution of sodium carbonate in water slowly. The suspension was stirred for 1 hour, and then diluted with 300 mL of ethyl acetate. The water phase and the suspension were separated, and extracted with 200 mL of EA. The combined organic phase was washed with water, brine, and dried over anhydrous Na 2 S0 4 . The solvent was removed under reduced pressure, and the residue was purified by biotage flash to afford 1.46 g of white solid.
- Example 2c 54 mg, 0.20 mmol
- tert-Butyl carbamate 67 mg, 0.57 mmol
- Pd(AcO) 2 5 mg, 0.02 mmol
- BINAP 25 mg, 0.04 mmol
- Example 2d To a solution of Example 2d (52 mg, 0.17 mmol) in 1 mL of DCM was added TFA (0.2 mL, 2.7 mmol) dropwise. Then the reaction mixture was stirred at room temperature for 4 hours. TLC showed the reaction was completed. The reaction mixture was concentrated to afford 45 mg of yellow oil. The oil was used at next step without further purification.
- Example 2f (210 mg, 0.81 mmol) in SOCl 2 (3 mL, 41.3 mmol) was heated to refluxed, stirred for 1.5 hours. Then the reaction mixture was concentrated. The obtained white solid was added to a solution of Example 2e (150 mg, 0.73 mmol) and TEA (0.4 mL, 2.9 mmol) in DCM in portions. The reaction mixture was stirred at room temperature for 1 hour. LC-MS showed the reaction was completed. The reaction mixture was diluted with DCM, and washed with water, brine and dried over anhydrous sodium sulfate. The solvent was removed under reduced pressure.
- Example 3d To a solution of Example 3d (800 mg,3.9 mmol) in DCM (50 mL) was added m-CPBA(l g, 5.9 mmol), The mixture was stirred at room temperature for 18h. Water (5 mL) was added to the mixture, then extracted with DCM (50 mL*2) and combined the organic phase, washed with brine, dried over anhydrous Na 2 S0 4 , filtered and concentrated under reduced pressure to give the crude product and further purified by silica chromatography to give the product 200mg as a yellow solid.
- Example 3j 600 mg, 2.4 mmol
- Example 3i 400 mg, 3.6 mmol
- Cul 45 mg, 0.24 mmol
- K 3 P0 4 (1 g, 4.8 mmol)
- TBAB 486 mg, 1.2 mmol
- Example 3k 210 mg, 0.77 mmol
- DIEA 200.6 mg, 1.54 mmol
- HBTU 410 mg, 1.15 mmol
- Example 5d (444 mg, 2.0 mmol)and tert-butyl carbamate (370 mg, 3.16 mmol) in 6 mL of toluene wereadded Pd(OAc) 2 (23 mg, 0.1 mmol), BINAP (146 mg, 0.2 mmol), Cs 2 C0 3 (914 mg, 2.8 mmol) , and then stirred at 100 °C overnight.
- the mixture was diluted by DCM, washed with water, dried and stripped of solvent. The residue was purified by flash chromatography to give product Example 5f (550 mg yield: 91%).
- LCMS [M+l] + 304.0
- Example 5j To a solution of Example 5j (92 mg, 0.35 mmol) in 5mL of DMF were added isobutyl carbonochloridate (61 mg, 0.44 mmol) and Et3N (101 mg, 1.0 mmol) at 0 °C and stirred for lh. Then added Example 5i (102 mg, 0.5 mmol) and stirred 100oC for 4h. The mixture was diluted by DCM, washed with water, dried and stripped of solvent.
- Example 6a (5.00 g, 36.47 mmol) and NIS (9.55 g, 42.44 mmol) in DMF (50 mL) was stirred at room temperature for 1 h and at 50°C for 48 h. The reaction mixture was cooled to room temperature and poured into water (150 mL) with stirring and filtered. The cake was washed with water (30 mL*3) and dried in vacuo to afford the desired product Example 6b (7.8 g, yield 86% ) as a yellow solid.
- LC-MS [M+l] + 280
- Example 6b To a suspension of Example 6b (1.00 g, 3.58 mmol), Example lc (483 mg, 4.48 mmol) and Cs 2 C0 3 (3.50 g, 10.75 mmol) in DMF (12.5 mL) was added Cul (68 mg, 0.36 mmol) and (1R,2S)-N',N 2 - dimethylcyclohexane-l,2-diamine (112 mg, 0.79mmol) under N 2 at room temperature. The reaction mixture was heated to 130°C and stirred for 10 h. The reaction mixture was cooled to room temperature and diluted with MeOH (20 mL) and filtered.
- Example 6d To a mixture of Example 6d (70 mg, 0.24 mmol) in MeOH (4.0 mL) was added a solution of NaOH (39 mg, 0.97 mmol) in water (1.0 mL) at room temperature, which was stirred for 4 h. The mixture was concentrated under reduced pressure and water was added. The resulting solution was extracted with EtOAc (10 mL*4). The aqueous layer was adjusted with aqueous HC1 solution (2.0 N) to pH about 4, and then concentrated to afford the crude product Example 6e (66 mg, crude yield 100%) as a white solid.
- LC-MS [M+l] + 274
- Example 6e A mixture of Example 6e (66 mg, 0.24 mmol), Example lg (44 mg, 0.22 mmol), DIEA (156 mg, 1.21 mmol), DMAP (3 mg, 0.024 mmol) and HATU (138 mg, 0.36 mmol) in DMF (3 mL) was heated to 45°C and stirred for 16 h.
- LC-MS [M+l] + 459.0
- Example 7a (12.5 g, 87.07 mmol) and con.HCl (30mL) in 100 mL of water and 50 mL of ether was cooled to 0 °C.
- a solution of NaNC>2 (9.6 g, 175 mmol)in 10 mL of water was added dropwise, the temperature was maintained below 5 °C at which the reaction was allowed to proceed for 2 hours , and then the organic phase was separated. The aqueous phase was extracted with ether. The ether solution were combined, washed with water, dried over Na 2 S0 4 and stripped of solvent. The residue was purified by flash chromatography (PE/EA 4/1) to give product Example 7b (10.0 g, yield: 75%).
- LCMS [M+l] + 155.0
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Selon l'invention, l'activation et la signalisation de la kinase 1 de régulation du signal apoptotique jouent un rôle important dans une vaste gamme de maladies comprenant les troubles neurodégénératifs, cardiovasculaires, inflammatoires, auto-immuns et métaboliques. L'invention concerne la synthèse d'agents thérapeutiques issus de pyridinyle servant d'inhibiteurs de ASK1, ainsi que des compositions pharmaceutiques et des méthodes d'utilisation associées.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762460527P | 2017-02-17 | 2017-02-17 | |
US62/460,527 | 2017-02-17 | ||
US201762531336P | 2017-07-11 | 2017-07-11 | |
US62/531,336 | 2017-07-11 | ||
US201862621374P | 2018-01-24 | 2018-01-24 | |
US62/621,374 | 2018-01-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018151830A1 true WO2018151830A1 (fr) | 2018-08-23 |
Family
ID=63169875
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2018/000044 WO2018151830A1 (fr) | 2017-02-17 | 2018-02-16 | Inhibiteurs de kinase de régulation du signal apoptotique à base de pyridinyle |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2018151830A1 (fr) |
Cited By (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10150755B2 (en) | 2017-04-05 | 2018-12-11 | Seal Rock Therapeutics, Inc. | ASK1 inhibitor compounds and uses thereof |
WO2019034096A1 (fr) * | 2017-08-17 | 2019-02-21 | Sunshine Lake Pharma Co., Ltd. | Composés bicycliques fusionnés et leurs utilisations en médecine |
WO2019046186A1 (fr) * | 2017-08-28 | 2019-03-07 | Enanta Pharmaceuticals, Inc. | Inhibiteurs de la kinase 1 régulant le signal apoptotique contenant des tétrazoles et méthodes d'utilisation de ceux-ci |
US10246439B2 (en) | 2017-05-25 | 2019-04-02 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
US10253018B2 (en) | 2017-05-25 | 2019-04-09 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
CN109956928A (zh) * | 2017-12-14 | 2019-07-02 | 四川科伦博泰生物医药股份有限公司 | 吡啶类化合物、其制备方法及用途 |
US10450301B2 (en) | 2017-05-25 | 2019-10-22 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
WO2019213244A1 (fr) | 2018-05-02 | 2019-11-07 | Enanta Pharmaceuticals, Inc. | Inhibiteurs de la kinase 1 régulant le signal d'apoptose contenant des tétrazoles et leurs méthodes d'utilisation |
CN110577541A (zh) * | 2019-07-16 | 2019-12-17 | 广州安岩仁医药科技有限公司 | 苯甲酰氨基吡啶衍生物的盐及其在药物中的应用 |
CN110577540A (zh) * | 2019-07-16 | 2019-12-17 | 广州安岩仁医药科技有限公司 | 苯甲酰氨基吡啶衍生物的盐及其在药物中的应用 |
CN110577535A (zh) * | 2019-07-16 | 2019-12-17 | 广州安岩仁医药科技有限公司 | 苯甲酰氨基吡啶衍生物的盐及其在药物中的应用 |
CN110577539A (zh) * | 2019-07-16 | 2019-12-17 | 广州安岩仁医药科技有限公司 | 苯甲酰氨基吡啶衍生物的盐及其在药物中的应用 |
CN110577536A (zh) * | 2019-07-16 | 2019-12-17 | 广州安岩仁医药科技有限公司 | 苯甲酰氨基吡啶衍生物的盐及其在药物中的应用 |
CN110577533A (zh) * | 2019-07-16 | 2019-12-17 | 广州安岩仁医药科技有限公司 | 苯甲酰氨基吡啶衍生物的盐及其在药物中的应用 |
CN110577537A (zh) * | 2019-07-16 | 2019-12-17 | 广州安岩仁医药科技有限公司 | 苯甲酰氨基吡啶衍生物的盐及其在药物中的应用 |
CN110577534A (zh) * | 2019-07-16 | 2019-12-17 | 广州安岩仁医药科技有限公司 | 苯甲酰氨基吡啶衍生物的盐及其在药物中的应用 |
CN110577538A (zh) * | 2019-07-16 | 2019-12-17 | 广州安岩仁医药科技有限公司 | 苯甲酰氨基吡啶衍生物的盐及其在药物中的应用 |
WO2020006031A1 (fr) * | 2018-06-27 | 2020-01-02 | Biogen Ma Inc. | Agents inhibiteurs d'ask1 |
KR20200007000A (ko) * | 2017-05-12 | 2020-01-21 | 이난타 파마슈티칼스, 인코포레이티드 | 아폽토시스 신호 조절 키나아제 1 억제제 및 이의 사용 방법 |
WO2020015721A1 (fr) * | 2018-07-20 | 2020-01-23 | 福建广生堂药业股份有限公司 | Forme cristalline utilisée en tant qu'inhibiteur d'ask1, son procédé de préparation et son utilisation |
WO2020030107A1 (fr) * | 2018-08-10 | 2020-02-13 | 江苏豪森药业集团有限公司 | Composition pharmaceutique contenant des dérivés amides, son procédé de préparation et application associée |
WO2020034988A1 (fr) * | 2018-08-14 | 2020-02-20 | 江苏豪森药业集团有限公司 | Sel d'inhibiteur de kinase 1 de régulation du signal de l'apoptose et forme cristalline de celui-ci |
CN110818683A (zh) * | 2018-08-10 | 2020-02-21 | 中国科学院上海药物研究所 | 2-吡啶取代脲结构小分子化合物及其合成和应用 |
CN110922407A (zh) * | 2018-09-19 | 2020-03-27 | 广东东阳光药业有限公司 | 苯甲酰氨基吡啶衍生物的晶型及其用途 |
WO2020080742A1 (fr) | 2018-10-18 | 2020-04-23 | Cj Healthcare Corporation | Nouveaux dérivés de benzooxazinone ou de benzothiazinone substitués par (isopropyl-triazolyl)pyridinyle et leur utilisation |
WO2020080741A1 (fr) | 2018-10-18 | 2020-04-23 | Cj Healthcare Corporation | Nouveaux dérivés de n-(isopropyl-triazolyl)pyridinyl)-hétéroaryl-carboxamide et leur utilisation |
US10683289B2 (en) | 2018-05-02 | 2020-06-16 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
EP3572401A4 (fr) * | 2017-01-22 | 2020-08-26 | Fujian Cosunter Pharmaceutical Co., Ltd. | Inhibiteur de ask1, sa méthode de préparation et son utilisation |
EP3590931A4 (fr) * | 2017-03-03 | 2020-11-18 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | Inhibiteur de dérivé d'amide, son procédé de préparation et son application |
WO2021021986A1 (fr) * | 2019-07-31 | 2021-02-04 | Ribon Therapeutics, Inc. | Amides hétérobicycliques servant d'inhibiteurs de cd38 |
CN112409332A (zh) * | 2019-08-23 | 2021-02-26 | 广东东阳光药业有限公司 | 三氮唑衍生物及其在药物中的应用 |
US10968199B2 (en) | 2018-08-22 | 2021-04-06 | Enanta Pharmaceuticals, Inc. | Cycloalkyl-containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
WO2021224818A1 (fr) * | 2020-05-08 | 2021-11-11 | Pfizer Inc. | Composés d'isoindolone en tant qu'inhibiteurs de hpk1 |
EP3924334A1 (fr) * | 2019-02-15 | 2021-12-22 | Centre national de la recherche scientifique | Échafaudages de 2-pyridinaldoxime 3,6-disubstitués |
CN113831323A (zh) * | 2020-06-24 | 2021-12-24 | 武汉人福创新药物研发中心有限公司 | 芳杂环酰胺类化合物及其用途 |
WO2022056449A1 (fr) * | 2020-09-14 | 2022-03-17 | Genzyme Corporation | Composés utilisés en tant que modulateurs de la bisphosphoglycérate mutase pour le traitement de la drépanocytose |
US11345699B2 (en) | 2018-11-19 | 2022-05-31 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
US11434249B1 (en) | 2018-01-02 | 2022-09-06 | Seal Rock Therapeutics, Inc. | ASK1 inhibitor compounds and uses thereof |
US11466033B2 (en) | 2019-03-25 | 2022-10-11 | Enanta Pharmaceuticals, Inc. | Substituted pyridines as apoptosis signal-regulating kinase 1 inhibitors |
KR20230040940A (ko) * | 2021-09-16 | 2023-03-23 | 울산과학기술원 | 광 산화-환원 고리화 첨가반응을 이용한 이중고리 n-헤테로환의 제조 방법 |
US11684616B2 (en) | 2020-05-01 | 2023-06-27 | Pfizer Inc. | Azalactam compounds as HPK1 inhibitors |
CN116987022A (zh) * | 2022-04-25 | 2023-11-03 | 台州臻挚生物科技有限公司 | 一种含有氮杂双环-[3.1.0]-己烷-2-酮的化合物的制备方法 |
US11878958B2 (en) | 2022-05-25 | 2024-01-23 | Ikena Oncology, Inc. | MEK inhibitors and uses thereof |
US11952377B2 (en) | 2021-01-29 | 2024-04-09 | Boehringer Ingelheim International Gmbh | Quinolines and azaquinolines as inhibitors of CD38 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6605626B2 (en) * | 1997-06-26 | 2003-08-12 | Eli Lilly And Company | Antithrombotic agents |
US7795259B2 (en) * | 2004-11-22 | 2010-09-14 | Vertex Pharmaceuticals Incorporated | Pyrrolopyrazines and pyrazolopyrazines useful as inhibitors of protein kinases |
-
2018
- 2018-02-16 WO PCT/US2018/000044 patent/WO2018151830A1/fr active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6605626B2 (en) * | 1997-06-26 | 2003-08-12 | Eli Lilly And Company | Antithrombotic agents |
US7795259B2 (en) * | 2004-11-22 | 2010-09-14 | Vertex Pharmaceuticals Incorporated | Pyrrolopyrazines and pyrazolopyrazines useful as inhibitors of protein kinases |
Non-Patent Citations (1)
Title |
---|
DATABASE PubChem compound [O] 2 December 2013 (2013-12-02), XP055533871, retrieved from NCBI Database accession no. CID72138841 * |
Cited By (98)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3572401A4 (fr) * | 2017-01-22 | 2020-08-26 | Fujian Cosunter Pharmaceutical Co., Ltd. | Inhibiteur de ask1, sa méthode de préparation et son utilisation |
US11136324B2 (en) * | 2017-03-03 | 2021-10-05 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | Substituted imidazoles as apoptosis signal regulating kinase 1 inhibitors |
EP3590931A4 (fr) * | 2017-03-03 | 2020-11-18 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | Inhibiteur de dérivé d'amide, son procédé de préparation et son application |
US10150755B2 (en) | 2017-04-05 | 2018-12-11 | Seal Rock Therapeutics, Inc. | ASK1 inhibitor compounds and uses thereof |
US10988458B2 (en) | 2017-05-12 | 2021-04-27 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
US12018017B2 (en) | 2017-05-12 | 2024-06-25 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
KR20200007000A (ko) * | 2017-05-12 | 2020-01-21 | 이난타 파마슈티칼스, 인코포레이티드 | 아폽토시스 신호 조절 키나아제 1 억제제 및 이의 사용 방법 |
AU2018266911B2 (en) * | 2017-05-12 | 2022-04-07 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
KR102629267B1 (ko) | 2017-05-12 | 2024-01-25 | 이난타 파마슈티칼스, 인코포레이티드 | 아폽토시스 신호 조절 키나아제 1 억제제 및 이의 사용 방법 |
US10683279B2 (en) | 2017-05-12 | 2020-06-16 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
AU2018266911C1 (en) * | 2017-05-12 | 2022-10-20 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
US11560368B2 (en) | 2017-05-12 | 2023-01-24 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
JP2020519584A (ja) * | 2017-05-12 | 2020-07-02 | エナンタ ファーマシューティカルズ インコーポレイテッド | アポトーシスシグナル調節キナーゼ1阻害剤およびその使用方法 |
JP7377718B2 (ja) | 2017-05-12 | 2023-11-10 | エナンタ ファーマシューティカルズ インコーポレイテッド | アポトーシスシグナル調節キナーゼ1阻害剤およびその使用方法 |
EP3621615A4 (fr) * | 2017-05-12 | 2020-09-09 | Enanta Pharmaceuticals, Inc. | Inhibiteurs de kinases de régulation du signal d'apoptose 1 et leurs procédés d'utilisation |
US10246439B2 (en) | 2017-05-25 | 2019-04-02 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
US10253018B2 (en) | 2017-05-25 | 2019-04-09 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
US10450301B2 (en) | 2017-05-25 | 2019-10-22 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
WO2019034096A1 (fr) * | 2017-08-17 | 2019-02-21 | Sunshine Lake Pharma Co., Ltd. | Composés bicycliques fusionnés et leurs utilisations en médecine |
WO2019046186A1 (fr) * | 2017-08-28 | 2019-03-07 | Enanta Pharmaceuticals, Inc. | Inhibiteurs de la kinase 1 régulant le signal apoptotique contenant des tétrazoles et méthodes d'utilisation de ceux-ci |
US10597382B2 (en) | 2017-08-28 | 2020-03-24 | Enanta Pharmaceuticals, Inc. | Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
CN109956928A (zh) * | 2017-12-14 | 2019-07-02 | 四川科伦博泰生物医药股份有限公司 | 吡啶类化合物、其制备方法及用途 |
US11434249B1 (en) | 2018-01-02 | 2022-09-06 | Seal Rock Therapeutics, Inc. | ASK1 inhibitor compounds and uses thereof |
CN112312905B (zh) * | 2018-05-02 | 2024-03-15 | 英安塔制药有限公司 | 含四唑的细胞凋亡信号调节激酶1抑制剂及其使用方法 |
CN112312905A (zh) * | 2018-05-02 | 2021-02-02 | 英安塔制药有限公司 | 含四唑的细胞凋亡信号调节激酶1抑制剂及其使用方法 |
WO2019213244A1 (fr) | 2018-05-02 | 2019-11-07 | Enanta Pharmaceuticals, Inc. | Inhibiteurs de la kinase 1 régulant le signal d'apoptose contenant des tétrazoles et leurs méthodes d'utilisation |
US11008304B2 (en) | 2018-05-02 | 2021-05-18 | Enanta Pharmaceuticals, Inc. | Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
US11834436B2 (en) | 2018-05-02 | 2023-12-05 | Enanta Pharmaceuticals, Inc. | Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
KR102798464B1 (ko) | 2018-05-02 | 2025-04-21 | 이난타 파마슈티칼스, 인코포레이티드 | 아폽토시스 신호 조절 키나제 1 억제제를 포함하는 테트라졸 및 이의 사용 방법 |
KR20210005195A (ko) * | 2018-05-02 | 2021-01-13 | 이난타 파마슈티칼스, 인코포레이티드 | 아폽토시스 신호 조절 키나제 1 억제제를 포함하는 테트라졸 및 이의 사용 방법 |
US10683289B2 (en) | 2018-05-02 | 2020-06-16 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
WO2020006031A1 (fr) * | 2018-06-27 | 2020-01-02 | Biogen Ma Inc. | Agents inhibiteurs d'ask1 |
US11814362B2 (en) | 2018-06-27 | 2023-11-14 | Biogen Ma Inc. | ASK1 inhibiting agents |
US12404263B2 (en) | 2018-06-27 | 2025-09-02 | Biogen Ma Inc. | ASK1 inhibiting agents |
WO2020015721A1 (fr) * | 2018-07-20 | 2020-01-23 | 福建广生堂药业股份有限公司 | Forme cristalline utilisée en tant qu'inhibiteur d'ask1, son procédé de préparation et son utilisation |
US11814382B2 (en) | 2018-07-20 | 2023-11-14 | Fujian Akeylink Biotechnology Co., Ltd. | Crystal form as ASK1 inhibitor and preparation method and application thereof |
WO2020030107A1 (fr) * | 2018-08-10 | 2020-02-13 | 江苏豪森药业集团有限公司 | Composition pharmaceutique contenant des dérivés amides, son procédé de préparation et application associée |
CN110818683A (zh) * | 2018-08-10 | 2020-02-21 | 中国科学院上海药物研究所 | 2-吡啶取代脲结构小分子化合物及其合成和应用 |
CN110818683B (zh) * | 2018-08-10 | 2023-04-14 | 中国科学院上海药物研究所 | 2-吡啶取代脲结构小分子化合物及其合成和应用 |
WO2020034988A1 (fr) * | 2018-08-14 | 2020-02-20 | 江苏豪森药业集团有限公司 | Sel d'inhibiteur de kinase 1 de régulation du signal de l'apoptose et forme cristalline de celui-ci |
US10968199B2 (en) | 2018-08-22 | 2021-04-06 | Enanta Pharmaceuticals, Inc. | Cycloalkyl-containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
CN110922407B (zh) * | 2018-09-19 | 2021-11-12 | 广东东阳光药业有限公司 | 苯甲酰氨基吡啶衍生物的晶型及其用途 |
CN110922407A (zh) * | 2018-09-19 | 2020-03-27 | 广东东阳光药业有限公司 | 苯甲酰氨基吡啶衍生物的晶型及其用途 |
CN112839936A (zh) * | 2018-10-18 | 2021-05-25 | 怡诺安有限公司 | 新颖的n-(异丙基-三唑基)吡啶基)-杂芳基-甲酰胺衍生物及其用途 |
KR102288434B1 (ko) * | 2018-10-18 | 2021-08-12 | 에이치케이이노엔 주식회사 | 신규한 (이소프로필-트리아졸릴)피리디닐 치환된 벤조옥사지논 또는 벤조티아지논 유도체 및 이의 용도 |
WO2020080742A1 (fr) | 2018-10-18 | 2020-04-23 | Cj Healthcare Corporation | Nouveaux dérivés de benzooxazinone ou de benzothiazinone substitués par (isopropyl-triazolyl)pyridinyle et leur utilisation |
US12077523B2 (en) | 2018-10-18 | 2024-09-03 | Hk Inno.N Corporation | N-(isopropyl-triazolyl)pyridinyl)-heteroaryl-carboxamide derivatives and use thereof |
WO2020080741A1 (fr) | 2018-10-18 | 2020-04-23 | Cj Healthcare Corporation | Nouveaux dérivés de n-(isopropyl-triazolyl)pyridinyl)-hétéroaryl-carboxamide et leur utilisation |
CN112839943A (zh) * | 2018-10-18 | 2021-05-25 | 怡诺安有限公司 | 新型(异丙基-三唑基)吡啶基取代的苯并噁嗪酮或苯并噻嗪酮衍生物及其用途 |
KR20200044269A (ko) * | 2018-10-18 | 2020-04-29 | 에이치케이이노엔 주식회사 | 신규한 n-(이소프로필-트리아졸릴)피리디닐)-헤테로아릴-카르복사미드 유도체 및 이의 용도 |
KR20200044268A (ko) * | 2018-10-18 | 2020-04-29 | 에이치케이이노엔 주식회사 | 신규한 (이소프로필-트리아졸릴)피리디닐 치환된 벤조옥사지논 또는 벤조티아지논 유도체 및 이의 용도 |
KR102298546B1 (ko) | 2018-10-18 | 2021-09-08 | 에이치케이이노엔 주식회사 | 신규한 n-(이소프로필-트리아졸릴)피리디닐)-헤테로아릴-카르복사미드 유도체 및 이의 용도 |
US11345699B2 (en) | 2018-11-19 | 2022-05-31 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
US12209090B2 (en) | 2019-02-15 | 2025-01-28 | Centre National De La Recherche Scientifique | 3,6-disubstituted-2-pyridinaldoxime scaffolds |
JP7728389B2 (ja) | 2019-02-15 | 2025-08-22 | サントル ナシオナル ドゥ ラ ルシェルシェ サイアンティフィク | 3,6-二置換-2-ピリジンアルドキシム骨格 |
CN113891879B (zh) * | 2019-02-15 | 2025-03-04 | 国家科学研究中心 | 3,6-二取代的-2-吡啶醛肟骨架 |
JP2022520631A (ja) * | 2019-02-15 | 2022-03-31 | サントル ナシオナル ドゥ ラ ルシェルシェ サイアンティフィク | 3,6-二置換-2-ピリジンアルドキシム骨格 |
EP3924334A1 (fr) * | 2019-02-15 | 2021-12-22 | Centre national de la recherche scientifique | Échafaudages de 2-pyridinaldoxime 3,6-disubstitués |
JP2024072852A (ja) * | 2019-02-15 | 2024-05-28 | サントル ナシオナル ドゥ ラ ルシェルシェ サイアンティフィク | 3,6-二置換-2-ピリジンアルドキシム骨格 |
CN113891879A (zh) * | 2019-02-15 | 2022-01-04 | 国家科学研究中心 | 3,6-二取代的-2-吡啶醛肟骨架 |
US11466033B2 (en) | 2019-03-25 | 2022-10-11 | Enanta Pharmaceuticals, Inc. | Substituted pyridines as apoptosis signal-regulating kinase 1 inhibitors |
CN110577539B (zh) * | 2019-07-16 | 2021-07-23 | 广州安岩仁医药科技有限公司 | 苯甲酰氨基吡啶衍生物的盐及其在药物中的应用 |
CN110577535B (zh) * | 2019-07-16 | 2021-07-23 | 广州安岩仁医药科技有限公司 | 苯甲酰氨基吡啶衍生物的盐及其在药物中的应用 |
CN110577541A (zh) * | 2019-07-16 | 2019-12-17 | 广州安岩仁医药科技有限公司 | 苯甲酰氨基吡啶衍生物的盐及其在药物中的应用 |
CN110577534A (zh) * | 2019-07-16 | 2019-12-17 | 广州安岩仁医药科技有限公司 | 苯甲酰氨基吡啶衍生物的盐及其在药物中的应用 |
CN110577537A (zh) * | 2019-07-16 | 2019-12-17 | 广州安岩仁医药科技有限公司 | 苯甲酰氨基吡啶衍生物的盐及其在药物中的应用 |
CN110577533B (zh) * | 2019-07-16 | 2021-07-23 | 广州安岩仁医药科技有限公司 | 苯甲酰氨基吡啶衍生物的盐及其在药物中的应用 |
CN110577537B (zh) * | 2019-07-16 | 2021-07-23 | 广州安岩仁医药科技有限公司 | 苯甲酰氨基吡啶衍生物的盐及其在药物中的应用 |
CN110577540B (zh) * | 2019-07-16 | 2021-07-23 | 广州安岩仁医药科技有限公司 | 苯甲酰氨基吡啶衍生物的盐及其在药物中的应用 |
CN110577541B (zh) * | 2019-07-16 | 2021-07-23 | 广州安岩仁医药科技有限公司 | 苯甲酰氨基吡啶衍生物的盐及其在药物中的应用 |
CN110577534B (zh) * | 2019-07-16 | 2021-07-23 | 广州安岩仁医药科技有限公司 | 苯甲酰氨基吡啶衍生物的盐及其在药物中的应用 |
CN110577540A (zh) * | 2019-07-16 | 2019-12-17 | 广州安岩仁医药科技有限公司 | 苯甲酰氨基吡啶衍生物的盐及其在药物中的应用 |
CN110577538A (zh) * | 2019-07-16 | 2019-12-17 | 广州安岩仁医药科技有限公司 | 苯甲酰氨基吡啶衍生物的盐及其在药物中的应用 |
CN110577535A (zh) * | 2019-07-16 | 2019-12-17 | 广州安岩仁医药科技有限公司 | 苯甲酰氨基吡啶衍生物的盐及其在药物中的应用 |
CN110577539A (zh) * | 2019-07-16 | 2019-12-17 | 广州安岩仁医药科技有限公司 | 苯甲酰氨基吡啶衍生物的盐及其在药物中的应用 |
CN110577536A (zh) * | 2019-07-16 | 2019-12-17 | 广州安岩仁医药科技有限公司 | 苯甲酰氨基吡啶衍生物的盐及其在药物中的应用 |
CN110577533A (zh) * | 2019-07-16 | 2019-12-17 | 广州安岩仁医药科技有限公司 | 苯甲酰氨基吡啶衍生物的盐及其在药物中的应用 |
CN110577536B (zh) * | 2019-07-16 | 2021-07-23 | 广州安岩仁医药科技有限公司 | 苯甲酰氨基吡啶衍生物的盐及其在药物中的应用 |
CN110577538B (zh) * | 2019-07-16 | 2021-07-23 | 广州安岩仁医药科技有限公司 | 苯甲酰氨基吡啶衍生物的盐及其在药物中的应用 |
US11535621B2 (en) | 2019-07-31 | 2022-12-27 | Ribon Therapeutics, Inc. | Heterobicyclic amides as inhibitors of CD38 |
US12398146B2 (en) | 2019-07-31 | 2025-08-26 | Boehringer Ingelheim International Gmbh | Heterobicyclic amides as inhibitors of CD38 |
CN114423753A (zh) * | 2019-07-31 | 2022-04-29 | 里邦医疗公司 | 作为cd38抑制剂的杂双环酰胺 |
US11987584B2 (en) | 2019-07-31 | 2024-05-21 | Boehringer Ingelheim International Gmbh | Heterobicyclic amides as inhibitors of CD38 |
WO2021021986A1 (fr) * | 2019-07-31 | 2021-02-04 | Ribon Therapeutics, Inc. | Amides hétérobicycliques servant d'inhibiteurs de cd38 |
CN112409332A (zh) * | 2019-08-23 | 2021-02-26 | 广东东阳光药业有限公司 | 三氮唑衍生物及其在药物中的应用 |
CN112409332B (zh) * | 2019-08-23 | 2023-12-08 | 广东东阳光药业股份有限公司 | 三氮唑衍生物及其在药物中的应用 |
US11684616B2 (en) | 2020-05-01 | 2023-06-27 | Pfizer Inc. | Azalactam compounds as HPK1 inhibitors |
WO2021224818A1 (fr) * | 2020-05-08 | 2021-11-11 | Pfizer Inc. | Composés d'isoindolone en tant qu'inhibiteurs de hpk1 |
CN113831323A (zh) * | 2020-06-24 | 2021-12-24 | 武汉人福创新药物研发中心有限公司 | 芳杂环酰胺类化合物及其用途 |
CN113831323B (zh) * | 2020-06-24 | 2025-08-29 | 武汉人福创新药物研发中心有限公司 | 芳杂环酰胺类化合物及其用途 |
CN116406361A (zh) * | 2020-09-14 | 2023-07-07 | 健赞公司 | 用于治疗镰状细胞病的作为二磷酸甘油酸变位酶调节剂的化合物 |
JP2023541152A (ja) * | 2020-09-14 | 2023-09-28 | ジェンザイム・コーポレーション | 鎌状赤血球症を処置するためのビスホスホグリセリン酸ムターゼのモジュレーターとしての化合物 |
WO2022056449A1 (fr) * | 2020-09-14 | 2022-03-17 | Genzyme Corporation | Composés utilisés en tant que modulateurs de la bisphosphoglycérate mutase pour le traitement de la drépanocytose |
US11952377B2 (en) | 2021-01-29 | 2024-04-09 | Boehringer Ingelheim International Gmbh | Quinolines and azaquinolines as inhibitors of CD38 |
KR102775095B1 (ko) | 2021-09-16 | 2025-03-04 | 울산과학기술원 | 광 산화-환원 고리화 첨가반응을 이용한 이중고리 n-헤테로환의 제조 방법 |
KR20230040940A (ko) * | 2021-09-16 | 2023-03-23 | 울산과학기술원 | 광 산화-환원 고리화 첨가반응을 이용한 이중고리 n-헤테로환의 제조 방법 |
CN116987022A (zh) * | 2022-04-25 | 2023-11-03 | 台州臻挚生物科技有限公司 | 一种含有氮杂双环-[3.1.0]-己烷-2-酮的化合物的制备方法 |
US11878958B2 (en) | 2022-05-25 | 2024-01-23 | Ikena Oncology, Inc. | MEK inhibitors and uses thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2018151830A1 (fr) | Inhibiteurs de kinase de régulation du signal apoptotique à base de pyridinyle | |
JP7212693B2 (ja) | ファルネソイドx受容体モジュレーターとしての架橋二環化合物 | |
US11261173B2 (en) | Bradykinin B2 receptor antagonists | |
KR20210013145A (ko) | 키나아제 억제제로서 헤테로시클릭 화합물, 헤테로시클릭 화합물을 포함하는 조성물 및 그 사용 방법 | |
AU2014234909B2 (en) | Acyclic cyanoethylpyrazolo pyridones as Janus kinase inhibitors | |
JP6412102B2 (ja) | ヤヌスキナーゼ阻害剤としてのシクロアルキルニトリルピラゾロピリドン | |
US11034671B2 (en) | Apoptosis signal-regulating kinase inhibitors and uses thereof | |
MX2014008158A (es) | Compuestos de piridazina-amida. | |
JP2015526411A (ja) | 窒素複素環誘導体及びその医薬品への応用 | |
JP2023553297A (ja) | Trpm3媒介性障害を治療するための複素環誘導体 | |
CA2897469A1 (fr) | Derives de pyridine comme modulateurs allosteriques positifs de recepteur muscarinique m1 | |
CN112969694A (zh) | Rho相关蛋白激酶抑制剂、包含其的药物组合物及其用途 | |
JP2013522364A (ja) | 置換イミダゾ[1,2−b]ピリダジン誘導体、医薬組成物、及びβ−セクレターゼ阻害剤としての使用の方法 | |
CA3186769A1 (fr) | Composes bicycliques et utilisation connexe | |
JP2016514710A (ja) | ヤヌスキナーゼ阻害剤としてのn−(2−シアノヘテロシクリル)ピラゾロピリドン | |
AU2022288945A1 (en) | Heteroaryl compounds as inhibitors of tyk2, composition and application thereof | |
AU2019344240B2 (en) | Novel thiazole derivatives and pharmaceutically acceptable salts thereof | |
US12319696B2 (en) | 2,6-dimethyl-n-((pyridin-4-yl)methyl)imidazo[1,2-b]pyridazin-8-amine and 2,5-dimethyl-n-[(pyridin-4-yl)methyl]pyrazolo[1,5-a]pyrimidin-7-amine derivatives for treating viral infections | |
WO2024124002A1 (fr) | Composés et compositions utilisés en tant qu'inhibiteurs de la kinase c-kit | |
EP4577206A2 (fr) | Nouveaux modulateurs de fshr et leurs utilisations | |
JP2025517511A (ja) | Trpm3媒介性障害を治療するための新たな誘導体 | |
CN110294742A (zh) | 并环类ask1抑制剂及其应用 | |
KR20250021375A (ko) | Sarm1 조절제, 이의 제조 및 용도 | |
CN108864080B (zh) | 作为选择性雌激素受体下调剂的四环类化合物及其应用 | |
US20210155634A1 (en) | Novel tryptophan hydroxylase inhibitor and pharmaceutical composition including same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18754143 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 18754143 Country of ref document: EP Kind code of ref document: A1 |